{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 399645, "items": [{"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T04:30:02Z", "timestamp": 1574224202779}, "reference-count": 0, "publisher": "The Endocrine Society", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "published-print": {"date-parts": [[2006, 10]]}, "DOI": "10.1210/jc.2006-0968", "type": "journal-article", "created": {"date-parts": [[2006, 8, 2]], "date-time": "2006-08-02T18:54:14Z", "timestamp": 1154544854000}, "page": "3850-3856", "source": "Crossref", "is-referenced-by-count": 129, "title": ["Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men"], "prefix": "10.1210", "volume": "91", "author": [{"given": "Stephanie T.", "family": "Page", "sequence": "first", "affiliation": []}, {"given": "Daniel W.", "family": "Lin", "sequence": "additional", "affiliation": []}, {"given": "Elahe A.", "family": "Mostaghel", "sequence": "additional", "affiliation": []}, {"given": "David L.", "family": "Hess", "sequence": "additional", "affiliation": []}, {"given": "Lawrence D.", "family": "True", "sequence": "additional", "affiliation": []}, {"given": "John K.", "family": "Amory", "sequence": "additional", "affiliation": []}, {"given": "Peter S.", "family": "Nelson", "sequence": "additional", "affiliation": []}, {"given": "Alvin M.", "family": "Matsumoto", "sequence": "additional", "affiliation": []}, {"given": "William J.", "family": "Bremner", "sequence": "additional", "affiliation": []}], "member": "80", "container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "language": "en", "link": [{"URL": "http://academic.oup.com/jcem/article-pdf/91/10/3850/9061698/jcem3850.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 25]], "date-time": "2017-08-25T00:52:52Z", "timestamp": 1503622372000}, "score": 53.171032, "issued": {"date-parts": [[2006, 10]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2006, 10]]}, "issue": "10"}, "alternative-id": ["10.1210/jc.2006-0968"], "URL": "http://dx.doi.org/10.1210/jc.2006-0968", "ISSN": ["0021-972X", "1945-7197"], "issn-type": [{"value": "0021-972X", "type": "print"}, {"value": "1945-7197", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T05:14:17Z", "timestamp": 1574486057570}, "reference-count": 0, "publisher": "The Endocrine Society", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "published-print": {"date-parts": [[2011, 2]]}, "DOI": "10.1210/jc.2010-1865", "type": "journal-article", "created": {"date-parts": [[2010, 12, 23]], "date-time": "2010-12-23T02:58:28Z", "timestamp": 1293073108000}, "page": "430-437", "source": "Crossref", "is-referenced-by-count": 37, "title": ["Dihydrotestosterone Administration Does Not Increase Intraprostatic Androgen Concentrations or Alter Prostate Androgen Action in Healthy Men: A Randomized-Controlled Trial"], "prefix": "10.1210", "volume": "96", "author": [{"given": "Stephanie T.", "family": "Page", "sequence": "first", "affiliation": []}, {"given": "Daniel W.", "family": "Lin", "sequence": "additional", "affiliation": []}, {"given": "Elahe A.", "family": "Mostaghel", "sequence": "additional", "affiliation": []}, {"given": "Brett T.", "family": "Marck", "sequence": "additional", "affiliation": []}, {"given": "Jonathan L.", "family": "Wright", "sequence": "additional", "affiliation": []}, {"given": "Jennifer", "family": "Wu", "sequence": "additional", "affiliation": []}, {"given": "John K.", "family": "Amory", "sequence": "additional", "affiliation": []}, {"given": "Peter S.", "family": "Nelson", "sequence": "additional", "affiliation": []}, {"given": "Alvin M.", "family": "Matsumoto", "sequence": "additional", "affiliation": []}], "member": "80", "container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "language": "en", "link": [{"URL": "http://academic.oup.com/jcem/article-pdf/96/2/430/9068463/jcem0430.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 25]], "date-time": "2017-08-25T03:22:37Z", "timestamp": 1503631357000}, "score": 34.68959, "issued": {"date-parts": [[2011, 2]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2011, 2]]}, "issue": "2"}, "alternative-id": ["10.1210/jc.2010-1865"], "URL": "http://dx.doi.org/10.1210/jc.2010-1865", "ISSN": ["0021-972X", "1945-7197"], "issn-type": [{"value": "0021-972X", "type": "print"}, {"value": "1945-7197", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T15:28:22Z", "timestamp": 1574782102120}, "reference-count": 139, "publisher": "Springer Science and Business Media LLC", "issue": "5", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 4, 4]], "date-time": "2016-04-04T00:00:00Z", "timestamp": 1459728000000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["Med Oncol"], "published-print": {"date-parts": [[2016, 5]]}, "DOI": "10.1007/s12032-016-0759-3", "type": "journal-article", "created": {"date-parts": [[2016, 4, 4]], "date-time": "2016-04-04T13:46:10Z", "timestamp": 1459777570000}, "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 15, "title": ["Targeting persistent androgen receptor signaling in castration-resistant prostate cancer"], "prefix": "10.1007", "volume": "33", "author": [{"given": "Laura", "family": "Graham", "sequence": "first", "affiliation": []}, {"given": "Michael T.", "family": "Schweizer", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 4, 4]]}, "reference": [{"key": "759_CR1", "doi-asserted-by": "crossref", "first-page": "7", "DOI": "10.3322/caac.21332", "volume": "66", "author": "RL Siegel", "year": "2016", "unstructured": "Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.", "journal-title": "CA Cancer J Clin"}, {"key": "759_CR2", "doi-asserted-by": "crossref", "first-page": "9", "DOI": "10.1016/S0022-5347(05)64820-3", "volume": "168", "author": "C Huggins", "year": "2002", "unstructured": "Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168:9\u201312.", "journal-title": "J Urol"}, {"key": "759_CR3", "doi-asserted-by": "crossref", "first-page": "1589", "DOI": "10.1093/annonc/mdv257", "volume": "26", "author": "S Gillessen", "year": "2015", "unstructured": "Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26:1589\u2013604.", "journal-title": "Ann Oncol"}, {"key": "759_CR4", "doi-asserted-by": "crossref", "first-page": "275", "DOI": "10.1016/j.ctrv.2012.09.005", "volume": "39", "author": "S Oudard", "year": "2013", "unstructured": "Oudard S. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev. 2013;39:275\u201389.", "journal-title": "Cancer Treat Rev"}, {"key": "759_CR5", "doi-asserted-by": "crossref", "first-page": "1916", "DOI": "10.1016/j.ejca.2014.04.004", "volume": "50", "author": "TA West", "year": "2014", "unstructured": "West TA, Kiely BE, Stockler MR. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: a systematic review of randomised trials. Eur J Cancer. 2014;50:1916\u201324.", "journal-title": "Eur J Cancer"}, {"key": "759_CR6", "doi-asserted-by": "crossref", "first-page": "1148", "DOI": "10.1200/JCO.2007.12.4487", "volume": "26", "author": "HI Scher", "year": "2008", "unstructured": "Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148\u201359.", "journal-title": "J Clin Oncol"}, {"key": "759_CR7", "doi-asserted-by": "crossref", "first-page": "3001", "DOI": "10.1200/JCO.2002.10.018", "volume": "20", "author": "EP Gelmann", "year": "2002", "unstructured": "Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20:3001\u201315.", "journal-title": "J Clin Oncol"}, {"key": "759_CR8", "unstructured": "Jentzmik F, Azoitei A, Zengerling F, Damjanoski I, Cronauer MV. Androgen receptor aberrations in the era of abiraterone and enzalutamide. World J Urol. 2016;34(3):297\u2013303.", "DOI": "10.1007/s00345-015-1624-2", "doi-asserted-by": "crossref"}, {"key": "759_CR9", "doi-asserted-by": "crossref", "first-page": "1970", "DOI": "10.1242/jcs.096792", "volume": "125", "author": "ME Royen van", "year": "2012", "unstructured": "van Royen ME, van Cappellen WA, de Vos C, Houtsmuller AB, Trapman J. Stepwise androgen receptor dimerization. J Cell Sci. 2012;125:1970\u20139.", "journal-title": "J Cell Sci"}, {"key": "759_CR10", "doi-asserted-by": "crossref", "first-page": "459", "DOI": "10.1677/erc.1.00525", "volume": "11", "author": "HI Scher", "year": "2004", "unstructured": "Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004;11:459\u201376.", "journal-title": "Endocr Relat Cancer"}, {"key": "759_CR11", "doi-asserted-by": "crossref", "first-page": "1028", "DOI": "10.1056/NEJMoa1315815", "volume": "371", "author": "ES Antonarakis", "year": "2014", "unstructured": "Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.", "journal-title": "N Engl J Med"}, {"key": "759_CR12", "doi-asserted-by": "crossref", "first-page": "4447", "DOI": "10.1158/0008-5472.CAN-08-0249", "volume": "68", "author": "RB Montgomery", "year": "2008", "unstructured": "Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447\u201354.", "journal-title": "Cancer Res"}, {"key": "759_CR13", "doi-asserted-by": "crossref", "first-page": "4653", "DOI": "10.1158/1078-0432.CCR-05-0525", "volume": "11", "author": "MA Titus", "year": "2005", "unstructured": "Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11:4653\u20137.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR14", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.1038/nm972", "volume": "10", "author": "CD Chen", "year": "2004", "unstructured": "Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33\u20139.", "journal-title": "Nat Med"}, {"key": "759_CR15", "doi-asserted-by": "crossref", "first-page": "4792", "DOI": "10.1158/1078-0432.CCR-08-2660", "volume": "15", "author": "KE Knudsen", "year": "2009", "unstructured": "Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15:4792\u20138.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR16", "doi-asserted-by": "crossref", "first-page": "582", "DOI": "10.1002/cpt.256", "volume": "98", "author": "DJ Crona", "year": "2015", "unstructured": "Crona DJ, Milowsky MI, Whang YE. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin Pharmacol Ther. 2015;98:582\u20139.", "journal-title": "Clin Pharmacol Ther"}, {"key": "759_CR17", "doi-asserted-by": "crossref", "first-page": "1215", "DOI": "10.1016/j.cell.2015.05.001", "volume": "161", "author": "D Robinson", "year": "2015", "unstructured": "Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.", "journal-title": "Cell"}, {"key": "759_CR18", "first-page": "1383", "volume": "3", "author": "MA Fenton", "year": "1997", "unstructured": "Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997;3:1383\u20138.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR19", "first-page": "2511", "volume": "59", "author": "ME Taplin", "year": "1999", "unstructured": "Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999;59:2511\u20135.", "journal-title": "Cancer Res"}, {"key": "759_CR20", "doi-asserted-by": "crossref", "first-page": "1502", "DOI": "10.1056/NEJMoa040720", "volume": "351", "author": "IF Tannock", "year": "2004", "unstructured": "Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.", "journal-title": "N Engl J Med"}, {"key": "759_CR21", "doi-asserted-by": "crossref", "first-page": "1513", "DOI": "10.1056/NEJMoa041318", "volume": "351", "author": "DP Petrylak", "year": "2004", "unstructured": "Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513\u201320.", "journal-title": "N Engl J Med"}, {"key": "759_CR22", "unstructured": "Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016.", "DOI": "10.1200/JCO.2015.64.9285", "doi-asserted-by": "crossref"}, {"key": "759_CR23", "doi-asserted-by": "crossref", "first-page": "38", "DOI": "10.1016/S0090-4295(96)80007-0", "volume": "47", "author": "GT Bales", "year": "1996", "unstructured": "Bales GT, Chodak GW. A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer. Urology. 1996;47:38\u201343 (discussion 48\u201353).", "journal-title": "Urology"}, {"key": "759_CR24", "doi-asserted-by": "crossref", "first-page": "1491", "DOI": "10.1016/S0140-6736(00)02163-2", "volume": "355", "author": "Prostate Cancer Trialists\u2019 Collaborative Group", "year": "2000", "unstructured": "Prostate Cancer Trialists\u2019 Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491\u20138.", "journal-title": "Lancet"}, {"key": "759_CR25", "first-page": "149", "volume": "63", "author": "T Hara", "year": "2003", "unstructured": "Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003;63:149\u201353.", "journal-title": "Cancer Res"}, {"key": "759_CR26", "doi-asserted-by": "crossref", "first-page": "981", "DOI": "10.1016/S1470-2045(09)70229-3", "volume": "10", "author": "Y Chen", "year": "2009", "unstructured": "Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10:981\u201391.", "journal-title": "Lancet Oncol"}, {"key": "759_CR27", "doi-asserted-by": "crossref", "first-page": "1756", "DOI": "10.1200/JCO.1996.14.6.1756", "volume": "14", "author": "IF Tannock", "year": "1996", "unstructured": "Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756\u201364.", "journal-title": "J Clin Oncol"}, {"key": "759_CR28", "doi-asserted-by": "crossref", "first-page": "334", "DOI": "10.4103/1008-682X.122593", "volume": "16", "author": "MT Schweizer", "year": "2014", "unstructured": "Schweizer MT, Antonarakis ES. Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl. 2014;16:334\u201340.", "journal-title": "Asian J Androl"}, {"key": "759_CR29", "doi-asserted-by": "crossref", "first-page": "1654", "DOI": "10.1200/JCO.1999.17.6.1654", "volume": "17", "author": "D Osoba", "year": "1999", "unstructured": "Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654\u201363.", "journal-title": "J Clin Oncol"}, {"key": "759_CR30", "doi-asserted-by": "crossref", "first-page": "1147", "DOI": "10.1016/S0140-6736(10)61389-X", "volume": "376", "author": "JS Bono de", "year": "2010", "unstructured": "de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO, TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.", "journal-title": "Lancet"}, {"key": "759_CR31", "doi-asserted-by": "crossref", "first-page": "138", "DOI": "10.1056/NEJMoa1209096", "volume": "368", "author": "CJ Ryan", "year": "2013", "unstructured": "Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.", "journal-title": "N Engl J Med"}, {"key": "759_CR32", "doi-asserted-by": "crossref", "first-page": "424", "DOI": "10.1056/NEJMoa1405095", "volume": "371", "author": "TM Beer", "year": "2014", "unstructured": "Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B, PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.", "journal-title": "N Engl J Med"}, {"key": "759_CR33", "doi-asserted-by": "crossref", "first-page": "1187", "DOI": "10.1056/NEJMoa1207506", "volume": "367", "author": "HI Scher", "year": "2012", "unstructured": "Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.", "journal-title": "N Engl J Med"}, {"key": "759_CR34", "doi-asserted-by": "crossref", "first-page": "1995", "DOI": "10.1056/NEJMoa1014618", "volume": "364", "author": "JS Bono de", "year": "2011", "unstructured": "de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.", "journal-title": "N Engl J Med"}, {"key": "759_CR35", "doi-asserted-by": "crossref", "first-page": "1025", "DOI": "10.1200/JCO.2004.06.037", "volume": "22", "author": "EJ Small", "year": "2004", "unstructured": "Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004;22:1025\u201333.", "journal-title": "J Clin Oncol"}, {"key": "759_CR36", "doi-asserted-by": "crossref", "first-page": "310", "DOI": "10.1016/j.urolonc.2015.01.008", "volume": "33", "author": "DJ Maeseneer De", "year": "2015", "unstructured": "De Maeseneer DJ, Van Praet C, Lumen N, Rottey S. Battling resistance mechanisms in antihormonal prostate cancer treatment: novel agents and combinations. Urol Oncol. 2015;33:310\u201321.", "journal-title": "Urol Oncol"}, {"key": "759_CR37", "doi-asserted-by": "crossref", "first-page": "637", "DOI": "10.1200/JCO.2010.33.7675", "volume": "30", "author": "E Efstathiou", "year": "2012", "unstructured": "Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012;30:637\u201343.", "journal-title": "J Clin Oncol"}, {"key": "759_CR38", "doi-asserted-by": "crossref", "first-page": "152", "DOI": "10.1016/S1470-2045(14)71205-7", "volume": "16", "author": "CJ Ryan", "year": "2015", "unstructured": "Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.", "journal-title": "Lancet Oncol"}, {"key": "759_CR39", "doi-asserted-by": "crossref", "first-page": "787", "DOI": "10.1126/science.1168175", "volume": "324", "author": "C Tran", "year": "2009", "unstructured": "Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787\u201390.", "journal-title": "Science"}, {"key": "759_CR40", "doi-asserted-by": "crossref", "first-page": "1802", "DOI": "10.1093/annonc/mdt138", "volume": "24", "author": "KL Noonan", "year": "2013", "unstructured": "Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24:1802\u20137.", "journal-title": "Ann Oncol"}, {"key": "759_CR41", "doi-asserted-by": "crossref", "first-page": "1807", "DOI": "10.1093/annonc/mdt136", "volume": "24", "author": "Y Loriot", "year": "2013", "unstructured": "Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24:1807\u201312.", "journal-title": "Ann Oncol"}, {"key": "759_CR42", "doi-asserted-by": "crossref", "first-page": "78", "DOI": "10.1016/j.ejca.2013.08.020", "volume": "50", "author": "D Bianchini", "year": "2014", "unstructured": "Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer. 2014;50:78\u201384.", "journal-title": "Eur J Cancer"}, {"key": "759_CR43", "doi-asserted-by": "crossref", "first-page": "2943", "DOI": "10.1093/annonc/mds119", "volume": "23", "author": "J Mezynski", "year": "2012", "unstructured": "Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E, Hunt J, Sheridan E, Baikady B, Sarvadikar A, Maier G, Reid AH, Cassidy AM, Olmos D, Attard G, de Bono J. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol. 2012;23:2943\u20137.", "journal-title": "Ann Oncol"}, {"key": "759_CR44", "doi-asserted-by": "crossref", "first-page": "459", "DOI": "10.1016/j.eururo.2013.11.044", "volume": "66", "author": "CJ Pezaro", "year": "2014", "unstructured": "Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur Urol. 2014;66:459\u201365.", "journal-title": "Eur Urol"}, {"key": "759_CR45", "doi-asserted-by": "crossref", "first-page": "582", "DOI": "10.1001/jamaoncol.2015.1341", "volume": "1", "author": "ES Antonarakis", "year": "2015", "unstructured": "Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1:582\u201391.", "journal-title": "JAMA Oncol"}, {"key": "759_CR46", "doi-asserted-by": "crossref", "first-page": "8386", "DOI": "10.1158/0008-5472.CAN-09-1504", "volume": "69", "author": "L Gan", "year": "2009", "unstructured": "Gan L, Chen S, Wang Y, Watahiki A, Bohrer L, Sun Z, Wang Y, Huang H. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res. 2009;69:8386\u201394.", "journal-title": "Cancer Res"}, {"key": "759_CR47", "doi-asserted-by": "crossref", "first-page": "646", "DOI": "10.1016/j.eururo.2014.01.018", "volume": "66", "author": "MT Schweizer", "year": "2014", "unstructured": "Schweizer MT, Zhou XC, Wang H, Bassi S, Carducci MA, Eisenberger MA, Antonarakis ES. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;66:646\u201352.", "journal-title": "Eur Urol"}, {"key": "759_CR48", "doi-asserted-by": "crossref", "first-page": "723", "DOI": "10.1158/1078-0432.CCR-08-0596", "volume": "15", "author": "AC Mita", "year": "2009", "unstructured": "Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3\u00a0weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723\u201330.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR49", "doi-asserted-by": "crossref", "first-page": "411", "DOI": "10.1056/NEJMoa1001294", "volume": "363", "author": "PW Kantoff", "year": "2010", "unstructured": "Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.", "journal-title": "N Engl J Med"}, {"key": "759_CR50", "doi-asserted-by": "crossref", "first-page": "213", "DOI": "10.1056/NEJMoa1213755", "volume": "369", "author": "C Parker", "year": "2013", "unstructured": "Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall\u2019Oglio M, Franzen L, Coleman R, Vogelzang NJ, O\u2019Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O. ALSYMPCA investigators: alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.", "journal-title": "N Engl J Med"}, {"key": "759_CR51", "doi-asserted-by": "crossref", "first-page": "5913", "DOI": "10.1158/1078-0432.CCR-11-0728", "volume": "17", "author": "EA Mostaghel", "year": "2011", "unstructured": "Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17:5913\u201325.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR52", "doi-asserted-by": "crossref", "first-page": "6503", "DOI": "10.1158/0008-5472.CAN-11-0532", "volume": "71", "author": "C Cai", "year": "2011", "unstructured": "Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71:6503\u201313.", "journal-title": "Cancer Res"}, {"key": "759_CR53", "doi-asserted-by": "crossref", "first-page": "1309", "DOI": "10.1016/j.cell.2013.11.012", "volume": "155", "author": "VK Arora", "year": "2013", "unstructured": "Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155:1309\u201322.", "journal-title": "Cell"}, {"key": "759_CR54", "doi-asserted-by": "crossref", "first-page": "278", "DOI": "10.1038/nature13229", "volume": "510", "author": "IA Asangani", "year": "2014", "unstructured": "Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510:278\u201382.", "journal-title": "Nature"}, {"key": "759_CR55", "doi-asserted-by": "crossref", "first-page": "2315", "DOI": "10.1158/1078-0432.CCR-14-2666", "volume": "21", "author": "AA Azad", "year": "2015", "unstructured": "Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 2015;21:2315\u201324.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR56", "doi-asserted-by": "crossref", "first-page": "312re10", "DOI": "10.1126/scitranslmed.aac9511", "volume": "7", "author": "A Romanel", "year": "2015", "unstructured": "Romanel A, Tandefelt DG, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, Salvi S, Amadori D, Zafeiriou Z, Rescigno P, Bianchini D, Gurioli G, Casadio V, Carreira S, Goodall J, Wingate A, Ferraldeschi R, Tunariu N, Flohr P, De Giorgi U, de Bono JS, Demichelis F, Attard G. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7:312re10.", "journal-title": "Sci Transl Med"}, {"key": "759_CR57", "doi-asserted-by": "crossref", "first-page": "1074", "DOI": "10.1016/j.cell.2013.07.029", "volume": "154", "author": "KH Chang", "year": "2013", "unstructured": "Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, Mirzaei H, Auchus RJ, Sharifi N. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell. 2013;154:1074\u201384.", "journal-title": "Cell"}, {"key": "759_CR58", "doi-asserted-by": "crossref", "first-page": "4124", "DOI": "10.1210/en.2014-1337", "volume": "155", "author": "E Cho", "year": "2014", "unstructured": "Cho E, Montgomery RB, Mostaghel EA. Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression. Endocrinology. 2014;155:4124\u201332.", "journal-title": "Endocrinology"}, {"key": "759_CR59", "doi-asserted-by": "crossref", "first-page": "E4762", "DOI": "10.1073/pnas.1319948110", "volume": "110", "author": "JM Drake", "year": "2013", "unstructured": "Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci USA. 2013;110:E4762\u20139.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "759_CR60", "doi-asserted-by": "crossref", "first-page": "3514", "DOI": "10.1210/en.2010-0138", "volume": "151", "author": "K Evaul", "year": "2010", "unstructured": "Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. 3beta-Hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology. 2010;151:3514\u201320.", "journal-title": "Endocrinology"}, {"key": "759_CR61", "doi-asserted-by": "crossref", "first-page": "347", "DOI": "10.1038/nature14406", "volume": "523", "author": "Z Li", "year": "2015", "unstructured": "Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ, Sharifi N. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523:347\u201351.", "journal-title": "Nature"}, {"key": "759_CR62", "doi-asserted-by": "crossref", "first-page": "344", "DOI": "10.1038/nm.3830", "volume": "21", "author": "R Malik", "year": "2015", "unstructured": "Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum AK, Mellacheruvu D, Nesvizhskii AI, Cao X, Dhanasekaran SM, Feng FY, Grembecka J, Cierpicki T, Chinnaiyan AM. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015;21:344\u201352.", "journal-title": "Nat Med"}, {"key": "759_CR63", "doi-asserted-by": "crossref", "first-page": "e30062", "DOI": "10.1371/journal.pone.0030062", "volume": "7", "author": "EA Mostaghel", "year": "2012", "unstructured": "Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS ONE. 2012;7:e30062.", "journal-title": "PLoS ONE"}, {"key": "759_CR64", "doi-asserted-by": "crossref", "first-page": "619", "DOI": "10.1158/1055-9965.EPI-10-1023", "volume": "20", "author": "JL Wright", "year": "2011", "unstructured": "Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL, Mostaghel EA. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomark Prev. 2011;20:619\u201327.", "journal-title": "Cancer Epidemiol Biomark Prev"}, {"key": "759_CR65", "doi-asserted-by": "crossref", "first-page": "2565", "DOI": "10.1200/JCO.2010.31.2405", "volume": "29", "author": "M Yang", "year": "2011", "unstructured": "Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011;29:2565\u201373.", "journal-title": "J Clin Oncol"}, {"key": "759_CR66", "doi-asserted-by": "crossref", "first-page": "5458", "DOI": "10.1073/pnas.96.10.5458", "volume": "96", "author": "S Yeh", "year": "1999", "unstructured": "Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA. 1999;96:5458\u201363.", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "759_CR67", "doi-asserted-by": "crossref", "first-page": "1590", "DOI": "10.1158/1078-0432.CCR-13-1863", "volume": "20", "author": "Z Yu", "year": "2014", "unstructured": "Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014;20:1590\u2013600.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR68", "doi-asserted-by": "crossref", "first-page": "507", "DOI": "10.1016/j.critrevonc.2015.07.005", "volume": "96", "author": "L Chang", "year": "2015", "unstructured": "Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ, Li Y. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol. 2015;96:507\u201317.", "journal-title": "Crit Rev Oncol Hematol"}, {"key": "759_CR69", "doi-asserted-by": "crossref", "first-page": "128", "DOI": "10.1038/nm0202-128", "volume": "8", "author": "M Guba", "year": "2002", "unstructured": "Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128\u201335.", "journal-title": "Nat Med"}, {"key": "759_CR70", "doi-asserted-by": "crossref", "first-page": "128", "DOI": "10.1186/s13045-015-0225-2", "volume": "8", "author": "MT Schweizer", "year": "2015", "unstructured": "Schweizer MT, Yu EY. Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol. 2015;8:128.", "journal-title": "J Hematol Oncol"}, {"key": "759_CR71", "doi-asserted-by": "crossref", "first-page": "3705", "DOI": "10.1200/JCO.2013.53.4578", "volume": "32", "author": "ME Taplin", "year": "2014", "unstructured": "Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, Sanda MG, Davis JW, Loda M, True LD, Troncoso P, Ye H, Lis RT, Marck BT, Matsumoto AM, Balk SP, Mostaghel EA, Penning TM, Nelson PS, Xie W, Jiang Z, Haqq CM, Tamae D, Tran N, Peng W, Kheoh T, Molina A, Kantoff PW. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32:3705\u201315.", "journal-title": "J Clin Oncol"}, {"key": "759_CR72", "doi-asserted-by": "crossref", "first-page": "229", "DOI": "10.1200/JCO.2012.48.6431", "volume": "32", "author": "EA Mostaghel", "year": "2014", "unstructured": "Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter RM, Gulati R, Montgomery B. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014;32:229\u201337.", "journal-title": "J Clin Oncol"}, {"key": "759_CR73", "doi-asserted-by": "crossref", "first-page": "332", "DOI": "10.1016/j.cbi.2014.12.012", "volume": "234", "author": "D Tamae", "year": "2015", "unstructured": "Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin ME, Penning TM. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact. 2015;234:332\u20138.", "journal-title": "Chem Biol Interact"}, {"key": "759_CR74", "doi-asserted-by": "crossref", "first-page": "1413", "DOI": "10.1158/0008-5472.CAN-14-3080", "volume": "75", "author": "C Liu", "year": "2015", "unstructured": "Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res. 2015;75:1413\u201322.", "journal-title": "Cancer Res"}, {"key": "759_CR75", "doi-asserted-by": "crossref", "first-page": "3312", "DOI": "10.1158/1078-0432.CCR-07-4118", "volume": "14", "author": "A Hamada", "year": "2008", "unstructured": "Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008;14:3312\u20138.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR76", "doi-asserted-by": "crossref", "first-page": "495", "DOI": "10.1001/jamaoncol.2015.0829", "volume": "1", "author": "LC Harshman", "year": "2015", "unstructured": "Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, Yu Y, Kantoff AM, Sweeney CJ, Mucci LA, Pomerantz M, Lee GS, Kantoff PW. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1:495\u2013504.", "journal-title": "JAMA Oncol"}, {"key": "759_CR77", "doi-asserted-by": "crossref", "first-page": "16", "DOI": "10.1158/0008-5472.CAN-08-2764", "volume": "69", "author": "R Hu", "year": "2009", "unstructured": "Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69:16\u201322.", "journal-title": "Cancer Res"}, {"key": "759_CR78", "doi-asserted-by": "crossref", "first-page": "T87", "DOI": "10.1530/ERC-13-0470", "volume": "21", "author": "KE Ware", "year": "2014", "unstructured": "Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer. 2014;21:T87\u2013103.", "journal-title": "Endocr Relat Cancer"}, {"key": "759_CR79", "doi-asserted-by": "crossref", "first-page": "53", "DOI": "10.1016/j.eururo.2014.05.005", "volume": "67", "author": "E Efstathiou", "year": "2015", "unstructured": "Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015;67:53\u201360.", "journal-title": "Eur Urol"}, {"key": "759_CR80", "doi-asserted-by": "crossref", "first-page": "535", "DOI": "10.1016/j.ccr.2010.04.027", "volume": "17", "author": "RJ Andersen", "year": "2010", "unstructured": "Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Banuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell. 2010;17:535\u201346.", "journal-title": "Cancer Cell"}, {"key": "759_CR81", "doi-asserted-by": "crossref", "first-page": "2715", "DOI": "10.1172/JCI41824", "volume": "120", "author": "S Sun", "year": "2010", "unstructured": "Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120:2715\u201330.", "journal-title": "J Clin Invest"}, {"key": "759_CR82", "doi-asserted-by": "crossref", "first-page": "3811", "DOI": "10.18632/oncotarget.2924", "volume": "6", "author": "LJ Brand", "year": "2015", "unstructured": "Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA, Dehm SM. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015;6:3811\u201324.", "journal-title": "Oncotarget"}, {"key": "759_CR83", "doi-asserted-by": "crossref", "first-page": "2948", "DOI": "10.1172/JCI66398", "volume": "123", "author": "JK Myung", "year": "2013", "unstructured": "Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013;123:2948\u201360.", "journal-title": "J Clin Invest"}, {"key": "759_CR84", "doi-asserted-by": "crossref", "first-page": "6458", "DOI": "10.1021/jm500802j", "volume": "57", "author": "H Li", "year": "2014", "unstructured": "Li H, Ban F, Dalal K, Leblanc E, Frewin K, Ma D, Adomat H, Rennie PS, Cherkasov A. Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor. J Med Chem. 2014;57:6458\u201367.", "journal-title": "J Med Chem"}, {"key": "759_CR85", "unstructured": "Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM. BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol Cancer Res. 2016.", "DOI": "10.1158/1541-7786.MCR-15-0472", "doi-asserted-by": "crossref"}, {"key": "759_CR86", "doi-asserted-by": "crossref", "first-page": "1356", "DOI": "10.1158/1078-0432.CCR-15-1432", "volume": "22", "author": "B Montgomery", "year": "2016", "unstructured": "Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, Stephenson JJ, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME. Androgen receptor modulation optimized for response (ARMOR) Phase I and II studies: galeterone for the treatment of castration-resistant prostate cancer. Clin Cancer Res. 2016;22:1356-63.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR87", "doi-asserted-by": "crossref", "first-page": "3777", "DOI": "10.1074/jbc.M111.261933", "volume": "287", "author": "HS Soifer", "year": "2012", "unstructured": "Soifer HS, Souleimanian N, Wu S, Voskresenskiy AM, Collak FK, Cinar B, Stein CA. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem. 2012;287:3777\u201387.", "journal-title": "J Biol Chem"}, {"key": "759_CR88", "doi-asserted-by": "crossref", "first-page": "2348", "DOI": "10.1158/1535-7163.MCT-08-0230", "volume": "7", "author": "T Vasaitis", "year": "2008", "unstructured": "Vasaitis T, Belosay A, Schayowitz A, Khandelwal A, Chopra P, Gediya LK, Guo Z, Fang HB, Njar VC, Brodie AM. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther. 2008;7:2348\u201357.", "journal-title": "Mol Cancer Ther"}, {"key": "759_CR89", "doi-asserted-by": "crossref", "first-page": "4075", "DOI": "10.1158/1078-0432.CCR-14-0292", "volume": "20", "author": "Z Yu", "year": "2014", "unstructured": "Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res. 2014;20:4075\u201385.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR90", "doi-asserted-by": "crossref", "first-page": "2077", "DOI": "10.1021/jm501239f", "volume": "58", "author": "VC Njar", "year": "2015", "unstructured": "Njar VC, Brodie AM. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem. 2015;58:2077\u201387.", "journal-title": "J Med Chem"}, {"key": "759_CR91", "doi-asserted-by": "crossref", "first-page": "27440", "DOI": "10.18632/oncotarget.4578", "volume": "6", "author": "AK Kwegyir-Afful", "year": "2015", "unstructured": "Kwegyir-Afful AK, Ramalingam S, Purushottamachar P, Ramamurthy VP, Njar VC. Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo. Oncotarget. 2015;6:27440\u201360.", "journal-title": "Oncotarget"}, {"key": "759_CR92", "unstructured": "Kajiwara D, Minamiguchi K, Seki M, Mizutani H, Aoyagi H, Okajima S, Sasaki E, Utsugi T, Iwasawa Y. Effect of a new type androgen receptor antagonist, TAS3681, on ligand-independent AR activation through its AR downregulation activity. J Clin Oncol. 2016;34(2_suppl) (2016 Genitourinary Cancers Symposium).", "DOI": "10.1200/jco.2016.34.2_suppl.199", "doi-asserted-by": "crossref"}, {"key": "759_CR93", "doi-asserted-by": "crossref", "first-page": "e10", "DOI": "10.1016/S1470-2045(14)71165-9", "volume": "16", "author": "F Yaqub", "year": "2015", "unstructured": "Yaqub F. Galeterone activity in castration-resistant prostate cancer. Lancet Oncol. 2015;16:e10.", "journal-title": "Lancet Oncol"}, {"key": "759_CR94", "doi-asserted-by": "crossref", "first-page": "3198", "DOI": "10.1158/1078-0432.CCR-13-3296", "volume": "20", "author": "C Liu", "year": "2014", "unstructured": "Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014;20:3198\u2013210.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR95", "doi-asserted-by": "crossref", "first-page": "245", "DOI": "10.1016/0163-7258(82)90064-X", "volume": "19", "author": "P Andrews", "year": "1982", "unstructured": "Andrews P, Thyssen J, Lorke D. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19:245\u201395.", "journal-title": "Pharmacol Ther"}, {"key": "759_CR96", "doi-asserted-by": "crossref", "first-page": "1494", "DOI": "10.1158/0008-5472.CAN-11-3948", "volume": "72", "author": "NJ Clegg", "year": "2012", "unstructured": "Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72:1494\u2013503.", "journal-title": "Cancer Res"}, {"key": "759_CR97", "doi-asserted-by": "crossref", "first-page": "3525", "DOI": "10.1200/JCO.2013.50.1684", "volume": "31", "author": "DE Rathkopf", "year": "2013", "unstructured": "Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Maneval EC, Chen I, Gonen M, Fleisher M, Larson SM, Sawyers CL, Scher HI. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31:3525\u201330.", "journal-title": "J Clin Oncol"}, {"key": "759_CR98", "doi-asserted-by": "crossref", "first-page": "975", "DOI": "10.1016/S1470-2045(14)70240-2", "volume": "15", "author": "K Fizazi", "year": "2014", "unstructured": "Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M, ARADES study group. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15:975\u201385.", "journal-title": "Lancet Oncol"}, {"key": "759_CR99", "doi-asserted-by": "crossref", "first-page": "2881", "DOI": "10.1093/annonc/mdt335", "volume": "24", "author": "MT Schweizer", "year": "2013", "unstructured": "Schweizer MT, Zhou XC, Wang H, Yang T, Shaukat F, Partin AW, Eisenberger MA, Antonarakis ES. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol. 2013;24:2881\u20136.", "journal-title": "Ann Oncol"}, {"key": "759_CR100", "doi-asserted-by": "crossref", "first-page": "723", "DOI": "10.1200/JCO.2014.56.5119", "volume": "33", "author": "K Fizazi", "year": "2015", "unstructured": "Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol. 2015;33:723\u201331.", "journal-title": "J Clin Oncol"}, {"key": "759_CR101", "doi-asserted-by": "crossref", "first-page": "338", "DOI": "10.1016/S1470-2045(15)70027-6", "volume": "16", "author": "F Saad", "year": "2015", "unstructured": "Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R, ELM-PC 4 Investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015;16:338\u201348.", "journal-title": "Lancet Oncol"}, {"key": "759_CR102", "doi-asserted-by": "crossref", "first-page": "59", "DOI": "10.1158/1535-7163.MCT-14-0521", "volume": "14", "author": "PJ Toren", "year": "2015", "unstructured": "Toren PJ, Kim S, Pham S, Mangalji A, Adomat H, Guns ES, Zoubeidi A, Moore W, Gleave ME. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther. 2015;14:59\u201369.", "journal-title": "Mol Cancer Ther"}, {"key": "759_CR103", "unstructured": "Maity SN, Titus M, Wu G, Lu J-F, Ramachandran S, Eisner JR, Rafferty SW, Schotzinger RJ, Moore WR, Logothetis CJ, Araujo JC, Efstathiou E. Efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20 lyase, in castrate-resistant prostate cancer. 2013.", "DOI": "10.1158/1538-7445.AM2013-4772", "doi-asserted-by": "crossref"}, {"key": "759_CR104", "doi-asserted-by": "crossref", "first-page": "909", "DOI": "10.1007/s00280-013-2250-6", "volume": "72", "author": "HJ Meulenbeld", "year": "2013", "unstructured": "Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR, de Wit R. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemother Pharmacol. 2013;72:909\u201316.", "journal-title": "Cancer Chemother Pharmacol"}, {"key": "759_CR105", "doi-asserted-by": "crossref", "first-page": "2399", "DOI": "10.1093/annonc/mds011", "volume": "23", "author": "B Markman", "year": "2012", "unstructured": "Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Cuero MM, Stutvoet S, Birle D, Anak O, Hackl W, Baselga J. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012;23:2399\u2013408.", "journal-title": "Ann Oncol"}, {"key": "759_CR106", "doi-asserted-by": "crossref", "first-page": "1729", "DOI": "10.1111/j.1464-410X.2012.11456.x", "volume": "110", "author": "M Nakabayashi", "year": "2012", "unstructured": "Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012;110:1729\u201335.", "journal-title": "BJU Int"}, {"key": "759_CR107", "doi-asserted-by": "crossref", "first-page": "150", "DOI": "10.1016/j.eururo.2013.03.040", "volume": "64", "author": "AJ Templeton", "year": "2013", "unstructured": "Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bartschi D, Droge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Muller B, Schiess R, Wild PJ, Ruschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol. 2013;64:150\u20138.", "journal-title": "Eur Urol"}, {"key": "759_CR108", "doi-asserted-by": "crossref", "first-page": "397", "DOI": "10.1016/j.clgc.2013.05.007", "volume": "11", "author": "AJ Armstrong", "year": "2013", "unstructured": "Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, Embree E, Morris K, Winters C, Jaffe T, Fleming M, George DJ. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer. 2013;11:397\u2013406.", "journal-title": "Clin Genitourin Cancer"}, {"key": "759_CR109", "doi-asserted-by": "crossref", "first-page": "10040", "DOI": "10.1158/0008-5472.CAN-06-0802", "volume": "66", "author": "C Cao", "year": "2006", "unstructured": "Cao C, Subhawong T, Albert JM, Kim KW, Geng L, Sekhar KR, Gi YJ, Lu B. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res. 2006;66:10040\u20137.", "journal-title": "Cancer Res"}, {"key": "759_CR110", "doi-asserted-by": "crossref", "first-page": "594", "DOI": "10.1038/nm1052", "volume": "10", "author": "PK Majumder", "year": "2004", "unstructured": "Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594\u2013601.", "journal-title": "Nat Med"}, {"key": "759_CR111", "doi-asserted-by": "crossref", "first-page": "861", "DOI": "10.1002/pros.20752", "volume": "68", "author": "TM Morgan", "year": "2008", "unstructured": "Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate. 2008;68:861\u201371.", "journal-title": "Prostate"}, {"key": "759_CR112", "doi-asserted-by": "crossref", "first-page": "209", "DOI": "10.1016/S1535-6108(03)00215-0", "volume": "4", "author": "S Wang", "year": "2003", "unstructured": "Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS, Liu X, Wu H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003;4:209\u201321.", "journal-title": "Cancer Cell"}, {"key": "759_CR113", "doi-asserted-by": "crossref", "first-page": "575", "DOI": "10.1016/j.ccr.2011.04.008", "volume": "19", "author": "BS Carver", "year": "2011", "unstructured": "Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575\u201386.", "journal-title": "Cancer Cell"}, {"key": "759_CR114", "doi-asserted-by": "crossref", "first-page": "7106", "DOI": "10.1038/onc.2008.318", "volume": "27", "author": "Y Wang", "year": "2008", "unstructured": "Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008;27:7106\u201317.", "journal-title": "Oncogene"}, {"key": "759_CR115", "doi-asserted-by": "crossref", "first-page": "55", "DOI": "10.1038/nature10912", "volume": "485", "author": "AC Hsieh", "year": "2012", "unstructured": "Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, Wang S, Ren P, Martin M, Jessen K, Feldman ME, Weissman JS, Shokat KM, Rommel C, Ruggero D. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485:55\u201361.", "journal-title": "Nature"}, {"key": "759_CR116", "doi-asserted-by": "crossref", "first-page": "159", "DOI": "10.1016/j.molcel.2006.03.029", "volume": "22", "author": "DD Sarbassov", "year": "2006", "unstructured": "Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159\u201368.", "journal-title": "Mol Cell"}, {"key": "759_CR117", "doi-asserted-by": "crossref", "first-page": "1601", "DOI": "10.1200/JCO.2014.59.4127", "volume": "33", "author": "EY Yu", "year": "2015", "unstructured": "Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr. SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2015;33:1601\u20138.", "journal-title": "J Clin Oncol"}, {"key": "759_CR118", "doi-asserted-by": "crossref", "first-page": "1714", "DOI": "10.1016/j.ejca.2015.05.019", "volume": "51", "author": "M Hussain", "year": "2015", "unstructured": "Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. Eur J Cancer. 2015;51:1714\u201324.", "journal-title": "Eur J Cancer"}, {"key": "759_CR119", "doi-asserted-by": "crossref", "first-page": "269", "DOI": "10.3816/CGC.2006.n.006", "volume": "4", "author": "PA Humphrey", "year": "2006", "unstructured": "Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 2006;4:269\u201374.", "journal-title": "Clin Genitourin Cancer"}, {"key": "759_CR120", "doi-asserted-by": "crossref", "first-page": "1325", "DOI": "10.1016/S0022-5347(01)69893-8", "volume": "165", "author": "M Naughton", "year": "2001", "unstructured": "Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol. 2001;165:1325\u20138.", "journal-title": "J Urol"}, {"key": "759_CR121", "doi-asserted-by": "crossref", "first-page": "215", "DOI": "10.1158/1078-0432.CCR-12-2605", "volume": "19", "author": "CJ Ryan", "year": "2013", "unstructured": "Ryan CJ, Rosenthal M, Ng S, Alumkal J, Picus J, Gravis G, Fizazi K, Forget F, Machiels JP, Srinivas S, Zhu M, Tang R, Oliner KS, Jiang Y, Loh E, Dubey S, Gerritsen WR. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013;19:215\u201324.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR122", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1016/j.neo.2015.11.009", "volume": "18", "author": "Y Qiao", "year": "2016", "unstructured": "Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM. Mechanistic support for combined MET and AR blockade in castration-resistant prostate cancer. Neoplasia. 2016;18:1\u20139.", "journal-title": "Neoplasia"}, {"key": "759_CR123", "doi-asserted-by": "crossref", "first-page": "1001", "DOI": "10.1517/13543780902997928", "volume": "18", "author": "RA Madan", "year": "2009", "unstructured": "Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001\u201311.", "journal-title": "Expert Opin Investig Drugs"}, {"key": "759_CR124", "doi-asserted-by": "crossref", "first-page": "641", "DOI": "10.1007/s10555-013-9479-8", "volume": "33", "author": "MT Schweizer", "year": "2014", "unstructured": "Schweizer MT, Drake CG. Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev. 2014;33:641\u201355.", "journal-title": "Cancer Metastasis Rev"}, {"key": "759_CR125", "doi-asserted-by": "crossref", "first-page": "580", "DOI": "10.1038/nri2817", "volume": "10", "author": "CG Drake", "year": "2010", "unstructured": "Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580\u201393.", "journal-title": "Nat Rev Immunol"}, {"key": "759_CR126", "doi-asserted-by": "crossref", "first-page": "3394", "DOI": "10.1158/1078-0432.CCR-06-0145", "volume": "12", "author": "JW Simons", "year": "2006", "unstructured": "Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006;12:3394\u2013401.", "journal-title": "Clin Cancer Res"}, {"key": "759_CR127", "doi-asserted-by": "crossref", "first-page": "639", "DOI": "10.1097/CJI.0b013e3181dda23e", "volume": "33", "author": "JT Becker", "year": "2010", "unstructured": "Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother. 2010;33:639\u201347.", "journal-title": "J Immunother"}, {"key": "759_CR128", "doi-asserted-by": "crossref", "first-page": "4047", "DOI": "10.1200/JCO.2008.19.9968", "volume": "27", "author": "DG McNeel", "year": "2009", "unstructured": "McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol. 2009;27:4047\u201354.", "journal-title": "J Clin Oncol"}, {"key": "759_CR129", "doi-asserted-by": "crossref", "first-page": "700", "DOI": "10.1016/S1470-2045(14)70189-5", "volume": "15", "author": "ED Kwon", "year": "2014", "unstructured": "Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700\u201312.", "journal-title": "Lancet Oncol"}, {"key": "759_CR130", "doi-asserted-by": "crossref", "first-page": "311", "DOI": "10.1056/NEJMoa1411087", "volume": "372", "author": "SM Ansell", "year": "2015", "unstructured": "Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.", "journal-title": "N Engl J Med"}, {"key": "759_CR131", "doi-asserted-by": "crossref", "first-page": "123", "DOI": "10.1056/NEJMoa1504627", "volume": "373", "author": "J Brahmer", "year": "2015", "unstructured": "Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Aren Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123\u201335.", "journal-title": "N Engl J Med"}, {"key": "759_CR132", "doi-asserted-by": "crossref", "first-page": "2018", "DOI": "10.1056/NEJMoa1501824", "volume": "372", "author": "EB Garon", "year": "2015", "unstructured": "Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u201328.", "journal-title": "N Engl J Med"}, {"key": "759_CR133", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1056/NEJMoa1504030", "volume": "373", "author": "J Larkin", "year": "2015", "unstructured": "Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.", "journal-title": "N Engl J Med"}, {"key": "759_CR134", "doi-asserted-by": "crossref", "first-page": "2509", "DOI": "10.1056/NEJMoa1500596", "volume": "372", "author": "DT Le", "year": "2015", "unstructured": "Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509\u201320.", "journal-title": "N Engl J Med"}, {"key": "759_CR135", "doi-asserted-by": "crossref", "first-page": "2521", "DOI": "10.1056/NEJMoa1503093", "volume": "372", "author": "C Robert", "year": "2015", "unstructured": "Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A, KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.", "journal-title": "N Engl J Med"}, {"key": "759_CR136", "doi-asserted-by": "crossref", "first-page": "2443", "DOI": "10.1056/NEJMoa1200690", "volume": "366", "author": "SL Topalian", "year": "2012", "unstructured": "Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.", "journal-title": "N Engl J Med"}, {"key": "759_CR137", "doi-asserted-by": "crossref", "first-page": "2189", "DOI": "10.1056/NEJMoa1406498", "volume": "371", "author": "A Snyder", "year": "2014", "unstructured": "Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189\u201399.", "journal-title": "N Engl J Med"}, {"key": "759_CR138", "doi-asserted-by": "crossref", "first-page": "1546", "DOI": "10.1126/science.1235122", "volume": "339", "author": "B Vogelstein", "year": "2013", "unstructured": "Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339:1546\u201358.", "journal-title": "Science"}, {"key": "759_CR139", "doi-asserted-by": "crossref", "first-page": "4988", "DOI": "10.1038/ncomms5988", "volume": "5", "author": "CC Pritchard", "year": "2014", "unstructured": "Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, Salipante SJ, Milbank J, Yu M, Grady WM, Tait JF, Corey E, Vessella RL, Walsh T, Shendure J, Nelson PS. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun. 2014;5:4988.", "journal-title": "Nat Commun"}], "container-title": ["Medical Oncology"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/s12032-016-0759-3.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/s12032-016-0759-3/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s12032-016-0759-3", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 6]], "date-time": "2019-09-06T07:17:05Z", "timestamp": 1567754225000}, "score": 33.971184, "issued": {"date-parts": [[2016, 4, 4]]}, "references-count": 139, "journal-issue": {"published-print": {"date-parts": [[2016, 5]]}, "issue": "5"}, "alternative-id": ["759"], "URL": "http://dx.doi.org/10.1007/s12032-016-0759-3", "relation": {"cites": []}, "ISSN": ["1357-0560", "1559-131X"], "issn-type": [{"value": "1357-0560", "type": "print"}, {"value": "1559-131X", "type": "electronic"}], "article-number": "44"}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T18:19:47Z", "timestamp": 1574446787111}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "17", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Cancer Research"], "published-print": {"date-parts": [[2010, 9, 1]]}, "DOI": "10.1158/1078-0432.ccr-10-0255", "type": "journal-article", "created": {"date-parts": [[2010, 7, 21]], "date-time": "2010-07-21T03:56:42Z", "timestamp": 1279684602000}, "page": "4319-4324", "source": "Crossref", "is-referenced-by-count": 44, "title": ["Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer"], "prefix": "10.1158", "volume": "16", "author": [{"given": "M.", "family": "Yamaoka", "sequence": "first", "affiliation": []}, {"given": "T.", "family": "Hara", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "Kusaka", "sequence": "additional", "affiliation": []}], "member": "1086", "published-online": {"date-parts": [[2010, 7, 20]]}, "container-title": ["Clinical Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-10-0255", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T11:51:03Z", "timestamp": 1482493863000}, "score": 29.821867, "issued": {"date-parts": [[2010, 7, 20]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2010, 8, 31]]}, "published-print": {"date-parts": [[2010, 9, 1]]}, "issue": "17"}, "URL": "http://dx.doi.org/10.1158/1078-0432.ccr-10-0255", "ISSN": ["1078-0432", "1557-3265"], "issn-type": [{"value": "1078-0432", "type": "print"}, {"value": "1557-3265", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T04:43:07Z", "timestamp": 1574743387296}, "reference-count": 159, "publisher": "Springer Science and Business Media LLC", "issue": "1", "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["J Hematol Oncol"], "published-print": {"date-parts": [[2015, 12]]}, "DOI": "10.1186/s13045-015-0225-2", "type": "journal-article", "created": {"date-parts": [[2015, 11, 13]], "date-time": "2015-11-13T14:12:38Z", "timestamp": 1447423958000}, "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 28, "title": ["Persistent androgen receptor addiction in castration-resistant prostate cancer"], "prefix": "10.1186", "volume": "8", "author": [{"given": "Michael T.", "family": "Schweizer", "sequence": "first", "affiliation": []}, {"given": "Evan Y.", "family": "Yu", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2015, 11, 13]]}, "reference": [{"issue": "2 Pt 2", "key": "225_CR1", "doi-asserted-by": "crossref", "first-page": "948", "DOI": "10.1016/S0022-5347(02)80307-X", "volume": "167", "author": "C Huggins", "year": "2002", "unstructured": "Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;167(2 Pt 2):948\u201351. discussion 952.", "journal-title": "J Urol"}, {"issue": "7", "key": "225_CR2", "doi-asserted-by": "crossref", "first-page": "1148", "DOI": "10.1200/JCO.2007.12.4487", "volume": "26", "author": "HI Scher", "year": "2008", "unstructured": "Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148\u201359.", "journal-title": "J Clin Oncol"}, {"key": "225_CR3", "unstructured": "Scher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, Basch EM, Fizazi K, Ryan CJ, Antonarakis ES, Corn PG, Liu G, De Bono JS, Schwartz LH, Beer TM, Kelly WK, Hussain M, Sartor AO, Kantoff PW, Armstrong AJ: The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). In: American Society Of Clinical Oncology Annual Meeting: 2015; Chicago, IL", "DOI": "10.1200/jco.2015.33.15_suppl.5000", "doi-asserted-by": "crossref"}, {"issue": "32", "key": "225_CR4", "doi-asserted-by": "crossref", "first-page": "8253", "DOI": "10.1200/JCO.2005.03.4777", "volume": "23", "author": "HI Scher", "year": "2005", "unstructured": "Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253\u201361.", "journal-title": "J Clin Oncol"}, {"key": "225_CR5", "doi-asserted-by": "crossref", "first-page": "424", "DOI": "10.1056/NEJMoa1405095", "volume": "371", "author": "TM Beer", "year": "2014", "unstructured": "Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.", "journal-title": "N Engl J Med"}, {"issue": "21", "key": "225_CR6", "doi-asserted-by": "crossref", "first-page": "1995", "DOI": "10.1056/NEJMoa1014618", "volume": "364", "author": "JS Bono de", "year": "2011", "unstructured": "de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.", "journal-title": "N Engl J Med"}, {"issue": "2", "key": "225_CR7", "doi-asserted-by": "crossref", "first-page": "138", "DOI": "10.1056/NEJMoa1209096", "volume": "368", "author": "CJ Ryan", "year": "2013", "unstructured": "Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348.", "journal-title": "N Engl J Med"}, {"issue": "13", "key": "225_CR8", "doi-asserted-by": "crossref", "first-page": "1187", "DOI": "10.1056/NEJMoa1207506", "volume": "367", "author": "HI Scher", "year": "2012", "unstructured": "Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397.", "journal-title": "N Engl J Med"}, {"issue": "11", "key": "225_CR9", "doi-asserted-by": "crossref", "first-page": "1028", "DOI": "10.1056/NEJMoa1315815", "volume": "371", "author": "ES Antonarakis", "year": "2014", "unstructured": "Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028\u201338.", "journal-title": "N Engl J Med"}, {"issue": "7504", "key": "225_CR10", "doi-asserted-by": "crossref", "first-page": "278", "DOI": "10.1038/nature13229", "volume": "510", "author": "IA Asangani", "year": "2014", "unstructured": "Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510(7504):278\u201382.", "journal-title": "Nature"}, {"issue": "254", "key": "225_CR11", "doi-asserted-by": "crossref", "first-page": "254ra125", "DOI": "10.1126/scitranslmed.3009448", "volume": "6", "author": "S Carreira", "year": "2014", "unstructured": "Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014;6(254):254ra125.", "journal-title": "Sci Transl Med"}, {"issue": "5", "key": "225_CR12", "doi-asserted-by": "crossref", "first-page": "1074", "DOI": "10.1016/j.cell.2013.07.029", "volume": "154", "author": "KH Chang", "year": "2013", "unstructured": "Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell. 2013;154(5):1074\u201384.", "journal-title": "Cell"}, {"issue": "1", "key": "225_CR13", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.1038/nm972", "volume": "10", "author": "CD Chen", "year": "2004", "unstructured": "Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33\u20139.", "journal-title": "Nat Med"}, {"issue": "11", "key": "225_CR14", "doi-asserted-by": "crossref", "first-page": "4124", "DOI": "10.1210/en.2014-1337", "volume": "155", "author": "E Cho", "year": "2014", "unstructured": "Cho E, Montgomery RB, Mostaghel EA. Minireview: SLCO and ABC transporters: a role for steroid transport in prostate cancer progression. Endocrinology. 2014;155(11):4124\u201332.", "journal-title": "Endocrinology"}, {"issue": "49", "key": "225_CR15", "doi-asserted-by": "crossref", "first-page": "E4762", "DOI": "10.1073/pnas.1319948110", "volume": "110", "author": "JM Drake", "year": "2013", "unstructured": "Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A. 2013;110(49):E4762\u20134769.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "8", "key": "225_CR16", "doi-asserted-by": "crossref", "first-page": "3514", "DOI": "10.1210/en.2010-0138", "volume": "151", "author": "K Evaul", "year": "2010", "unstructured": "Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology. 2010;151(8):3514\u201320.", "journal-title": "Endocrinology"}, {"issue": "7560", "key": "225_CR17", "doi-asserted-by": "crossref", "first-page": "347", "DOI": "10.1038/nature14406", "volume": "523", "author": "Z Li", "year": "2015", "unstructured": "Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature. 2015;523(7560):347\u201351.", "journal-title": "Nature"}, {"issue": "4", "key": "225_CR18", "doi-asserted-by": "crossref", "first-page": "344", "DOI": "10.1038/nm.3830", "volume": "21", "author": "R Malik", "year": "2015", "unstructured": "Malik R, Khan AP, Asangani IA, Cieslik M, Prensner JR, Wang X, et al. Targeting the MLL complex in castration-resistant prostate cancer. Nat Med. 2015;21(4):344\u201352.", "journal-title": "Nat Med"}, {"issue": "11", "key": "225_CR19", "doi-asserted-by": "crossref", "first-page": "4447", "DOI": "10.1158/0008-5472.CAN-08-0249", "volume": "68", "author": "RB Montgomery", "year": "2008", "unstructured": "Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447\u201354.", "journal-title": "Cancer Res"}, {"issue": "18", "key": "225_CR20", "doi-asserted-by": "crossref", "first-page": "5913", "DOI": "10.1158/1078-0432.CCR-11-0728", "volume": "17", "author": "EA Mostaghel", "year": "2011", "unstructured": "Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17(18):5913\u201325.", "journal-title": "Clin Cancer Res"}, {"issue": "1", "key": "225_CR21", "doi-asserted-by": "crossref", "first-page": "e30062", "DOI": "10.1371/journal.pone.0030062", "volume": "7", "author": "EA Mostaghel", "year": "2012", "unstructured": "Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One. 2012;7(1):e30062.", "journal-title": "PLoS One"}, {"issue": "4", "key": "225_CR22", "doi-asserted-by": "crossref", "first-page": "619", "DOI": "10.1158/1055-9965.EPI-10-1023", "volume": "20", "author": "JL Wright", "year": "2011", "unstructured": "Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, et al. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev. 2011;20(4):619\u201327.", "journal-title": "Cancer Epidemiol Biomarkers Prev"}, {"issue": "18", "key": "225_CR23", "doi-asserted-by": "crossref", "first-page": "2565", "DOI": "10.1200/JCO.2010.31.2405", "volume": "29", "author": "M Yang", "year": "2011", "unstructured": "Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011;29(18):2565\u201373.", "journal-title": "J Clin Oncol"}, {"issue": "10", "key": "225_CR24", "doi-asserted-by": "crossref", "first-page": "5458", "DOI": "10.1073/pnas.96.10.5458", "volume": "96", "author": "S Yeh", "year": "1999", "unstructured": "Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A. 1999;96(10):5458\u201363.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "6", "key": "225_CR25", "doi-asserted-by": "crossref", "first-page": "1590", "DOI": "10.1158/1078-0432.CCR-13-1863", "volume": "20", "author": "Z Yu", "year": "2014", "unstructured": "Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, et al. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 2014;20(6):1590\u2013600.", "journal-title": "Clin Cancer Res"}, {"issue": "1", "key": "225_CR26", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1038/aps.2014.18", "volume": "36", "author": "MH Tan", "year": "2015", "unstructured": "Tan MH, Li J, Xu HE, Melcher K, Yong EL. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 2015;36(1):3\u201323.", "journal-title": "Acta Pharmacol Sin"}, {"issue": "3", "key": "225_CR27", "first-page": "178", "volume": "2", "author": "C Lu", "year": "2013", "unstructured": "Lu C, Luo J. Decoding the androgen receptor splice variants. Transl Andrology Urol. 2013;2(3):178\u201386.", "journal-title": "Transl Andrology Urol"}, {"issue": "4", "key": "225_CR28", "doi-asserted-by": "crossref", "first-page": "T131", "DOI": "10.1530/ERC-13-0472", "volume": "21", "author": "Y Koryakina", "year": "2014", "unstructured": "Koryakina Y, Ta HQ, Gioeli D. Androgen receptor phosphorylation: biological context and functional consequences. Endocr Relat Cancer. 2014;21(4):T131\u2013145.", "journal-title": "Endocr Relat Cancer"}, {"issue": "8", "key": "225_CR29", "doi-asserted-by": "crossref", "first-page": "593", "DOI": "10.1038/nrc1947", "volume": "6", "author": "LA Garraway", "year": "2006", "unstructured": "Garraway LA, Sellers WR. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer. 2006;6(8):593\u2013602.", "journal-title": "Nat Rev Cancer"}, {"issue": "6", "key": "225_CR30", "doi-asserted-by": "crossref", "first-page": "644", "DOI": "10.1200/JCO.2011.39.1300", "volume": "30", "author": "PS Nelson", "year": "2012", "unstructured": "Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol. 2012;30(6):644\u20136.", "journal-title": "J Clin Oncol"}, {"issue": "5", "key": "225_CR31", "doi-asserted-by": "crossref", "first-page": "1215", "DOI": "10.1016/j.cell.2015.05.001", "volume": "161", "author": "D Robinson", "year": "2015", "unstructured": "Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215\u201328.", "journal-title": "Cell"}, {"issue": "2", "key": "225_CR32", "doi-asserted-by": "crossref", "first-page": "152", "DOI": "10.1016/S1470-2045(14)71205-7", "volume": "16", "author": "CJ Ryan", "year": "2015", "unstructured": "Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152\u201360.", "journal-title": "Lancet Oncol"}, {"issue": "10", "key": "225_CR33", "doi-asserted-by": "crossref", "first-page": "1717", "DOI": "10.1038/bjc.2015.128", "volume": "112", "author": "S Salvi", "year": "2015", "unstructured": "Salvi S, Casadio V, Conteduca V, Burgio SL, Menna C, Bianchi E, et al. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br J Cancer. 2015;112(10):1717\u201324.", "journal-title": "Br J Cancer"}, {"issue": "10", "key": "225_CR34", "doi-asserted-by": "crossref", "first-page": "2315", "DOI": "10.1158/1078-0432.CCR-14-2666", "volume": "21", "author": "AA Azad", "year": "2015", "unstructured": "Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 2015;21(10):2315\u201324.", "journal-title": "Clin Cancer Res"}, {"key": "225_CR35", "doi-asserted-by": "crossref", "first-page": "332", "DOI": "10.1016/j.cbi.2014.12.012", "volume": "234", "author": "D Tamae", "year": "2015", "unstructured": "Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, et al. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chem Biol Interact. 2015;234:332\u20138.", "journal-title": "Chem Biol Interact"}, {"issue": "33", "key": "225_CR36", "doi-asserted-by": "crossref", "first-page": "3705", "DOI": "10.1200/JCO.2013.53.4578", "volume": "32", "author": "ME Taplin", "year": "2014", "unstructured": "Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32(33):3705\u201315.", "journal-title": "J Clin Oncol"}, {"issue": "24", "key": "225_CR37", "doi-asserted-by": "crossref", "first-page": "9209", "DOI": "10.1158/0008-5472.CAN-04-2442", "volume": "64", "author": "RB Shah", "year": "2004", "unstructured": "Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res. 2004;64(24):9209\u201316.", "journal-title": "Cancer Res"}, {"issue": "10", "key": "225_CR38", "doi-asserted-by": "crossref", "first-page": "e111545", "DOI": "10.1371/journal.pone.0111545", "volume": "9", "author": "EA Mostaghel", "year": "2014", "unstructured": "Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, et al. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis. PLoS One. 2014;9(10):e111545.", "journal-title": "PLoS One"}, {"issue": "10", "key": "225_CR39", "doi-asserted-by": "crossref", "first-page": "5033", "DOI": "10.1158/0008-5472.CAN-06-3332", "volume": "67", "author": "EA Mostaghel", "year": "2007", "unstructured": "Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67(10):5033\u201341.", "journal-title": "Cancer Res"}, {"issue": "13", "key": "225_CR40", "doi-asserted-by": "crossref", "first-page": "4653", "DOI": "10.1158/1078-0432.CCR-05-0525", "volume": "11", "author": "MA Titus", "year": "2005", "unstructured": "Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11(13):4653\u20137.", "journal-title": "Clin Cancer Res"}, {"issue": "7", "key": "225_CR41", "doi-asserted-by": "crossref", "first-page": "1413", "DOI": "10.1158/0008-5472.CAN-14-3080", "volume": "75", "author": "C Liu", "year": "2015", "unstructured": "Liu C, Lou W, Zhu Y, Yang JC, Natiminty N, Gaikwad N, et al. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res. 2015;75(7):1413\u201322.", "journal-title": "Cancer Res"}, {"issue": "20", "key": "225_CR42", "doi-asserted-by": "crossref", "first-page": "6503", "DOI": "10.1158/0008-5472.CAN-11-0532", "volume": "71", "author": "C Cai", "year": "2011", "unstructured": "Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71(20):6503\u201313.", "journal-title": "Cancer Res"}, {"issue": "2", "key": "225_CR43", "first-page": "505", "volume": "63", "author": "JC Desmond", "year": "2003", "unstructured": "Desmond JC, Mountford JC, Drayson MT, Walker EA, Hewison M, Ride JP, et al. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res. 2003;63(2):505\u201312.", "journal-title": "Cancer Res"}, {"issue": "6", "key": "225_CR44", "doi-asserted-by": "crossref", "first-page": "2429", "DOI": "10.1021/jm3017656", "volume": "56", "author": "AJ Liedtke", "year": "2013", "unstructured": "Liedtke AJ, Adeniji AO, Chen M, Byrns MC, Jin Y, Christianson DW, et al. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. J Med Chem. 2013;56(6):2429\u201346.", "journal-title": "J Med Chem"}, {"issue": "11", "key": "225_CR45", "doi-asserted-by": "crossref", "first-page": "4010", "DOI": "10.1210/en.2013-1466", "volume": "154", "author": "N Sharifi", "year": "2013", "unstructured": "Sharifi N. Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology. 2013;154(11):4010\u20137.", "journal-title": "Endocrinology"}, {"issue": "11", "key": "225_CR46", "doi-asserted-by": "crossref", "first-page": "3312", "DOI": "10.1158/1078-0432.CCR-07-4118", "volume": "14", "author": "A Hamada", "year": "2008", "unstructured": "Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res. 2008;14(11):3312\u20138.", "journal-title": "Clin Cancer Res"}, {"issue": "5", "key": "225_CR47", "doi-asserted-by": "crossref", "first-page": "617", "DOI": "10.1111/j.1464-410X.2008.07629.x", "volume": "102", "author": "N Sharifi", "year": "2008", "unstructured": "Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int. 2008;102(5):617\u201321.", "journal-title": "BJU Int"}, {"key": "225_CR48", "unstructured": "Kantoff PW, Wang X, Xie W, Nakabayashi M, Pomerantz M, Lee GM: Genetic variants of the organic anion transporter SLCO2B1 as pharmacogenomic determinants of response to androgen deprivation therapy (ADT) for prostate cancer. In: Genitourinary Cancers Symposium: 2015; Orlando, FL.", "DOI": "10.1200/jco.2015.33.7_suppl.36", "doi-asserted-by": "crossref"}, {"key": "225_CR49", "unstructured": "Mostaghel EA, Wright JL, Kwon EM, Montgomery RB, Ostrander EA, Vessella R, Nelson P, Stanford JL: Genetic variation in SLCO2B1, SLCO1B3, and prostate cancer risk and mortality. In: Genitourinary Cancers Symposium: 2010; San Francisco, CA."}, {"issue": "4", "key": "225_CR50", "doi-asserted-by": "crossref", "first-page": "495", "DOI": "10.1001/jamaoncol.2015.0829", "volume": "1", "author": "LC Harshman", "year": "2015", "unstructured": "Harshman LC, Wang X, Nakabayashi M, Xie W, Valenca L, Werner L, et al. Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. JAMA Oncol. 2015;1(4):495\u2013504.", "journal-title": "JAMA Oncol"}, {"issue": "4", "key": "225_CR51", "doi-asserted-by": "crossref", "first-page": "428", "DOI": "10.1001/jamaoncol.2015.0833", "volume": "1", "author": "JD Ramos", "year": "2015", "unstructured": "Ramos JD, Yu EY. Progress in understanding what is being statin(ed) in prostate cancer. JAMA Oncol. 2015;1(4):428\u201330.", "journal-title": "JAMA Oncol"}, {"issue": "5", "key": "225_CR52", "doi-asserted-by": "crossref", "first-page": "753", "DOI": "10.1586/eem.10.49", "volume": "5", "author": "R Hu", "year": "2010", "unstructured": "Hu R, Denmeade SR, Luo J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab. 2010;5(5):753\u201364.", "journal-title": "Expert Rev Endocrinol Metab"}, {"issue": "13", "key": "225_CR53", "doi-asserted-by": "crossref", "first-page": "5469", "DOI": "10.1158/0008-5472.CAN-08-0594", "volume": "68", "author": "SM Dehm", "year": "2008", "unstructured": "Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68(13):5469\u201377.", "journal-title": "Cancer Res"}, {"issue": "1", "key": "225_CR54", "doi-asserted-by": "crossref", "first-page": "16", "DOI": "10.1158/0008-5472.CAN-08-2764", "volume": "69", "author": "R Hu", "year": "2009", "unstructured": "Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009;69(1):16\u201322.", "journal-title": "Cancer Res"}, {"issue": "8", "key": "225_CR55", "doi-asserted-by": "crossref", "first-page": "2715", "DOI": "10.1172/JCI41824", "volume": "120", "author": "S Sun", "year": "2010", "unstructured": "Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120(8):2715\u201330.", "journal-title": "J Clin Invest"}, {"issue": "8", "key": "225_CR56", "doi-asserted-by": "crossref", "first-page": "1629", "DOI": "10.1158/1535-7163.MCT-13-0027", "volume": "12", "author": "N Nadiminty", "year": "2013", "unstructured": "Nadiminty N, Tummala R, Liu C, Yang J, Lou W, Evans CP, et al. NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther. 2013;12(8):1629\u201337.", "journal-title": "Mol Cancer Ther"}, {"issue": "10", "key": "225_CR57", "doi-asserted-by": "crossref", "first-page": "970", "DOI": "10.1056/NEJMcibr1315706", "volume": "370", "author": "N Sharifi", "year": "2014", "unstructured": "Sharifi N. Steroid receptors aplenty in prostate cancer. N Engl J Med. 2014;370(10):970\u20131.", "journal-title": "N Engl J Med"}, {"issue": "6", "key": "225_CR58", "doi-asserted-by": "crossref", "first-page": "1309", "DOI": "10.1016/j.cell.2013.11.012", "volume": "155", "author": "VK Arora", "year": "2013", "unstructured": "Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell. 2013;155(6):1309\u201322.", "journal-title": "Cell"}, {"issue": "2", "key": "225_CR59", "doi-asserted-by": "crossref", "first-page": "72", "DOI": "10.1007/s12672-014-0173-2", "volume": "5", "author": "M Isikbay", "year": "2014", "unstructured": "Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5(2):72\u201389.", "journal-title": "Horm Cancer"}, {"key": "225_CR60", "unstructured": "Efstathiou E, Troncoso P, Tapia EM, Davis JW, Titus MA, Hoang A, Prokhorova IN, Wen S, Logothetis CJ: Effects of preoperative abiraterone acetate (AA) plus enzalutamide (E) and leuprolide acetate (LHRHa) versus AA and LHRHa in localized high-risk prostate cancer (LHRPC). In: American Society of Clinical Oncology Annual Meeting: 2015; Chicago, IL.", "DOI": "10.1200/jco.2015.33.15_suppl.5061", "doi-asserted-by": "crossref"}, {"issue": "8", "key": "225_CR61", "first-page": "1383", "volume": "3", "author": "MA Fenton", "year": "1997", "unstructured": "Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res. 1997;3(8):1383\u20138.", "journal-title": "Clin Cancer Res"}, {"issue": "11", "key": "225_CR62", "first-page": "2511", "volume": "59", "author": "ME Taplin", "year": "1999", "unstructured": "Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 1999;59(11):2511\u20135.", "journal-title": "Cancer Res"}, {"issue": "1", "key": "225_CR63", "first-page": "149", "volume": "63", "author": "T Hara", "year": "2003", "unstructured": "Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003;63(1):149\u201353.", "journal-title": "Cancer Res"}, {"issue": "9", "key": "225_CR64", "doi-asserted-by": "crossref", "first-page": "1020", "DOI": "10.1158/2159-8290.CD-13-0226", "volume": "3", "author": "JD Joseph", "year": "2013", "unstructured": "Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3(9):1020\u20139.", "journal-title": "Cancer Discov"}, {"issue": "9", "key": "225_CR65", "doi-asserted-by": "crossref", "first-page": "1030", "DOI": "10.1158/2159-8290.CD-13-0142", "volume": "3", "author": "M Korpal", "year": "2013", "unstructured": "Korpal M, Korn JM, Gao X, Rakiec DP, Ruddy DA, Doshi S, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013;3(9):1030\u201343.", "journal-title": "Cancer Discov"}, {"key": "225_CR66", "doi-asserted-by": "crossref", "first-page": "e00499", "DOI": "10.7554/eLife.00499", "volume": "2", "author": "MD Balbas", "year": "2013", "unstructured": "Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. eLife. 2013;2:e00499.", "journal-title": "eLife"}, {"key": "225_CR67", "doi-asserted-by": "crossref", "first-page": "12007", "DOI": "10.1038/srep12007", "volume": "5", "author": "AM Moilanen", "year": "2015", "unstructured": "Moilanen AM, Riikonen R, Oksala R, Ravanti L, Aho E, Wohlfahrt G, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.", "journal-title": "Sci Rep"}, {"issue": "9", "key": "225_CR68", "doi-asserted-by": "crossref", "first-page": "975", "DOI": "10.1016/S1470-2045(14)70240-2", "volume": "15", "author": "K Fizazi", "year": "2014", "unstructured": "Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975\u201385.", "journal-title": "Lancet Oncol"}, {"issue": "6", "key": "225_CR69", "doi-asserted-by": "crossref", "first-page": "2305", "DOI": "10.1158/0008-5472.CAN-08-3795", "volume": "69", "author": "Z Guo", "year": "2009", "unstructured": "Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69(6):2305\u201313.", "journal-title": "Cancer Res"}, {"issue": "14", "key": "225_CR70", "doi-asserted-by": "crossref", "first-page": "3457", "DOI": "10.1158/0008-5472.CAN-11-3892", "volume": "72", "author": "R Hu", "year": "2012", "unstructured": "Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72(14):3457\u201362.", "journal-title": "Cancer Res"}, {"issue": "5", "key": "225_CR71", "doi-asserted-by": "crossref", "first-page": "582", "DOI": "10.1001/jamaoncol.2015.1341", "volume": "1", "author": "ES Antonarakis", "year": "2015", "unstructured": "Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015;1(5):582\u201391.", "journal-title": "JAMA Oncol"}, {"key": "225_CR72", "unstructured": "Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ: Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget 2015, [Epub ahead of print]", "DOI": "10.18632/oncotarget.3925", "doi-asserted-by": "crossref"}, {"issue": "13", "key": "225_CR73", "doi-asserted-by": "crossref", "first-page": "3001", "DOI": "10.1200/JCO.2002.10.018", "volume": "20", "author": "EP Gelmann", "year": "2002", "unstructured": "Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20(13):3001\u201315.", "journal-title": "J Clin Oncol"}, {"key": "225_CR74", "unstructured": "Montgomery RB, Antonarakis ES, Hussain M, Fizazi K, Joshua AM, Attard G, Sadar M, Perabo F, Chi KN: A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. In: American Society of Clinical Oncology Annual Meeting: 2015; Chicago, IL.", "DOI": "10.1200/jco.2015.33.15_suppl.tps5072", "doi-asserted-by": "crossref"}, {"issue": "15", "key": "225_CR75", "doi-asserted-by": "crossref", "first-page": "4075", "DOI": "10.1158/1078-0432.CCR-14-0292", "volume": "20", "author": "Z Yu", "year": "2014", "unstructured": "Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res. 2014;20(15):4075\u201385.", "journal-title": "Clin Cancer Res"}, {"issue": "5", "key": "225_CR76", "doi-asserted-by": "crossref", "first-page": "2077", "DOI": "10.1021/jm501239f", "volume": "58", "author": "VC Njar", "year": "2015", "unstructured": "Njar VC, Brodie AM. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem. 2015;58(5):2077\u201387.", "journal-title": "J Med Chem"}, {"issue": "12", "key": "225_CR77", "doi-asserted-by": "crossref", "first-page": "3198", "DOI": "10.1158/1078-0432.CCR-13-3296", "volume": "20", "author": "C Liu", "year": "2014", "unstructured": "Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res. 2014;20(12):3198\u2013210.", "journal-title": "Clin Cancer Res"}, {"issue": "269", "key": "225_CR78", "doi-asserted-by": "crossref", "first-page": "269ra262", "DOI": "10.1126/scitranslmed.3010563", "volume": "7", "author": "MT Schweizer", "year": "2015", "unstructured": "Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, et al. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7(269):269ra262.", "journal-title": "Sci Transl Med"}, {"issue": "12", "key": "225_CR79", "doi-asserted-by": "crossref", "first-page": "2855", "DOI": "10.1210/me.2007-0223", "volume": "21", "author": "SM Dehm", "year": "2007", "unstructured": "Dehm SM, Tindall DJ. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol. 2007;21(12):2855\u201363.", "journal-title": "Mol Endocrinol"}, {"issue": "7", "key": "225_CR80", "doi-asserted-by": "crossref", "first-page": "2948", "DOI": "10.1172/JCI66398", "volume": "123", "author": "JK Myung", "year": "2013", "unstructured": "Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, et al. An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest. 2013;123(7):2948\u201360.", "journal-title": "J Clin Invest"}, {"issue": "6", "key": "225_CR81", "doi-asserted-by": "crossref", "first-page": "3811", "DOI": "10.18632/oncotarget.2924", "volume": "6", "author": "LJ Brand", "year": "2015", "unstructured": "Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, et al. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015;6(6):3811\u201324.", "journal-title": "Oncotarget"}, {"issue": "3", "key": "225_CR82", "doi-asserted-by": "crossref", "first-page": "601", "DOI": "10.1016/S1097-2765(02)00471-9", "volume": "9", "author": "Y Shang", "year": "2002", "unstructured": "Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell. 2002;9(3):601\u201310.", "journal-title": "Mol Cell"}, {"issue": "7406", "key": "225_CR83", "doi-asserted-by": "crossref", "first-page": "239", "DOI": "10.1038/nature11125", "volume": "487", "author": "CS Grasso", "year": "2012", "unstructured": "Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487(7406):239\u201343.", "journal-title": "Nature"}, {"issue": "3", "key": "225_CR84", "doi-asserted-by": "crossref", "first-page": "958", "DOI": "10.1158/0008-5472.CAN-08-2216", "volume": "69", "author": "DS Welsbie", "year": "2009", "unstructured": "Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res. 2009;69(3):958\u201366.", "journal-title": "Cancer Res"}, {"issue": "1", "key": "225_CR85", "doi-asserted-by": "crossref", "first-page": "109", "DOI": "10.1093/annonc/mdp270", "volume": "21", "author": "LR Molife", "year": "2010", "unstructured": "Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2010;21(1):109\u201313.", "journal-title": "Ann Oncol"}, {"key": "225_CR86", "unstructured": "Montgomery RB, Eisenberger MA, Heath EI, Sartor AO, Chu F, Shore ND, Edenfield WJ, Koletsky AJ, Lipsitz DU, Cochran JS, Nordquist LT, Roberts J, Taplin ME: Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study. In: American Society of Clinical Oncology Annual Meeting: 2014; Chicago, IL.", "DOI": "10.1200/jco.2014.32.15_suppl.5029", "doi-asserted-by": "crossref"}, {"key": "225_CR87", "unstructured": "Roberts J, Dhillon R, Dransfield DT, Mamlouk KK, Ferrante KJ: Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone versus enzalutamide (enz) in men expressing AR-V7 splice variant (SV), metastatic castrate resistant prostate cancer (mCRPC). In: Genitourinary Cancers Symposium: 2015; Orlando, FL.", "DOI": "10.1200/jco.2015.33.7_suppl.259", "doi-asserted-by": "crossref"}, {"issue": "2", "key": "225_CR88", "doi-asserted-by": "crossref", "first-page": "245", "DOI": "10.1016/0163-7258(82)90064-X", "volume": "19", "author": "P Andrews", "year": "1982", "unstructured": "Andrews P, Thyssen J, Lorke D. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245\u201395.", "journal-title": "Pharmacol Ther"}, {"issue": "7", "key": "225_CR89", "doi-asserted-by": "crossref", "first-page": "1807", "DOI": "10.1093/annonc/mdt136", "volume": "24", "author": "Y Loriot", "year": "2013", "unstructured": "Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24(7):1807\u201312.", "journal-title": "Ann Oncol"}, {"issue": "7", "key": "225_CR90", "doi-asserted-by": "crossref", "first-page": "1802", "DOI": "10.1093/annonc/mdt138", "volume": "24", "author": "KL Noonan", "year": "2013", "unstructured": "Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7):1802\u20137.", "journal-title": "Ann Oncol"}, {"issue": "1", "key": "225_CR91", "doi-asserted-by": "crossref", "first-page": "30", "DOI": "10.1016/j.eururo.2013.06.042", "volume": "65", "author": "AJ Schrader", "year": "2014", "unstructured": "Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol. 2014;65(1):30\u20136.", "journal-title": "Eur Urol"}, {"issue": "1", "key": "225_CR92", "doi-asserted-by": "crossref", "first-page": "78", "DOI": "10.1016/j.ejca.2013.08.020", "volume": "50", "author": "D Bianchini", "year": "2014", "unstructured": "Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer. 2014;50(1):78\u201384.", "journal-title": "Eur J Cancer"}, {"issue": "13", "key": "225_CR93", "doi-asserted-by": "crossref", "first-page": "1278", "DOI": "10.1002/pros.22844", "volume": "74", "author": "DL Suzman", "year": "2014", "unstructured": "Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate. 2014;74(13):1278\u201385.", "journal-title": "Prostate"}, {"issue": "7", "key": "225_CR94", "doi-asserted-by": "crossref", "first-page": "968", "DOI": "10.1002/cncr.28518", "volume": "120", "author": "S Badrising", "year": "2014", "unstructured": "Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer. 2014;120(7):968\u201375.", "journal-title": "Cancer"}, {"issue": "2", "key": "225_CR95", "doi-asserted-by": "crossref", "first-page": "122", "DOI": "10.1038/pcan.2014.53", "volume": "18", "author": "HH Cheng", "year": "2015", "unstructured": "Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015;18(2):122\u20137.", "journal-title": "Prostate Cancer Prostatic Dis"}, {"issue": "1", "key": "225_CR96", "doi-asserted-by": "crossref", "first-page": "23", "DOI": "10.1016/j.eururo.2014.06.045", "volume": "67", "author": "AA Azad", "year": "2015", "unstructured": "Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol. 2015;67(1):23\u20139.", "journal-title": "Eur Urol"}, {"issue": "9", "key": "225_CR97", "doi-asserted-by": "crossref", "first-page": "1084", "DOI": "10.1111/j.1464-410X.2008.07509.x", "volume": "101", "author": "ME Taplin", "year": "2008", "unstructured": "Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, et al. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008;101(9):1084\u20139.", "journal-title": "BJU Int"}, {"key": "225_CR98", "doi-asserted-by": "crossref", "first-page": "20", "DOI": "10.4103/1477-3163.83937", "volume": "10", "author": "PE Lonergan", "year": "2011", "unstructured": "Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. J Carcinogenesis. 2011;10:20.", "journal-title": "J Carcinogenesis"}, {"issue": "56", "key": "225_CR99", "doi-asserted-by": "crossref", "first-page": "7106", "DOI": "10.1038/onc.2008.318", "volume": "27", "author": "Y Wang", "year": "2008", "unstructured": "Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008;27(56):7106\u201317.", "journal-title": "Oncogene"}, {"issue": "41", "key": "225_CR100", "doi-asserted-by": "crossref", "first-page": "27707", "DOI": "10.1074/jbc.M802759200", "volume": "283", "author": "Y Li", "year": "2008", "unstructured": "Li Y, Wang Z, Kong D, Li R, Sarkar SH, Sarkar FH. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem. 2008;283(41):27707\u201316.", "journal-title": "J Biol Chem"}, {"issue": "3", "key": "225_CR101", "doi-asserted-by": "crossref", "first-page": "R83", "DOI": "10.1530/ERC-12-0394", "volume": "20", "author": "RL Bitting", "year": "2013", "unstructured": "Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013;20(3):R83\u201399.", "journal-title": "Endocr Relat Cancer"}, {"issue": "5", "key": "225_CR102", "doi-asserted-by": "crossref", "first-page": "575", "DOI": "10.1016/j.ccr.2011.04.008", "volume": "19", "author": "BS Carver", "year": "2011", "unstructured": "Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575\u201386.", "journal-title": "Cancer Cell"}, {"issue": "269", "key": "225_CR103", "first-page": "l1", "volume": "6", "author": "J Gao", "year": "2013", "unstructured": "Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.", "journal-title": "Sci Signal"}, {"issue": "5", "key": "225_CR104", "doi-asserted-by": "crossref", "first-page": "401", "DOI": "10.1158/2159-8290.CD-12-0095", "volume": "2", "author": "E Cerami", "year": "2012", "unstructured": "Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.", "journal-title": "Cancer Discov"}, {"key": "225_CR105", "unstructured": "Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ, Li Y: Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Critical reviews in oncology/hematology 2015, doi: 10.1016/j.critrevonc.2015.07.005 .", "DOI": "10.1016/j.critrevonc.2015.07.005", "doi-asserted-by": "crossref"}, {"issue": "7396", "key": "225_CR106", "doi-asserted-by": "crossref", "first-page": "55", "DOI": "10.1038/nature10912", "volume": "485", "author": "AC Hsieh", "year": "2012", "unstructured": "Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485(7396):55\u201361.", "journal-title": "Nature"}, {"issue": "1", "key": "225_CR107", "doi-asserted-by": "crossref", "first-page": "268", "DOI": "10.1073/pnas.0810956106", "volume": "106", "author": "A Dubrovska", "year": "2009", "unstructured": "Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A. 2009;106(1):268\u201373.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "2", "key": "225_CR108", "doi-asserted-by": "crossref", "first-page": "128", "DOI": "10.1038/nm0202-128", "volume": "8", "author": "M Guba", "year": "2002", "unstructured": "Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128\u201335.", "journal-title": "Nat Med"}, {"issue": "17", "key": "225_CR109", "first-page": "4291", "volume": "59", "author": "ME McMenamin", "year": "1999", "unstructured": "McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999;59(17):4291\u20136.", "journal-title": "Cancer Res"}, {"issue": "11", "key": "225_CR110", "doi-asserted-by": "crossref", "first-page": "1206", "DOI": "10.1002/pros.23003", "volume": "75", "author": "DA Troyer", "year": "2015", "unstructured": "Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, et al. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate. 2015;75(11):1206\u201315.", "journal-title": "Prostate"}, {"issue": "4", "key": "225_CR111", "doi-asserted-by": "crossref", "first-page": "909", "DOI": "10.1007/s00280-013-2250-6", "volume": "72", "author": "HJ Meulenbeld", "year": "2013", "unstructured": "Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, et al. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemother Pharmacol. 2013;72(4):909\u201316.", "journal-title": "Cancer Chemother Pharmacol"}, {"issue": "9", "key": "225_CR112", "doi-asserted-by": "crossref", "first-page": "2399", "DOI": "10.1093/annonc/mds011", "volume": "23", "author": "B Markman", "year": "2012", "unstructured": "Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol. 2012;23(9):2399\u2013408.", "journal-title": "Ann Oncol"}, {"issue": "11", "key": "225_CR113", "doi-asserted-by": "crossref", "first-page": "1729", "DOI": "10.1111/j.1464-410X.2012.11456.x", "volume": "110", "author": "M Nakabayashi", "year": "2012", "unstructured": "Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, et al. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012;110(11):1729\u201335.", "journal-title": "BJU Int"}, {"issue": "1", "key": "225_CR114", "doi-asserted-by": "crossref", "first-page": "150", "DOI": "10.1016/j.eururo.2013.03.040", "volume": "64", "author": "AJ Templeton", "year": "2013", "unstructured": "Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bartschi D, Droge C, et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol. 2013;64(1):150\u20138.", "journal-title": "Eur Urol"}, {"issue": "4", "key": "225_CR115", "doi-asserted-by": "crossref", "first-page": "397", "DOI": "10.1016/j.clgc.2013.05.007", "volume": "11", "author": "AJ Armstrong", "year": "2013", "unstructured": "Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, et al. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer. 2013;11(4):397\u2013406.", "journal-title": "Clin Genitourin Cancer"}, {"issue": "3", "key": "225_CR116", "doi-asserted-by": "crossref", "first-page": "282", "DOI": "10.1200/JCO.2011.36.1360", "volume": "30", "author": "JC Bendell", "year": "2012", "unstructured": "Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282\u201390.", "journal-title": "J Clin Oncol"}, {"issue": "1", "key": "225_CR117", "doi-asserted-by": "crossref", "first-page": "88", "DOI": "10.1186/1756-8722-6-88", "volume": "6", "author": "A Akinleye", "year": "2013", "unstructured": "Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88.", "journal-title": "J Hematol Oncol"}, {"issue": "2", "key": "225_CR118", "doi-asserted-by": "crossref", "first-page": "159", "DOI": "10.1016/j.molcel.2006.03.029", "volume": "22", "author": "DD Sarbassov", "year": "2006", "unstructured": "Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22(2):159\u201368.", "journal-title": "Mol Cell"}, {"issue": "3", "key": "225_CR119", "doi-asserted-by": "crossref", "first-page": "378", "DOI": "10.4103/1008-682X.122876", "volume": "16", "author": "MP Edlind", "year": "2014", "unstructured": "Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl. 2014;16(3):378\u201386.", "journal-title": "Asian J Androl"}, {"issue": "12", "key": "225_CR120", "doi-asserted-by": "crossref", "first-page": "1949", "DOI": "10.1038/sj.bjc.6605376", "volume": "101", "author": "AM Traish", "year": "2009", "unstructured": "Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer. 2009;101(12):1949\u201356.", "journal-title": "Br J Cancer"}, {"issue": "11", "key": "225_CR121", "doi-asserted-by": "crossref", "first-page": "5723", "DOI": "10.1158/0008-5472.CAN-05-3928", "volume": "66", "author": "R Berger", "year": "2006", "unstructured": "Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, et al. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006;66(11):5723\u20138.", "journal-title": "Cancer Res"}, {"issue": "5", "key": "225_CR122", "doi-asserted-by": "crossref", "first-page": "781", "DOI": "10.1038/sj.onc.1206066", "volume": "22", "author": "MS Lee", "year": "2003", "unstructured": "Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene. 2003;22(5):781\u201396.", "journal-title": "Oncogene"}, {"issue": "3", "key": "225_CR123", "doi-asserted-by": "crossref", "first-page": "842", "DOI": "10.1016/j.juro.2010.04.077", "volume": "184", "author": "AS Neto", "year": "2010", "unstructured": "Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD, et al. Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol. 2010;184(3):842\u201350.", "journal-title": "J Urol"}, {"issue": "3", "key": "225_CR124", "doi-asserted-by": "crossref", "first-page": "241", "DOI": "10.1200/JCO.2006.08.8187", "volume": "25", "author": "DB Solit", "year": "2007", "unstructured": "Solit DB, Rosen N. Targeting HER2 in prostate cancer: where to next? J Clin Oncol. 2007;25(3):241\u20133.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "225_CR125", "doi-asserted-by": "crossref", "first-page": "219", "DOI": "10.2217/fon.13.250", "volume": "10", "author": "LR Molife", "year": "2014", "unstructured": "Molife LR, Omlin A, Jones RJ, Karavasilis V, Bloomfield D, Lumsden G, et al. Randomized phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. Future Oncol. 2014;10(2):219\u201331.", "journal-title": "Future Oncol"}, {"issue": "2", "key": "225_CR126", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.1016/j.urolonc.2011.01.002", "volume": "31", "author": "G Liu", "year": "2013", "unstructured": "Liu G, Chen YH, Kolesar J, Huang W, Dipaola R, Pins M, et al. Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol. 2013;31(2):211\u20138.", "journal-title": "Urol Oncol"}, {"issue": "1", "key": "225_CR127", "doi-asserted-by": "crossref", "first-page": "82", "DOI": "10.1016/j.urolonc.2010.09.018", "volume": "31", "author": "YE Whang", "year": "2013", "unstructured": "Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, et al. A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol. 2013;31(1):82\u20136.", "journal-title": "Urol Oncol"}, {"issue": "6", "key": "225_CR128", "doi-asserted-by": "crossref", "first-page": "609", "DOI": "10.1097/COC.0b013e3181beac33", "volume": "33", "author": "SS Sridhar", "year": "2010", "unstructured": "Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, et al. A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer. Am J Clin Oncol. 2010;33(6):609\u201313.", "journal-title": "Am J Clin Oncol"}, {"issue": "4", "key": "225_CR129", "doi-asserted-by": "crossref", "first-page": "332", "DOI": "10.1002/pros.20065", "volume": "60", "author": "A Ziada", "year": "2004", "unstructured": "Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004;60(4):332\u20137.", "journal-title": "Prostate"}, {"issue": "3", "key": "225_CR130", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1200/JCO.2006.07.0888", "volume": "25", "author": "JS Bono de", "year": "2007", "unstructured": "de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol. 2007;25(3):257\u201362.", "journal-title": "J Clin Oncol"}, {"key": "225_CR131", "doi-asserted-by": "crossref", "first-page": "120", "DOI": "10.1016/j.cbi.2015.08.009", "volume": "240", "author": "G Joshi", "year": "2015", "unstructured": "Joshi G, Singh PK, Negi A, Rana A, Singh S, Kumar R. Growth factors mediated cell signalling in prostate cancer progression: implications in discovery of anti-prostate cancer agents. Chem Biol Interact. 2015;240:120\u201333.", "journal-title": "Chem Biol Interact"}, {"issue": "2", "key": "225_CR132", "doi-asserted-by": "crossref", "first-page": "392", "DOI": "10.1002/jcb.20929", "volume": "99", "author": "JD Wu", "year": "2006", "unstructured": "Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem. 2006;99(2):392\u2013401.", "journal-title": "J Cell Biochem"}, {"issue": "3", "key": "225_CR133", "doi-asserted-by": "crossref", "first-page": "276", "DOI": "10.1002/pros.20099", "volume": "61", "author": "SR Plymate", "year": "2004", "unstructured": "Plymate SR, Tennant MK, Culp SH, Woodke L, Marcelli M, Colman I, et al. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate. 2004;61(3):276\u201390.", "journal-title": "Prostate"}, {"issue": "13", "key": "225_CR134", "doi-asserted-by": "crossref", "first-page": "7200", "DOI": "10.1073/pnas.121173298", "volume": "98", "author": "HK Lin", "year": "2001", "unstructured": "Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A. 2001;98(13):7200\u20135.", "journal-title": "Proc Natl Acad Sci U S A"}, {"issue": "10", "key": "225_CR135", "doi-asserted-by": "crossref", "first-page": "2418", "DOI": "10.1002/ijc.29295", "volume": "136", "author": "Y Cao", "year": "2015", "unstructured": "Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, et al. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer. 2015;136(10):2418\u201326.", "journal-title": "Int J Cancer"}, {"issue": "15", "key": "225_CR136", "doi-asserted-by": "crossref", "first-page": "3104", "DOI": "10.1200/JCO.2004.10.105", "volume": "22", "author": "P Stattin", "year": "2004", "unstructured": "Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol. 2004;22(15):3104\u201312.", "journal-title": "J Clin Oncol"}, {"issue": "5350", "key": "225_CR137", "doi-asserted-by": "crossref", "first-page": "563", "DOI": "10.1126/science.279.5350.563", "volume": "279", "author": "JM Chan", "year": "1998", "unstructured": "Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279(5350):563\u20136.", "journal-title": "Science"}, {"issue": "10", "key": "225_CR138", "doi-asserted-by": "crossref", "first-page": "1224", "DOI": "10.1016/S0959-8049(00)00102-7", "volume": "36", "author": "M Pollak", "year": "2000", "unstructured": "Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer. 2000;36(10):1224\u20138.", "journal-title": "Eur J Cancer"}, {"issue": "14", "key": "225_CR139", "doi-asserted-by": "crossref", "first-page": "1601", "DOI": "10.1200/JCO.2014.59.4127", "volume": "33", "author": "EY Yu", "year": "2015", "unstructured": "Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, et al. SWOG S0925: a randomized phase II study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2015;33(14):1601\u20138.", "journal-title": "J Clin Oncol"}, {"issue": "13", "key": "225_CR140", "doi-asserted-by": "crossref", "first-page": "1714", "DOI": "10.1016/j.ejca.2015.05.019", "volume": "51", "author": "M Hussain", "year": "2015", "unstructured": "Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, et al. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. Eur J Cancer. 2015;51(13):1714\u201324.", "journal-title": "Eur J Cancer"}, {"issue": "1", "key": "225_CR141", "doi-asserted-by": "crossref", "first-page": "182", "DOI": "10.1016/S0022-5347(01)62092-5", "volume": "161", "author": "HL Adler", "year": "1999", "unstructured": "Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161(1):182\u20137.", "journal-title": "J Urol"}, {"issue": "6", "key": "225_CR142", "doi-asserted-by": "crossref", "first-page": "1008", "DOI": "10.1016/S0090-4295(01)01405-4", "volume": "58", "author": "SF Shariat", "year": "2001", "unstructured": "Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001;58(6):1008\u201315.", "journal-title": "Urology"}, {"issue": "7", "key": "225_CR143", "first-page": "2702", "volume": "6", "author": "J Nakashima", "year": "2000", "unstructured": "Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6(7):2702\u20136.", "journal-title": "Clin Cancer Res"}, {"issue": "5", "key": "225_CR144", "doi-asserted-by": "crossref", "first-page": "1815", "DOI": "10.1158/1078-0432.CCR-04-1560", "volume": "11", "author": "DJ George", "year": "2005", "unstructured": "George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005;11(5):1815\u201320.", "journal-title": "Clin Cancer Res"}, {"issue": "4", "key": "225_CR145", "doi-asserted-by": "crossref", "first-page": "841", "DOI": "10.1677/ERC-08-0084", "volume": "15", "author": "ML Zhu", "year": "2008", "unstructured": "Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer. 2008;15(4):841\u20139.", "journal-title": "Endocr Relat Cancer"}, {"issue": "1\u20132", "key": "225_CR146", "doi-asserted-by": "crossref", "first-page": "50", "DOI": "10.1016/j.mce.2007.02.006", "volume": "270", "author": "DS Aaronson", "year": "2007", "unstructured": "Aaronson DS, Muller M, Neves SR, Chung WC, Jayaram G, Iyengar R, et al. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Mol Cell Endocrinol. 2007;270(1\u20132):50\u20136.", "journal-title": "Mol Cell Endocrinol"}, {"issue": "13", "key": "225_CR147", "doi-asserted-by": "crossref", "first-page": "1455", "DOI": "10.1002/pros.21362", "volume": "71", "author": "J Karkera", "year": "2011", "unstructured": "Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S, et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate. 2011;71(13):1455\u201365.", "journal-title": "Prostate"}, {"issue": "3", "key": "225_CR148", "doi-asserted-by": "crossref", "first-page": "669", "DOI": "10.1007/s10637-012-9857-z", "volume": "31", "author": "G Hudes", "year": "2013", "unstructured": "Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, et al. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Investig New Drugs. 2013;31(3):669\u201376.", "journal-title": "Investig New Drugs"}, {"issue": "15", "key": "225_CR149", "doi-asserted-by": "crossref", "first-page": "1502", "DOI": "10.1056/NEJMoa040720", "volume": "351", "author": "IF Tannock", "year": "2004", "unstructured": "Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502\u201312.", "journal-title": "N Engl J Med"}, {"issue": "15", "key": "225_CR150", "doi-asserted-by": "crossref", "first-page": "1513", "DOI": "10.1056/NEJMoa041318", "volume": "351", "author": "DP Petrylak", "year": "2004", "unstructured": "Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513\u201320.", "journal-title": "N Engl J Med"}, {"issue": "1", "key": "225_CR151", "doi-asserted-by": "crossref", "first-page": "85", "DOI": "10.1016/j.ejca.2011.10.014", "volume": "48", "author": "K Fizazi", "year": "2012", "unstructured": "Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer. 2012;48(1):85\u201393.", "journal-title": "Eur J Cancer"}, {"issue": "1", "key": "225_CR152", "doi-asserted-by": "crossref", "first-page": "22", "DOI": "10.1016/j.canlet.2005.06.004", "volume": "237", "author": "M Verras", "year": "2006", "unstructured": "Verras M, Sun Z. Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett. 2006;237(1):22\u201332.", "journal-title": "Cancer Lett"}, {"issue": "20", "key": "225_CR153", "doi-asserted-by": "crossref", "first-page": "17933", "DOI": "10.1074/jbc.M200135200", "volume": "277", "author": "DJ Mulholland", "year": "2002", "unstructured": "Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC. The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli. J Biol Chem. 2002;277(20):17933\u201343.", "journal-title": "J Biol Chem"}, {"issue": "17", "key": "225_CR154", "first-page": "4709", "volume": "60", "author": "CI Truica", "year": "2000", "unstructured": "Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 2000;60(17):4709\u201313.", "journal-title": "Cancer Res"}, {"issue": "4", "key": "225_CR155", "doi-asserted-by": "crossref", "first-page": "537", "DOI": "10.1677/erc.0.0100537", "volume": "10", "author": "DR Chesire", "year": "2003", "unstructured": "Chesire DR, Isaacs WB. Beta-catenin signaling in prostate cancer: an early perspective. Endocr Relat Cancer. 2003;10(4):537\u201360.", "journal-title": "Endocr Relat Cancer"}, {"issue": "13", "key": "225_CR156", "doi-asserted-by": "crossref", "first-page": "11336", "DOI": "10.1074/jbc.M111962200", "volume": "277", "author": "F Yang", "year": "2002", "unstructured": "Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, et al. Linking beta-catenin to androgen-signaling pathway. J Biol Chem. 2002;277(13):11336\u201344.", "journal-title": "J Biol Chem"}, {"issue": "6254", "key": "225_CR157", "doi-asserted-by": "crossref", "first-page": "1351", "DOI": "10.1126/science.aab0917", "volume": "349", "author": "DT Miyamoto", "year": "2015", "unstructured": "Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349(6254):1351\u20136.", "journal-title": "Science"}, {"issue": "1", "key": "225_CR158", "doi-asserted-by": "crossref", "first-page": "8", "DOI": "10.1016/j.ejphar.2008.10.053", "volume": "602", "author": "W Lu", "year": "2009", "unstructured": "Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA, Li Y. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol. 2009;602(1):8\u201314.", "journal-title": "Eur J Pharmacol"}, {"issue": "18", "key": "225_CR159", "doi-asserted-by": "crossref", "first-page": "2723", "DOI": "10.1200/JCO.2005.03.7804", "volume": "24", "author": "MR Smith", "year": "2006", "unstructured": "Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006;24(18):2723\u20138.", "journal-title": "J Clin Oncol"}], "container-title": ["Journal of Hematology & Oncology"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1186/s13045-015-0225-2", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 1]], "date-time": "2019-09-01T14:21:51Z", "timestamp": 1567347711000}, "score": 29.403368, "issued": {"date-parts": [[2015, 11, 13]]}, "references-count": 159, "journal-issue": {"published-print": {"date-parts": [[2015, 12]]}, "issue": "1"}, "alternative-id": ["225"], "URL": "http://dx.doi.org/10.1186/s13045-015-0225-2", "relation": {"cites": []}, "ISSN": ["1756-8722"], "issn-type": [{"value": "1756-8722", "type": "electronic"}], "article-number": "128"}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T10:04:06Z", "timestamp": 1574244246128}, "reference-count": 0, "publisher": "Ovid Technologies (Wolters Kluwer Health)", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Epidemiology"], "published-print": {"date-parts": [[1995, 7]]}, "DOI": "10.1097/00001648-199507000-00020", "type": "journal-article", "created": {"date-parts": [[2006, 11, 14]], "date-time": "2006-11-14T10:32:10Z", "timestamp": 1163500330000}, "page": "432-435", "source": "Crossref", "is-referenced-by-count": 30, "title": ["Body Mass and Physical Activity Are Important Predictors of Serum Androgen Concentrations in Young Healthy Men"], "prefix": "10.1097", "volume": "6", "author": [{"given": "Christos S.", "family": "Mantzoros", "sequence": "first", "affiliation": []}, {"given": "Emmanuel I.", "family": "Georgiadis", "sequence": "additional", "affiliation": []}], "member": "276", "container-title": ["Epidemiology"], "language": "en", "deposited": {"date-parts": [[2018, 2, 8]], "date-time": "2018-02-08T21:09:10Z", "timestamp": 1518124150000}, "score": 27.95494, "subtitle": [""], "issued": {"date-parts": [[1995, 7]]}, "references-count": 0, "journal-issue": {"issue": "4"}, "URL": "http://dx.doi.org/10.1097/00001648-199507000-00020", "ISSN": ["1044-3983"], "issn-type": [{"value": "1044-3983", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T17:23:46Z", "timestamp": 1574443426384}, "reference-count": 50, "publisher": "Wiley", "issue": "14", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 1835, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Prostate"], "published-print": {"date-parts": [[2010, 10, 1]]}, "DOI": "10.1002/pros.21196", "type": "journal-article", "created": {"date-parts": [[2010, 7, 7]], "date-time": "2010-07-07T07:19:52Z", "timestamp": 1278487192000}, "page": "1600-1607", "source": "Crossref", "is-referenced-by-count": 30, "title": ["Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer"], "prefix": "10.1002", "volume": "70", "author": [{"given": "Samuel R.", "family": "Denmeade", "sequence": "first", "affiliation": []}, {"given": "John T.", "family": "Isaacs", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2010, 8, 23]]}, "reference": [{"key": "10.1002/pros.21196-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "71", "DOI": "10.3322/CA.2007.0010", "article-title": "Cancer statistics, 2008", "volume": "58", "author": "Jemal", "year": "2008", "journal-title": "CA Cancer J Clin"}, {"issue": "4", "key": "10.1002/pros.21196-BIB2|cit2", "first-page": "293", "article-title": "Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate", "volume": "1", "author": "Huggins", "year": "1941", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB3|cit3", "doi-asserted-by": "crossref", "first-page": "419", "DOI": "10.1056/NEJM198908173210702", "article-title": "A controlled trial of leuprolide with and without flutamide in prostatic carcinoma", "volume": "321", "author": "Crawford", "year": "1989", "journal-title": "N Engl J Med"}, {"key": "10.1002/pros.21196-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "3", "DOI": "10.1016/S0022-5347(05)67436-8", "article-title": "Complete androgen blockade for prostate cancer: What went wrong?", "volume": "164", "author": "Laufer", "year": "2000", "journal-title": "J Urol"}, {"key": "10.1002/pros.21196-BIB5|cit5", "first-page": "3550", "article-title": "Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer", "volume": "61", "author": "Linja", "year": "2001", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "9209", "DOI": "10.1158/0008-5472.CAN-04-2442", "article-title": "Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program", "volume": "64", "author": "Shah", "year": "2004", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB7|cit7", "first-page": "1008", "article-title": "Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells", "volume": "62", "author": "Zegarra-Moro", "year": "2002", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "709", "DOI": "10.1016/S0093-7754(03)00346-4", "article-title": "Hsp90 as a therapeutic target in prostate cancer", "volume": "30", "author": "Solit", "year": "2003", "journal-title": "Semin Oncol"}, {"key": "10.1002/pros.21196-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "1724", "DOI": "10.1002/pros.21028", "article-title": "Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone", "volume": "69", "author": "Sedelaar", "year": "2009", "journal-title": "Prostate"}, {"key": "10.1002/pros.21196-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "213", "DOI": "10.1002/pros.2990230304", "article-title": "Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP", "volume": "23", "author": "Langeler", "year": "1993", "journal-title": "Prostate"}, {"key": "10.1002/pros.21196-BIB11|cit11", "first-page": "1566", "article-title": "Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation", "volume": "54", "author": "Kokontis", "year": "1994", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB12|cit12", "first-page": "3474", "article-title": "Negative controls of cell proliferation: Human prostate cancer cells and androgens", "volume": "49", "author": "Sonnenschein", "year": "1989", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "237", "DOI": "10.1016/S0960-0760(00)00076-5", "article-title": "Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line", "volume": "73", "author": "Joly-Pharaboz", "year": "2000", "journal-title": "J Steroid Biochem Mol Biol"}, {"key": "10.1002/pros.21196-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "47", "DOI": "10.1038/bjc.1991.237", "article-title": "Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP", "volume": "64", "author": "Wolf", "year": "1991", "journal-title": "Br J Cancer"}, {"key": "10.1002/pros.21196-BIB15|cit15", "doi-asserted-by": "crossref", "first-page": "1699", "DOI": "10.1210/endo.141.5.7463", "article-title": "Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase", "volume": "141", "author": "Shen", "year": "2000", "journal-title": "Endocrinology"}, {"key": "10.1002/pros.21196-BIB16|cit16", "first-page": "1304", "article-title": "Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA", "volume": "53", "author": "Yuan", "year": "1993", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "1329", "DOI": "10.1002/pros.20483", "article-title": "PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor", "volume": "66", "author": "Litvinov", "year": "2006", "journal-title": "Prostate"}, {"key": "10.1002/pros.21196-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "647", "DOI": "10.4161/cc.6.6.4028", "article-title": "Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation", "volume": "6", "author": "Vander Griend", "year": "2007", "journal-title": "Cell Cycle"}, {"key": "10.1002/pros.21196-BIB19|cit19", "doi-asserted-by": "crossref", "first-page": "11802", "DOI": "10.1073/pnas.93.21.11802", "article-title": "Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride", "volume": "93", "author": "Umekita", "year": "1996", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/pros.21196-BIB20|cit20", "doi-asserted-by": "crossref", "first-page": "2082", "DOI": "10.1158/0008-5472.CAN-04-3992", "article-title": "Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice", "volume": "65", "author": "Chuu", "year": "2005", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB21|cit21", "doi-asserted-by": "crossref", "first-page": "33", "DOI": "10.1038/nm972", "article-title": "Molecular determinants of resistance to antiandrogen therapy", "volume": "10", "author": "Chen", "year": "2004", "journal-title": "Nat Med"}, {"key": "10.1002/pros.21196-BIB22|cit22", "author": "Brendler", "first-page": "433", "year": "1949", "article-title": "Prostatic cancer: Further investigation of hormone relationships", "journal-title": "Arch Surg"}, {"key": "10.1002/pros.21196-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "1871", "DOI": "10.1002/1097-0142(196711)20:11<1871::AID-CNCR2820201112>3.0.CO;2-D", "article-title": "Response of men with advanced prostatic carcinoma to exogenous administration of testosterone", "volume": "20", "author": "Prout", "year": "1967", "journal-title": "Cancer"}, {"key": "10.1002/pros.21196-BIB24|cit24", "first-page": "473", "article-title": "Discussion of Dr Huggins' paper \u201ccontrol of cancers of man by endocrinological methods\u201d", "volume": "17", "author": "Pearson", "year": "1957", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "395", "DOI": "10.1093/annonc/mdm568", "article-title": "Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: The case for a prospective trial", "volume": "19", "author": "Mathew", "year": "2008", "journal-title": "Ann Oncol"}, {"key": "10.1002/pros.21196-BIB26|cit26", "first-page": "134", "article-title": "Inhibition of human mammary and prostatic cancers by adrenalectomy", "volume": "12", "author": "Huggins", "year": "1952", "journal-title": "Cancer Res"}, {"issue": "2", "key": "10.1002/pros.21196-BIB27|cit27", "doi-asserted-by": "crossref", "first-page": "207", "DOI": "10.1016/j.beem.2008.01.008", "article-title": "Androgen biosynthetic pathways in the human prostate", "volume": "22", "author": "Luu-The", "year": "2008", "journal-title": "Best Pract Res Clin Endocrinol Metab"}, {"issue": "11", "key": "10.1002/pros.21196-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "4447", "DOI": "10.1158/0008-5472.CAN-08-0249", "article-title": "Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth", "volume": "68", "author": "Montgomery", "year": "2008", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB29|cit29", "author": "Denmeade", "first-page": "850", "year": "2006", "volume-title": "Cancer medicine"}, {"key": "10.1002/pros.21196-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "1496", "DOI": "10.1200/JCO.2009.25.9259", "article-title": "Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer", "volume": "28", "author": "Danila", "year": "2010", "journal-title": "J Clin Oncol"}, {"key": "10.1002/pros.21196-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "787", "DOI": "10.1126/science.1168175", "article-title": "Development of a second-generation antiandrogen for treatment of advanced prostate cancer", "volume": "324", "author": "Tran", "year": "2009", "journal-title": "Science"}, {"key": "10.1002/pros.21196-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "2091", "DOI": "10.1158/1078-0432.CCR-08-2036", "article-title": "Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer", "volume": "15", "author": "Leversha", "year": "2009", "journal-title": "Clin Cancer Res"}, {"key": "10.1002/pros.21196-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "2912", "DOI": "10.1158/0008-5472.CAN-08-3667", "article-title": "Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer", "volume": "69", "author": "Attard", "year": "2009", "journal-title": "Cancer Res"}, {"key": "10.1002/pros.21196-BIB34|cit34", "doi-asserted-by": "crossref", "first-page": "164", "DOI": "10.1016/j.canlet.2008.12.007", "article-title": "Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer", "volume": "277", "author": "Paris", "year": "2009", "journal-title": "Cancer Lett"}, {"issue": "2", "key": "10.1002/pros.21196-BIB35|cit35", "doi-asserted-by": "crossref", "first-page": "237", "DOI": "10.1002/path.1206", "article-title": "Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer", "volume": "198", "author": "Brown", "year": "2002", "journal-title": "J Pathol"}, {"issue": "Suppl 3", "key": "10.1002/pros.21196-BIB36|cit36", "doi-asserted-by": "crossref", "first-page": "37", "DOI": "10.1159/000052297", "article-title": "Intermittent androgen suppression for prostate cancer: Rationale and clinical experience", "volume": "34", "author": "Gleave", "year": "1998", "journal-title": "Eur Urol"}, {"key": "10.1002/pros.21196-BIB37|cit37", "doi-asserted-by": "crossref", "first-page": "1269", "DOI": "10.1016/j.eururo.2009.02.016", "article-title": "Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: Results from a randomised phase 3 study of the South European Uroncological Group", "volume": "55", "author": "Calais daSilva", "year": "2009", "journal-title": "Eur Urol"}, {"key": "10.1002/pros.21196-BIB38|cit38", "doi-asserted-by": "crossref", "first-page": "15152", "DOI": "10.1073/pnas.93.26.15152", "article-title": "Androgen-repressed phenotype in human prostate cancer", "volume": "93", "author": "Zhau", "year": "1996", "journal-title": "Proc Natl Acad Sci USA"}, {"issue": "8", "key": "10.1002/pros.21196-BIB39|cit39", "doi-asserted-by": "crossref", "first-page": "883", "DOI": "10.1002/pros.20758", "article-title": "Characterization of PacMetUT1, a recently isolated human prostate cancer cell line", "volume": "68", "author": "Troyer", "year": "2008", "journal-title": "Prostate"}, {"issue": "24", "key": "10.1002/pros.21196-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "11565", "DOI": "10.1158/0008-5472.CAN-05-3441", "article-title": "Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line", "volume": "65", "author": "Watson", "year": "2005", "journal-title": "Cancer Res"}, {"issue": "2", "key": "10.1002/pros.21196-BIB41|cit41", "first-page": "163", "article-title": "VCaP, a cell-based model system of human prostate cancer", "volume": "15", "author": "Korenchuk", "year": "2001", "journal-title": "In Vivo"}, {"key": "10.1002/pros.21196-BIB42|cit42", "doi-asserted-by": "crossref", "first-page": "e00", "DOI": "10.1621/nrs.06001", "article-title": "AR, the cell cycle, and prostate cancer", "volume": "6", "author": "Balk", "year": "2008", "journal-title": "Nucl Recept Signal"}, {"key": "10.1002/pros.21196-BIB43|cit43", "first-page": "1571", "article-title": "Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats", "volume": "7", "author": "Chen", "year": "1996", "journal-title": "Cell Growth Differ"}, {"key": "10.1002/pros.21196-BIB44|cit44", "doi-asserted-by": "crossref", "first-page": "1823", "DOI": "10.1128/MCB.01297-06", "article-title": "Ligand-specific dynamics of the androgen receptor at its response element in living cells", "volume": "27", "author": "Klokk", "year": "2007", "journal-title": "Mol Cell Biol"}, {"key": "10.1002/pros.21196-BIB45|cit45", "doi-asserted-by": "crossref", "first-page": "15085", "DOI": "10.1073/pnas.0603057103", "article-title": "Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells", "volume": "103", "author": "Litvinov", "year": "2006", "journal-title": "Proc Natl Acad Sci USA"}, {"key": "10.1002/pros.21196-BIB46|cit46", "doi-asserted-by": "crossref", "first-page": "1069", "DOI": "10.1016/j.cell.2009.11.030", "article-title": "Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer", "volume": "139", "author": "Lin", "year": "2009", "journal-title": "Cell"}, {"issue": "5781", "key": "10.1002/pros.21196-BIB47|cit47", "doi-asserted-by": "crossref", "first-page": "1798", "DOI": "10.1126/science.1127196", "article-title": "A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription", "volume": "312", "author": "Ju", "year": "2006", "journal-title": "Science"}, {"key": "10.1002/pros.21196-BIB48|cit48", "author": "Haffner", "year": "2010", "article-title": "Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangement", "journal-title": "Nat Genet", "DOI": "10.1038/ng.613", "doi-asserted-by": "crossref"}, {"key": "10.1002/pros.21196-BIB49|cit49", "doi-asserted-by": "crossref", "first-page": "97", "DOI": "10.1016/j.eururo.2009.02.022", "article-title": "A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer", "volume": "56", "author": "Szmulewitz", "year": "2009", "journal-title": "Eur Urol"}, {"issue": "2", "key": "10.1002/pros.21196-BIB50|cit50", "doi-asserted-by": "crossref", "first-page": "237", "DOI": "10.1016/j.eururo.2009.03.073", "article-title": "Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer", "volume": "56", "author": "Morris", "year": "2009", "journal-title": "Eur Urol"}], "container-title": ["The Prostate"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.21196", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1002/pros.21196", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 1]], "date-time": "2019-03-01T22:52:46Z", "timestamp": 1551480766000}, "score": 27.8691, "issued": {"date-parts": [[2010, 8, 23]]}, "references-count": 50, "journal-issue": {"published-print": {"date-parts": [[2010, 10, 1]]}, "issue": "14"}, "URL": "http://dx.doi.org/10.1002/pros.21196", "relation": {"cites": []}, "ISSN": ["0270-4137"], "issn-type": [{"value": "0270-4137", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T23:48:45Z", "timestamp": 1574293725496}, "reference-count": 0, "publisher": "American Association for Cancer Research (AACR)", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Cancer Research"], "published-print": {"date-parts": [[2007, 5, 15]]}, "DOI": "10.1158/0008-5472.can-06-3332", "type": "journal-article", "created": {"date-parts": [[2007, 5, 18]], "date-time": "2007-05-18T07:12:30Z", "timestamp": 1179472350000}, "page": "5033-5041", "source": "Crossref", "is-referenced-by-count": 315, "title": ["Intraprostatic Androgens and Androgen-Regulated Gene Expression Persist after Testosterone Suppression: Therapeutic Implications for Castration-Resistant Prostate Cancer"], "prefix": "10.1158", "volume": "67", "author": [{"given": "E. A.", "family": "Mostaghel", "sequence": "first", "affiliation": []}, {"given": "S. T.", "family": "Page", "sequence": "additional", "affiliation": []}, {"given": "D. W.", "family": "Lin", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Fazli", "sequence": "additional", "affiliation": []}, {"given": "I. M.", "family": "Coleman", "sequence": "additional", "affiliation": []}, {"given": "L. D.", "family": "True", "sequence": "additional", "affiliation": []}, {"given": "B.", "family": "Knudsen", "sequence": "additional", "affiliation": []}, {"given": "D. L.", "family": "Hess", "sequence": "additional", "affiliation": []}, {"given": "C. C.", "family": "Nelson", "sequence": "additional", "affiliation": []}, {"given": "A. M.", "family": "Matsumoto", "sequence": "additional", "affiliation": []}, {"given": "W. J.", "family": "Bremner", "sequence": "additional", "affiliation": []}, {"given": "M. E.", "family": "Gleave", "sequence": "additional", "affiliation": []}, {"given": "P. S.", "family": "Nelson", "sequence": "additional", "affiliation": []}], "member": "1086", "container-title": ["Cancer Research"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1158/0008-5472.CAN-06-3332", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T14:17:13Z", "timestamp": 1482502633000}, "score": 26.257088, "issued": {"date-parts": [[2007, 5, 15]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2007, 5, 15]]}, "issue": "10"}, "URL": "http://dx.doi.org/10.1158/0008-5472.can-06-3332", "ISSN": ["0008-5472", "1538-7445"], "issn-type": [{"value": "0008-5472", "type": "print"}, {"value": "1538-7445", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T20:57:10Z", "timestamp": 1574456230753}, "reference-count": 62, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 2321, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "DOI": "10.1111/j.0954-6820.1963.tb07948.x", "type": "journal-article", "created": {"date-parts": [[2010, 8, 15]], "date-time": "2010-08-15T04:28:07Z", "timestamp": 1281846487000}, "page": "479-499", "source": "Crossref", "is-referenced-by-count": 42, "title": ["Electrocardiographic Findings at Rest, during and after Exercise in Healthy Old Men Compared with Young Men"], "prefix": "10.1111", "volume": "174", "author": [{"given": "T.", "family": "Strandell", "sequence": "first", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2009, 4, 24]]}, "reference": [{"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB1|cit1", "doi-asserted-by": "crossref", "first-page": "26", "DOI": "10.1016/S0140-6736(57)92440-6", "article-title": "The electrocardiogram after exercise in the detection of latent coronary artery disease in R. A. F. personnel", "volume": "272", "author": "Acheson", "year": "1957", "journal-title": "Lancet"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB2|cit2", "doi-asserted-by": "crossref", "first-page": "155", "DOI": "10.1111/j.0954-6820.1958.tb01761.x", "article-title": "Clinical and physiological studies of manual workers 50-64 years old at rest and during work", "volume": "162", "author": "\u00c5strand", "year": "1958", "journal-title": "Acta Med. Scand"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB3|cit3", "author": "\u00c5strand", "issue": "Suppl. 169", "year": "1960", "article-title": "Aerobic work capacity in men and women with special reference to age", "journal-title": "Acta Physiol. Scand."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB4|cit4", "doi-asserted-by": "crossref", "first-page": "257", "DOI": "10.1111/j.0954-6820.1963.tb17405.x", "article-title": "Exercise electrocardiograms in a 5-year follow-up study", "volume": "173", "author": "\u00c5strand", "year": "1963", "journal-title": "Acta Med. Scand."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB5|cit5", "doi-asserted-by": "crossref", "first-page": "689", "DOI": "10.1016/0002-8703(46)90697-7", "article-title": "Anoxemia and exercise tests in the diagnosis of coronary disease", "volume": "32", "author": "Bi\u00f6rck", "year": "1946", "journal-title": "Amer. Heart J"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB6|cit6", "doi-asserted-by": "crossref", "first-page": "686", "DOI": "10.1161/01.CIR.25.4.686", "article-title": "Radioelectrocardiographic changes during strenuous exercise in normal subjects", "volume": "25", "author": "Beixet", "year": "1962", "journal-title": "Circulation"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB7|cit7", "doi-asserted-by": "crossref", "first-page": "225", "DOI": "10.1111/j.0954-6820.1956.tb14317.x", "article-title": "The exercise electrocardiogram in healthy children and in comparison with adults", "volume": "154", "author": "Bengtsson", "year": "1956", "journal-title": "Acta Med. Scand"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB8|cit8", "doi-asserted-by": "crossref", "first-page": "1195", "DOI": "10.1001/jama.1959.03010270031008", "article-title": "Master two-step exercise test in clinically unselected patients", "volume": "171", "author": "Brody", "year": "1959", "journal-title": "J. A. M. A"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB9|cit9", "doi-asserted-by": "crossref", "first-page": "377", "DOI": "10.1111/j.0954-6820.1960.tb03560.x", "article-title": "Serum lipids in normal men", "volume": "167", "author": "Carlson", "year": "1960", "journal-title": "Acta Med. Scand"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB10|cit10", "doi-asserted-by": "crossref", "first-page": "462", "DOI": "10.1016/0002-8703(61)90253-8", "article-title": "Marked left axis deviation. Indication of cardiac abnormality", "volume": "62", "author": "Curd", "year": "1961", "journal-title": "Amer. Heart J"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB11|cit11", "doi-asserted-by": "crossref", "first-page": "1090", "DOI": "10.1001/jama.1953.03690120006002", "article-title": "Coronary disease among United States soldiers killed in action in Korea", "volume": "152", "author": "Enos", "year": "1953", "journal-title": "J. A. M. A"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB12|cit12", "first-page": "616", "article-title": "The electrocardiogram in persons over 70", "volume": "12", "author": "Fisch", "year": "1957", "journal-title": "Geriatrics"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB13|cit13", "doi-asserted-by": "crossref", "first-page": "1868", "DOI": "10.1001/jama.1957.02980170008002", "article-title": "Energy cost of the Master two-step test", "volume": "164", "author": "Ford", "year": "1957", "journal-title": "J. A. M A."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB14|cit14", "doi-asserted-by": "crossref", "first-page": "120", "DOI": "10.7326/0003-4819-31-1-120", "article-title": "On the significance of the normal electrocardiogram in old age", "volume": "31", "author": "Fox", "year": "1949", "journal-title": "A. M. A. Ann intern. Med"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB15|cit15", "first-page": "1437", "article-title": "Stockholms stads h\u00e4lsounders\u00f6kning 1954", "volume": "58", "author": "Frisk", "year": "1957", "journal-title": "Nord. Med."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB16|cit16", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.1111/j.0954-6820.1959.tb10377.x", "article-title": "Stockholm's city health survey 1954", "volume": "163", "author": "Frisk", "year": "1959", "journal-title": "Acta Med. Scand."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB17|cit17", "doi-asserted-by": "crossref", "first-page": "125", "DOI": "10.1111/j.0954-6820.1961.tb17101.x", "article-title": "Studies on the central circulation at rest and during exercise in the supine and sitting body position in old men", "volume": "169", "author": "Granath", "year": "1961", "journal-title": "Acta Med. Scand"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB18|cit18", "doi-asserted-by": "crossref", "first-page": "233", "DOI": "10.1161/01.CIR.14.2.233", "article-title": "Left axis deviation. An electrocardiographic-pathologic correlation study", "volume": "14", "author": "Grant", "year": "1956", "journal-title": "Circulation"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB19|cit19", "author": "Grant", "year": "1957", "volume-title": "Clinical electrocardiography"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB20|cit20", "author": "Grewin", "issue": "Suppl. 209", "year": "1948", "article-title": "Some supplementary leads in clinical electrocardiography", "journal-title": "Acta Med. Scand."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB21|cit21", "first-page": "638", "article-title": "Die \u201cintrinsicoiddeflektion\u201d der kammerextrasystolen, ihre diagnostische und klinische bedeutung", "volume": "48", "author": "Gross", "year": "1959", "journal-title": "Z. Kreisl.-Forsch"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB22|cit22", "doi-asserted-by": "crossref", "first-page": "96", "DOI": "10.1016/0002-9149(60)90040-0", "article-title": "Electrocardiographic findings in 67,375 asymptomatic subjects. III. Ventricular rhythms", "volume": "6", "author": "Hiss", "year": "1960", "journal-title": "Amer. J. Cardiol."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB23|cit23", "doi-asserted-by": "crossref", "first-page": "259", "DOI": "10.1111/j.0954-6820.1959.tb14499.x", "article-title": "Ecg changes in vasoregulatory asthenia and the effect of physical training", "volume": "165", "author": "Holmgren", "year": "1959", "journal-title": "Acta Med. Scand"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB24|cit24", "doi-asserted-by": "crossref", "first-page": "137", "DOI": "10.3109/00365515409134855", "article-title": "A new ergometer with constant work load at varying pedalling rate", "volume": "6", "author": "Holmgren", "year": "1954", "journal-title": "Scand. J. clin. Lab. Invest"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB25|cit25", "doi-asserted-by": "crossref", "first-page": "57", "DOI": "10.1111/j.0954-6820.1961.tb17093.x", "article-title": "On the use of chest-head leads for recording of electrocardiogram during exercise", "volume": "169", "author": "Holmgren", "year": "1961", "journal-title": "Acta Med. Scand"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB26|cit26", "doi-asserted-by": "crossref", "first-page": "451", "DOI": "10.1016/0002-8703(62)90300-9", "article-title": "Electrocardiographic abnormalities in cerebral disorders. Report of six cases and review of the literature", "volume": "63", "author": "Hugenholtz", "year": "1962", "journal-title": "Amer. Heart J"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB27|cit27", "first-page": "5", "article-title": "Mortality studies of isolated electrocardiographic T-wave changes", "volume": "39", "author": "Kiessling", "year": "1955", "journal-title": "Trans. Ass. Life Insur. med. Dir. Amer."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB28|cit28", "doi-asserted-by": "crossref", "first-page": "305", "DOI": "10.1378/chest.39.3.305", "article-title": "Electrocardiographic ischaemic patterns without coronary artery disease", "volume": "39", "author": "Kwoczynski", "year": "1961", "journal-title": "Dis. Chest"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB29|cit29", "author": "Lepeschkin", "volume": "1", "year": "1951", "volume-title": "Modern electrocardiography"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB30|cit30", "doi-asserted-by": "crossref", "first-page": "986", "DOI": "10.1161/01.CIR.22.5.986", "article-title": "Exercise tests in diagnosis of coronary heart disease", "volume": "22", "author": "Lepeschkin", "year": "1960", "journal-title": "Circulation"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB31|cit31", "doi-asserted-by": "crossref", "first-page": "511", "DOI": "10.1056/NEJM195803132581101", "article-title": "Characteristics of true-positive and false-positive results of electrocardiographic Master two-step exercise tests", "volume": "258", "author": "Lepeschkin", "year": "1958", "journal-title": "New Engl. J. Med"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB32|cit32", "doi-asserted-by": "crossref", "first-page": "665", "DOI": "10.1111/j.0954-6820.1962.tb07206.x", "article-title": "Studies in neurocirculatory asthenia (Da Costa's syndrome). I. Variations with regard to symptoms and some pathophysiological signs", "volume": "172", "author": "Levander-Lindgren", "year": "1962", "journal-title": "Acta Med. Scand"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB33|cit33", "doi-asserted-by": "crossref", "first-page": "1199", "DOI": "10.1016/S0025-7125(16)33957-8", "article-title": "Certain aspects of the biochemistry and physiology of arrhythmia", "volume": "44", "author": "Levine", "year": "1960", "journal-title": "M. Clin. N. Amer"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB34|cit34", "first-page": "357", "article-title": "Pathogenesis of coronary sclerosis", "volume": "55", "author": "Lober", "year": "1953", "journal-title": "A. M. A. Arch. Path"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB35|cit35", "first-page": "1051", "article-title": "Coronary artery disease and the \u201ctwo-step exercise test\u201d", "volume": "57", "author": "Master", "year": "1957", "journal-title": "N. Y. st. J. Med."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB36|cit36", "author": "Master", "year": "1952", "volume-title": "Normal blood pressure and hypertension"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB37|cit37", "author": "Master", "first-page": "24", "year": "1961", "volume-title": "Hypertension, recent advances"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB38|cit38", "first-page": "1850", "article-title": "The \u201ctwo-step\u201d exercise test brought up to date", "volume": "61", "author": "Master", "year": "1961", "journal-title": "N. Y. st. J. Med"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB39|cit39", "doi-asserted-by": "crossref", "first-page": "196", "DOI": "10.1161/01.CIR.21.2.196", "article-title": "Abnormal electrocardiograms in apparently healthy people. I. Long term follow-up study", "volume": "21", "author": "Mathewson", "year": "1960", "journal-title": "Circulation"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB40|cit40", "doi-asserted-by": "crossref", "first-page": "645", "DOI": "10.7326/0003-4819-21-4-645", "article-title": "An electrocardiographic study of cardiac aging based on records at rest and after exercise", "volume": "21", "author": "Mazer", "year": "1944", "journal-title": "A. M. A. Ann. intern. Med"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB41|cit41", "first-page": "17", "article-title": "Kritische Betrachtungen zur Ursache und klinischen Bedeutung des Stehelektrokardiogramms", "volume": "201", "author": "Michel", "year": "1954", "journal-title": "Dtsch. Arch, klin. Med"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB42|cit42", "doi-asserted-by": "crossref", "first-page": "361", "DOI": "10.7326/0003-4819-43-2-361", "article-title": "The electrocardiographic diagnosis of acute myocardial ischaemia", "volume": "43", "author": "Myers", "year": "1955", "journal-title": "A. M. A. Ann. intern. Med"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB43|cit43", "author": "Owen", "first-page": "479", "year": "1962", "volume-title": "Handbook of statistical tables"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB44|cit44", "first-page": "52", "article-title": "The value of the double standard two-step exercise test in the detection o coronary disease", "volume": "40", "author": "Robb", "year": "1956", "journal-title": "Trans. Ass. Life Insur. med. Dir. Amer"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB45|cit45", "doi-asserted-by": "crossref", "first-page": "450", "DOI": "10.3181/00379727-103-25554", "article-title": "Evaluation of type and degree of changes in postexercise electrocardiogram in detecting coronary artery disease", "volume": "103", "author": "Robb", "year": "1960", "journal-title": "Proc. Soc. exp. Biol. (N. Y.)"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB46|cit46", "doi-asserted-by": "crossref", "first-page": "511", "DOI": "10.1136/hrt.21.4.511", "article-title": "Unexplained heart failure in the aged", "volume": "21", "author": "Rose", "year": "1959", "journal-title": "Brit. Heart J"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB47|cit47", "author": "R\u00f6ssle", "year": "1954", "volume-title": "Bedeutung und Ergebnisse der Kriegspathologie"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB48|cit48", "doi-asserted-by": "crossref", "first-page": "415", "DOI": "10.1136/hrt.22.3.415", "article-title": "Electrocardiograms of healthy men after strenuous exercise", "volume": "22", "author": "Rumball", "year": "1960", "journal-title": "Brit. Heart J"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB49|cit49", "doi-asserted-by": "crossref", "first-page": "1772", "DOI": "10.1001/jama.1957.02980320002002", "article-title": "Master two-step test in coronary artery disease", "volume": "165", "author": "Russek", "year": "1957", "journal-title": "J. A. M. A"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB50|cit50", "author": "Sandbero", "issue": "suppl. 365", "year": "1961", "article-title": "Studies on electrocardiographic changes during exercise tests", "journal-title": "Acta Med. Scand."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB51|cit51", "doi-asserted-by": "crossref", "first-page": "510", "DOI": "10.1161/01.CIR.8.4.510", "article-title": "The relation of age to certain electrocardiographic responses of normal adults to a standardized exercise", "volume": "8", "author": "Silver", "year": "1953", "journal-title": "Circulation"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB52|cit52", "doi-asserted-by": "crossref", "first-page": "584", "DOI": "10.1152/jappl.1953.5.10.584", "article-title": "Effect of moderate exercise on the electrocardiogram in healthy young and middle-aged men", "volume": "5", "author": "Simonsson", "year": "1953", "journal-title": "J. appl. Physiol."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB53|cit53", "author": "Simonsson", "year": "1961", "volume-title": "Differentiation between normal and abnormal in electrocardiography"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB54|cit54", "author": "Snedecor", "year": "1959", "volume-title": "Statistical methods"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB55|cit55", "doi-asserted-by": "crossref", "first-page": "191", "DOI": "10.1111/j.0954-6820.1950.tb10113.x", "article-title": "Experimental variations in the T-wave of the electrocardiogram", "volume": "138", "author": "Sj\u00f6strand", "year": "1950", "journal-title": "Acta Med. Scand"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB56|cit56", "doi-asserted-by": "crossref", "first-page": "201", "DOI": "10.1111/j.0954-6820.1950.tb10114.x", "article-title": "The relationship between the heart frequency and the S-T level of the electrocardiogram", "volume": "138", "author": "Sj\u00f6strand", "year": "1950", "journal-title": "Acta Med. Scand"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB57|cit57", "doi-asserted-by": "crossref", "first-page": "1", "DOI": "10.3109/00365515109060563", "article-title": "The electrocardiographic work and hypoxemia tests", "volume": "3", "author": "Sj\u00f6strand", "year": "1951", "journal-title": "Scand. J. clin. Lab. Invest"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB58|cit58", "author": "Sj\u00f6strand", "year": "1960", "volume-title": "Functional capacity and exercise tolerance in patients with impaired cardiovascular function. Clinical cardiopulmonary physiology"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB59|cit59", "unstructured": "Strandell , T."}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB60|cit60", "first-page": "665", "article-title": "Die verschiedene Bedeutung von Kammerextrasystolen", "volume": "48", "author": "Wenger", "year": "1959", "journal-title": "Z. Kreisl.-Forsch"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB61|cit61", "doi-asserted-by": "crossref", "first-page": "363", "DOI": "10.1136/hrt.12.4.363", "article-title": "The effort test in angina pectoris", "volume": "12", "author": "Wood", "year": "1950", "journal-title": "Brit. Heart J"}, {"key": "10.1111/j.0954-6820.1963.tb07948.x-BIB62|cit62", "doi-asserted-by": "crossref", "first-page": "334", "DOI": "10.1016/0002-8703(48)90334-2", "article-title": "Coronary artery disease in men eighteen to thirty-nine years of age", "volume": "36", "author": "Yater", "year": "1948", "journal-title": "Amer. Heart J"}], "container-title": ["Acta Medica Scandinavica"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.0954-6820.1963.tb07948.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 3, 3]], "date-time": "2019-03-03T16:28:28Z", "timestamp": 1551630508000}, "score": 25.522003, "issued": {"date-parts": [[2009, 4, 24]]}, "references-count": 62, "journal-issue": {"issue": "4"}, "URL": "http://dx.doi.org/10.1111/j.0954-6820.1963.tb07948.x", "relation": {"cites": []}, "ISSN": ["0001-6101"], "issn-type": [{"value": "0001-6101", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T04:48:30Z", "timestamp": 1574138910203}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "2", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[1983, 4, 1]], "date-time": "1983-04-01T00:00:00Z", "timestamp": 418003200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Urol. Res."], "published-print": {"date-parts": [[1983, 4]]}, "DOI": "10.1007/bf00256949", "type": "journal-article", "created": {"date-parts": [[2004, 9, 27]], "date-time": "2004-09-27T06:38:59Z", "timestamp": 1096267139000}, "source": "Crossref", "is-referenced-by-count": 4, "title": ["Relapse of androgen-dependent tumour of mouse (Shionogi Carcinoma 115) after castration and oestrogen treatment"], "prefix": "10.1007", "volume": "11", "author": [{"given": "T.", "family": "Miyauchi", "sequence": "first", "affiliation": []}, {"given": "M.", "family": "Wakisaka", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Hara", "sequence": "additional", "affiliation": []}, {"given": "O.", "family": "Matsuzaki", "sequence": "additional", "affiliation": []}, {"given": "J.", "family": "Shimazaki", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Urological Research"], "language": "en", "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/BF00256949.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/article/10.1007/BF00256949/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/BF00256949", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 3]], "date-time": "2019-04-03T18:30:32Z", "timestamp": 1554316232000}, "score": 24.864958, "issued": {"date-parts": [[1983, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1983, 4]]}, "issue": "2"}, "alternative-id": ["BF00256949"], "URL": "http://dx.doi.org/10.1007/bf00256949", "ISSN": ["0300-5623", "1434-0879"], "issn-type": [{"value": "0300-5623", "type": "print"}, {"value": "1434-0879", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T19:21:57Z", "timestamp": 1574796117016}, "reference-count": 0, "publisher": "The Endocrine Society", "issue": "7", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "published-print": {"date-parts": [[2016, 7]]}, "DOI": "10.1210/jc.2016-1483", "type": "journal-article", "created": {"date-parts": [[2016, 5, 12]], "date-time": "2016-05-12T17:00:45Z", "timestamp": 1463072445000}, "page": "2937-2944", "source": "Crossref", "is-referenced-by-count": 12, "title": ["Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone"], "prefix": "10.1210", "volume": "101", "author": [{"given": "Arthi", "family": "Thirumalai", "sequence": "first", "affiliation": []}, {"given": "Lori A.", "family": "Cooper", "sequence": "additional", "affiliation": []}, {"given": "Katya B.", "family": "Rubinow", "sequence": "additional", "affiliation": []}, {"given": "John K.", "family": "Amory", "sequence": "additional", "affiliation": []}, {"given": "Daniel W.", "family": "Lin", "sequence": "additional", "affiliation": []}, {"given": "Jonathan L.", "family": "Wright", "sequence": "additional", "affiliation": []}, {"given": "Brett T.", "family": "Marck", "sequence": "additional", "affiliation": []}, {"given": "Alvin M.", "family": "Matsumoto", "sequence": "additional", "affiliation": []}, {"given": "Stephanie T.", "family": "Page", "sequence": "additional", "affiliation": []}], "member": "80", "container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "language": "en", "link": [{"URL": "http://press.endocrine.org/doi/full/10.1210/jc.2016-1483", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 3, 30]], "date-time": "2017-03-30T21:38:43Z", "timestamp": 1490909923000}, "score": 24.317368, "issued": {"date-parts": [[2016, 7]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2016, 7]]}, "issue": "7"}, "alternative-id": ["10.1210/jc.2016-1483"], "URL": "http://dx.doi.org/10.1210/jc.2016-1483", "ISSN": ["0021-972X", "1945-7197"], "issn-type": [{"value": "0021-972X", "type": "print"}, {"value": "1945-7197", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T08:06:21Z", "timestamp": 1574496381148}, "reference-count": 21, "publisher": "Elsevier BV", "issue": "5", "license": [{"URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "start": {"date-parts": [[2012, 10, 1]], "date-time": "2012-10-01T00:00:00Z", "timestamp": 1349049600000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Neuropeptides"], "published-print": {"date-parts": [[2012, 10]]}, "DOI": "10.1016/j.npep.2012.07.001", "type": "journal-article", "created": {"date-parts": [[2012, 8, 11]], "date-time": "2012-08-11T01:31:17Z", "timestamp": 1344648677000}, "page": "211-215", "source": "Crossref", "is-referenced-by-count": 88, "title": ["Oxytocin plasma concentrations after single intranasal oxytocin administration \u2013 A study in healthy men"], "prefix": "10.1016", "volume": "46", "author": [{"given": "A.", "family": "Gossen", "sequence": "first", "affiliation": []}, {"given": "A.", "family": "Hahn", "sequence": "additional", "affiliation": []}, {"given": "L.", "family": "Westphal", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Prinz", "sequence": "additional", "affiliation": []}, {"given": "R.T.", "family": "Schultz", "sequence": "additional", "affiliation": []}, {"given": "G.", "family": "Gr\u00fcnder", "sequence": "additional", "affiliation": []}, {"given": "K.N.", "family": "Spreckelmeyer", "sequence": "additional", "affiliation": []}], "member": "78", "container-title": ["Neuropeptides"], "language": "en", "link": [{"URL": "https://api.elsevier.com/content/article/PII:S0143417912000686?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://api.elsevier.com/content/article/PII:S0143417912000686?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2019, 7, 2]], "date-time": "2019-07-02T19:08:50Z", "timestamp": 1562094530000}, "score": 23.884031, "issued": {"date-parts": [[2012, 10]]}, "references-count": 21, "journal-issue": {"published-print": {"date-parts": [[2012, 10]]}, "issue": "5"}, "alternative-id": ["S0143417912000686"], "URL": "http://dx.doi.org/10.1016/j.npep.2012.07.001", "ISSN": ["0143-4179"], "issn-type": [{"value": "0143-4179", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T14:31:13Z", "timestamp": 1574433073221}, "publisher-location": "New York, NY", "reference-count": 113, "publisher": "Springer New York", "isbn-type": [{"value": "9781461417637", "type": "print"}, {"value": "9781461417644", "type": "electronic"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2012]]}, "DOI": "10.1007/978-1-4614-1764-4_9", "type": "book-chapter", "created": {"date-parts": [[2011, 12, 13]], "date-time": "2011-12-13T21:43:14Z", "timestamp": 1323812594000}, "page": "145-163", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Differential Functions of Stromal and Epithelial Androgen Receptor in Prostate Cancer Before and After Castration Resistant Stage"], "prefix": "10.1007", "author": [{"given": "S.", "family": "Lee", "sequence": "first", "affiliation": []}, {"given": "K.- P.", "family": "Lai", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "Yeh", "sequence": "additional", "affiliation": []}, {"given": "C.", "family": "Chang", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2011, 12, 14]]}, "reference": [{"key": "9_CR1", "doi-asserted-by": "publisher", "first-page": "232", "DOI": "10.3322/canjclin.22.4.232", "volume": "22", "author": "C Huggins", "year": "1972", "unstructured": "Huggins C, Hodges CV (1972) Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232\u2013240", "journal-title": "CA Cancer J Clin"}, {"key": "9_CR2", "doi-asserted-by": "publisher", "first-page": "324", "DOI": "10.1126/science.3353726", "volume": "240", "author": "CS Chang", "year": "1988", "unstructured": "Chang CS, Kokontis J, Liao ST (1988) Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240:324\u2013326", "journal-title": "Science"}, {"key": "9_CR3", "doi-asserted-by": "publisher", "first-page": "43", "DOI": "10.1002/1097-0045(2000)45:10+<43::AID-PROS9>3.0.CO;2-L", "volume": "10", "author": "K Griffiths", "year": "2000", "unstructured": "Griffiths K, Denis LJ (2000) Exploitable mechanisms for the blockade of androgenic action. Prostate Suppl 10:43\u201351", "journal-title": "Prostate Suppl"}, {"key": "9_CR4", "doi-asserted-by": "publisher", "first-page": "309", "DOI": "10.1016/S0083-6729(08)60938-3", "volume": "55", "author": "AK Roy", "year": "1999", "unstructured": "Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH et al (1999) Regulation of androgen action. Vitam Horm 55:309\u2013352", "journal-title": "Vitam Horm"}, {"key": "9_CR5", "first-page": "313", "volume": "14", "author": "J Shimazaki", "year": "1965", "unstructured": "Shimazaki J, Kurihara H, Ito Y, Shida K (1965) Testosterone metabolism in prostate; formation of androstan-17-beta-ol-3-one and androst-4-ene-3, 17-dione, and inhibitory effect of natural and synthetic estrogens. Gunma J Med Sci 14:313\u2013325", "journal-title": "Gunma J Med Sci"}, {"key": "9_CR6", "doi-asserted-by": "publisher", "first-page": "277", "DOI": "10.1038/219277a0", "volume": "219", "author": "KM Anderson", "year": "1968", "unstructured": "Anderson KM, Liao S (1968) Selective retention of dihydrotestosterone by prostatic nuclei. Nature 219:277\u2013279", "journal-title": "Nature"}, {"key": "9_CR7", "doi-asserted-by": "publisher", "first-page": "765", "DOI": "10.1158/0008-5472.CAN-03-0130", "volume": "64", "author": "A Mizokami", "year": "2004", "unstructured": "Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M et al (2004) The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64:765\u2013771", "journal-title": "Cancer Res"}, {"key": "9_CR8", "doi-asserted-by": "publisher", "first-page": "4653", "DOI": "10.1158/1078-0432.CCR-05-0525", "volume": "11", "author": "MA Titus", "year": "2005", "unstructured": "Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653\u20134657", "journal-title": "Clin Cancer Res"}, {"key": "9_CR9", "doi-asserted-by": "publisher", "first-page": "4365", "DOI": "10.1158/1078-0432.CCR-04-0738", "volume": "11", "author": "MA Titus", "year": "2005", "unstructured": "Titus MA, Gregory CW, Ford OH 3rd, Schell MJ, Maygarden SJ et al (2005) Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 11:4365\u20134371", "journal-title": "Clin Cancer Res"}, {"key": "9_CR10", "doi-asserted-by": "publisher", "first-page": "13866", "DOI": "10.1074/jbc.M314143200", "volume": "279", "author": "H Huang", "year": "2004", "unstructured": "Huang H, Muddiman DC, Tindall DJ (2004) Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells. J Biol Chem 279:13866\u201313877", "journal-title": "J Biol Chem"}, {"key": "9_CR11", "doi-asserted-by": "publisher", "first-page": "3057", "DOI": "10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S", "volume": "67", "author": "MV Sadi", "year": "1991", "unstructured": "Sadi MV, Walsh PC, Barrack ER (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67:3057\u20133064", "journal-title": "Cancer"}, {"key": "9_CR12", "first-page": "889", "volume": "2", "author": "JL Mohler", "year": "1996", "unstructured": "Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA et al (1996) Androgen and glucocorticoid  receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res 2:889\u2013895", "journal-title": "Clin Cancer Res"}, {"key": "9_CR13", "doi-asserted-by": "publisher", "first-page": "129", "DOI": "10.1002/(SICI)1097-0045(199602)28:2<129::AID-PROS9>3.0.CO;2-B", "volume": "28", "author": "A Hobisch", "year": "1996", "unstructured": "Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H et al (1996) Androgen receptor status of lymph node metastases from prostate cancer. Prostate 28:129\u2013135", "journal-title": "Prostate"}, {"key": "9_CR14", "doi-asserted-by": "publisher", "first-page": "189", "DOI": "10.1002/ijc.2910480206", "volume": "48", "author": "TH Kwast van der", "year": "1991", "unstructured": "van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E et al (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48:189\u2013193", "journal-title": "Int J Cancer"}, {"key": "9_CR15", "doi-asserted-by": "publisher", "first-page": "48", "DOI": "10.1016/j.urolonc.2008.06.002", "volume": "27", "author": "HJ Kung", "year": "2009", "unstructured": "Kung HJ, Evans CP (2009) Oncogenic activation of androgen receptor. Urol Oncol 27:48\u201352", "journal-title": "Urol Oncol"}, {"key": "9_CR16", "doi-asserted-by": "publisher", "first-page": "764", "DOI": "10.1002/pros.20553", "volume": "67", "author": "SO Lee", "year": "2007", "unstructured": "Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC (2007) Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 67:764\u2013773", "journal-title": "Prostate"}, {"key": "9_CR17", "doi-asserted-by": "publisher", "first-page": "160", "DOI": "10.1002/pros.20218", "volume": "64", "author": "SO Lee", "year": "2005", "unstructured": "Lee SO, Lou W, Nadiminty N, Lin X, Gao AC (2005) Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 64:160\u2013167", "journal-title": "Prostate"}, {"key": "9_CR18", "doi-asserted-by": "publisher", "first-page": "10449", "DOI": "10.1158/0008-5472.CAN-06-2582", "volume": "66", "author": "SJ Desai", "year": "2006", "unstructured": "Desai SJ, Ma AH, Tepper CG, Chen HW, Kung HJ (2006) Inappropriate activation of the androgen receptor by nonsteroids: involvement of the src  kinase pathway and its therapeutic implications. Cancer Res 66:10449\u201310459", "journal-title": "Cancer Res"}, {"key": "9_CR19", "doi-asserted-by": "publisher", "first-page": "16369", "DOI": "10.1073/pnas.0907044106", "volume": "106", "author": "H Ishiguro", "year": "2009", "unstructured": "Ishiguro H, Akimoto K, Nagashima Y, Kojima Y, Sasaki T et al (2009) aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6. Proc Natl Acad Sci U S A 106:16369\u201316374", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR20", "first-page": "747", "volume": "91", "author": "A Cabrespine", "year": "2004", "unstructured": "Cabrespine A, Guy L, Chollet P, Debiton E, Bay JO (2004) Molecular mechanisms involved in hormone resistance of prostate cancer. Bull Cancer 91:747\u2013757", "journal-title": "Bull Cancer"}, {"key": "9_CR21", "doi-asserted-by": "publisher", "first-page": "442", "DOI": "10.1016/j.biocel.2004.07.011", "volume": "37", "author": "A Hammacher", "year": "2005", "unstructured": "Hammacher A, Thompson EW, Williams ED (2005) Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int J Biochem Cell Biol 37:442\u2013450", "journal-title": "Int J Biochem Cell Biol"}, {"key": "9_CR22", "doi-asserted-by": "publisher", "first-page": "23598", "DOI": "10.1074/jbc.M109.098301", "volume": "285", "author": "TD Chuang", "year": "2010", "unstructured": "Chuang TD, Chen SJ, Lin FF, Veeramani S, Kumar S et al (2010) Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J Biol Chem 285:23598\u201323606", "journal-title": "J Biol Chem"}, {"key": "9_CR23", "doi-asserted-by": "publisher", "first-page": "2193", "DOI": "10.1158/0008-5472.CAN-10-1791", "volume": "71", "author": "D Zhang", "year": "2011", "unstructured": "Zhang D, He D, Xue Y, Wang R, Wu K et al (2011) PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res 71:2193\u20132202", "journal-title": "Cancer Res"}, {"key": "9_CR24", "doi-asserted-by": "publisher", "first-page": "309", "DOI": "10.1016/j.ccr.2006.08.021", "volume": "10", "author": "Z Guo", "year": "2006", "unstructured": "Guo Z, Dai B, Jiang T, Xu K, Xie Y et al (2006) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10:309\u2013319", "journal-title": "Cancer Cell"}, {"key": "9_CR25", "doi-asserted-by": "crossref", "first-page": "99", "DOI": "10.1016/S1476-5586(03)80001-5", "volume": "5", "author": "SS El Sheikh", "year": "2003", "unstructured": "El Sheikh SS, Domin J, Abel P, Stamp G, Lalani el N (2003) Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia 5:99\u2013109", "journal-title": "Neoplasia"}, {"key": "9_CR26", "doi-asserted-by": "publisher", "first-page": "151", "DOI": "10.1677/JME-07-0021", "volume": "39", "author": "L Leotoing", "year": "2007", "unstructured": "Leotoing L, Manin M, Monte D, Baron S, Communal Y et al (2007) Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation. J Mol Endocrinol 39:151\u2013162", "journal-title": "J Mol Endocrinol"}, {"key": "9_CR27", "doi-asserted-by": "publisher", "first-page": "311", "DOI": "10.1016/S0898-6568(00)00072-3", "volume": "12", "author": "L Montalvo", "year": "2000", "unstructured": "Montalvo L, Carmena MJ, Solano RM, Clemente C, Roman ID et al (2000) Effect of flutamide-induced androgen-receptor blockade on adenylate cyclase activation through G-protein coupled receptors in rat prostate. Cell Signal 12:311\u2013316", "journal-title": "Cell Signal"}, {"key": "9_CR28", "doi-asserted-by": "publisher", "first-page": "2305", "DOI": "10.1158/0008-5472.CAN-08-3795", "volume": "69", "author": "Z Guo", "year": "2009", "unstructured": "Guo Z, Yang X, Sun F, Jiang R, Linn DE et al (2009) A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 69:2305\u20132313", "journal-title": "Cancer Res"}, {"key": "9_CR29", "doi-asserted-by": "publisher", "first-page": "16759", "DOI": "10.1073/pnas.1012443107", "volume": "107", "author": "PA Watson", "year": "2010", "unstructured": "Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND et al (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107:16759\u201316765", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR30", "doi-asserted-by": "publisher", "first-page": "175", "DOI": "10.1210/er.23.2.175", "volume": "23", "author": "CA Heinlein", "year": "2002", "unstructured": "Heinlein CA, Chang C (2002) Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175\u2013200", "journal-title": "Endocr Rev"}, {"key": "9_CR31", "doi-asserted-by": "publisher", "first-page": "2208", "DOI": "10.1158/1078-0432.CCR-0746-3", "volume": "10", "author": "M Rahman", "year": "2004", "unstructured": "Rahman M, Miyamoto H, Chang C (2004) Androgen receptor coregulators in prostate cancer: mechanisms and clinical implications. Clin Cancer Res 10:2208\u20132219", "journal-title": "Clin Cancer Res"}, {"key": "9_CR32", "doi-asserted-by": "publisher", "first-page": "5517", "DOI": "10.1073/pnas.93.11.5517", "volume": "93", "author": "S Yeh", "year": "1996", "unstructured": "Yeh S, Chang C (1996) Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A 93:5517\u20135521", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR33", "doi-asserted-by": "publisher", "first-page": "852", "DOI": "10.1016/S0140-6736(05)61756-4", "volume": "349", "author": "S Yeh", "year": "1997", "unstructured": "Yeh S, Miyamoto H, Chang C (1997) Hydroxyflutamide may not always be a pure antiandrogen. Lancet 349:852\u2013853", "journal-title": "Lancet"}, {"key": "9_CR34", "doi-asserted-by": "publisher", "first-page": "1354", "DOI": "10.1126/science.270.5240.1354", "volume": "270", "author": "SA Onate", "year": "1995", "unstructured": "Onate SA, Tsai SY, Tsai MJ, O\u2019Malley BW (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270:1354\u20131357", "journal-title": "Science"}, {"key": "9_CR35", "doi-asserted-by": "crossref", "first-page": "3667", "DOI": "10.1002/j.1460-2075.1996.tb00736.x", "volume": "15", "author": "JJ Voegel", "year": "1996", "unstructured": "Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H (1996) TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667\u20133675", "journal-title": "EMBO J"}, {"key": "9_CR36", "doi-asserted-by": "publisher", "first-page": "373", "DOI": "10.1016/S0092-8674(00)80218-4", "volume": "89", "author": "L Nagy", "year": "1997", "unstructured": "Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA et al (1997) Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373\u2013380", "journal-title": "Cell"}, {"key": "9_CR37", "doi-asserted-by": "publisher", "first-page": "49", "DOI": "10.1038/387049a0", "volume": "387", "author": "L Alland", "year": "1997", "unstructured": "Alland L, Muhle R, Hou H Jr, Potes J, Chin L et al (1997) Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature 387:49\u201355", "journal-title": "Nature"}, {"key": "9_CR38", "doi-asserted-by": "publisher", "first-page": "5458", "DOI": "10.1073/pnas.96.10.5458", "volume": "96", "author": "S Yeh", "year": "1999", "unstructured": "Yeh S, Lin HK, Kang HY, Thin TH, Lin MF et al (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A 96:5458\u20135463", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR39", "doi-asserted-by": "publisher", "first-page": "194", "DOI": "10.1038/38304", "volume": "389", "author": "TE Spencer", "year": "1997", "unstructured": "Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J et al (1997) Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194\u2013198", "journal-title": "Nature"}, {"key": "9_CR40", "doi-asserted-by": "publisher", "first-page": "20853", "DOI": "10.1074/jbc.M000660200", "volume": "275", "author": "M Fu", "year": "2000", "unstructured": "Fu M, Wang C, Reutens AT, Wang J, Angeletti RH et al (2000) p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853\u201320860", "journal-title": "J Biol Chem"}, {"key": "9_CR41", "doi-asserted-by": "publisher", "first-page": "2972", "DOI": "10.1210/jc.2002-022038", "volume": "88", "author": "IV Litvinov", "year": "2003", "unstructured": "Litvinov IV, De Marzo AM, Isaacs JT (2003) Is the Achilles\u2019 heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 88:2972\u20132982", "journal-title": "J Clin Endocrinol Metab"}, {"key": "9_CR42", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1002/mc.20255", "volume": "46", "author": "DG Tang", "year": "2007", "unstructured": "Tang DG, Patrawala L, Calhoun T, Bhatia B, Choy G et al (2007) Prostate cancer stem/progenitor cells: identification, characterization, and implications. Mol Carcinog 46:1\u201314", "journal-title": "Mol Carcinog"}, {"key": "9_CR43", "doi-asserted-by": "publisher", "first-page": "2610", "DOI": "10.1073/pnas.0913873107", "volume": "107", "author": "DA Lawson", "year": "2010", "unstructured": "Lawson DA, Zong Y, Memarzadeh S, Xin L, Huang J et al (2010) Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A 107:2610\u20132615", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR44", "doi-asserted-by": "publisher", "first-page": "563", "DOI": "10.1002/path.993", "volume": "195", "author": "GJ Leenders van", "year": "2001", "unstructured": "van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA (2001) Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 195:563\u2013570", "journal-title": "J Pathol"}, {"key": "9_CR45", "doi-asserted-by": "publisher", "first-page": "6796", "DOI": "10.1158/0008-5472.CAN-07-0490", "volume": "67", "author": "L Patrawala", "year": "2007", "unstructured": "Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG (2007) Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44 + alpha2beta1 + cell population is enriched in tumor-initiating cells. Cancer Res 67:6796\u20136805", "journal-title": "Cancer Res"}, {"key": "9_CR46", "doi-asserted-by": "publisher", "first-page": "177", "DOI": "10.1007/s10555-008-9175-2", "volume": "28", "author": "M Sund", "year": "2009", "unstructured": "Sund M, Kalluri R (2009) Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 28:177\u2013183", "journal-title": "Cancer Metastasis Rev"}, {"key": "9_CR47", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.1038/nrclinonc.2010.221", "volume": "8", "author": "VT DeVita Jr", "year": "2011", "unstructured": "DeVita VT Jr, Canellos GP (2011) Hematology in 2010: new therapies and standard of care in oncology. Nat Rev Clin Oncol 8:67\u201368", "journal-title": "Nat Rev Clin Oncol"}, {"key": "9_CR48", "doi-asserted-by": "publisher", "first-page": "395", "DOI": "10.1093/annonc/mdm568", "volume": "19", "author": "P Mathew", "year": "2008", "unstructured": "Mathew P (2008) Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial. Ann Oncol 19:395\u2013396", "journal-title": "Ann Oncol"}, {"key": "9_CR49", "first-page": "245", "volume": "5", "author": "RB Meacham", "year": "2003", "unstructured": "Meacham RB (2003) Androgen replacement therapy: treatment advances and clinical implications. Rev Urol 5:245\u2013247", "journal-title": "Rev Urol"}, {"key": "9_CR50", "doi-asserted-by": "publisher", "first-page": "237", "DOI": "10.1016/j.eururo.2009.03.073", "volume": "56", "author": "MJ Morris", "year": "2009", "unstructured": "Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD et al (2009) Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 56:237\u2013244", "journal-title": "Eur Urol"}, {"key": "9_CR51", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.1002/pros.10290", "volume": "57", "author": "A Bokhoven van", "year": "2003", "unstructured": "van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE et al (2003) Molecular characterization of human prostate carcinoma cell lines. Prostate 57:205\u2013225", "journal-title": "Prostate"}, {"key": "9_CR52", "doi-asserted-by": "publisher", "first-page": "534", "DOI": "10.1016/S0006-291X(05)80067-1", "volume": "173", "author": "J Veldscholte", "year": "1990", "unstructured": "Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C et al (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173:534\u2013540", "journal-title": "Biochem Biophys Res Commun"}, {"key": "9_CR53", "doi-asserted-by": "publisher", "first-page": "8", "DOI": "10.1186/1475-2867-5-8", "volume": "5", "author": "Q Yang", "year": "2005", "unstructured": "Yang Q, Fung KM, Day WV, Kropp BP, Lin HK (2005) Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 5:8", "journal-title": "Cancer Cell Int"}, {"key": "9_CR54", "doi-asserted-by": "publisher", "first-page": "e1006", "DOI": "10.1371/journal.pone.0001006", "volume": "2", "author": "D Compagno", "year": "2007", "unstructured": "Compagno D, Merle C, Morin A, Gilbert C, Mathieu JR et al (2007) SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS One 2:e1006", "journal-title": "PLoS One"}, {"key": "9_CR55", "doi-asserted-by": "publisher", "first-page": "505", "DOI": "10.1158/1535-7163.MCT-04-0313", "volume": "4", "author": "X Liao", "year": "2005", "unstructured": "Liao X, Tang S, Thrasher JB, Griebling TL, Li B (2005) Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 4:505\u2013515", "journal-title": "Mol Cancer Ther"}, {"key": "9_CR56", "doi-asserted-by": "publisher", "first-page": "997", "DOI": "10.1038/sj.cgt.7700202", "volume": "7", "author": "IE Eder", "year": "2000", "unstructured": "Eder IE, Culig Z, Ramoner R, Thurnher M, Putz T et al (2000) Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 7:997\u20131007", "journal-title": "Cancer Gene Ther"}, {"key": "9_CR57", "doi-asserted-by": "publisher", "first-page": "117", "DOI": "10.1038/sj.cgt.7700416", "volume": "9", "author": "IE Eder", "year": "2002", "unstructured": "Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D et al (2002) Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 9:117\u2013125", "journal-title": "Cancer Gene Ther"}, {"key": "9_CR58", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.1016/0960-0760(95)00155-S", "volume": "55", "author": "MO Joly-Pharaboz", "year": "1995", "unstructured": "Joly-Pharaboz MO, Soave MC, Nicolas B, Mebarki F, Renaud M et al (1995) Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. J Steroid Biochem Mol Biol 55:67\u201376", "journal-title": "J Steroid Biochem Mol Biol"}, {"key": "9_CR59", "doi-asserted-by": "publisher", "first-page": "941", "DOI": "10.1210/me.12.7.941", "volume": "12", "author": "JM Kokontis", "year": "1998", "unstructured": "Kokontis JM, Hay N, Liao S (1998) Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12:941\u2013953", "journal-title": "Mol Endocrinol"}, {"key": "9_CR60", "doi-asserted-by": "publisher", "first-page": "237", "DOI": "10.1016/S0960-0760(00)00076-5", "volume": "73", "author": "MO Joly-Pharaboz", "year": "2000", "unstructured": "Joly-Pharaboz MO, Ruffion A, Roch A, Michel-Calemard L, Andre J et al (2000) Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Steroid Biochem Mol Biol 73:237\u2013249", "journal-title": "J Steroid Biochem Mol Biol"}, {"key": "9_CR61", "first-page": "545", "volume": "7", "author": "AM Soto", "year": "1995", "unstructured": "Soto AM, Lin TM, Sakabe K, Olea N, Damassa DA et al (1995) Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response. Oncol Res 7:545\u2013558", "journal-title": "Oncol Res"}, {"key": "9_CR62", "doi-asserted-by": "publisher", "first-page": "1329", "DOI": "10.1002/pros.20483", "volume": "66", "author": "IV Litvinov", "year": "2006", "unstructured": "Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L et al (2006) PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 66:1329\u20131338", "journal-title": "Prostate"}, {"key": "9_CR63", "first-page": "1304", "volume": "53", "author": "S Yuan", "year": "1993", "unstructured": "Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F et al (1993) Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 53:1304\u20131311", "journal-title": "Cancer Res"}, {"key": "9_CR64", "doi-asserted-by": "publisher", "first-page": "181", "DOI": "10.1111/j.1745-7262.2007.00258.x", "volume": "9", "author": "S Altuwaijri", "year": "2007", "unstructured": "Altuwaijri S, Wu CC, Niu YJ, Mizokami A, Chang HC et al (2007) Expression of human AR cDNA driven by its own promoter results in mild promotion, but not suppression, of growth in human prostate cancer PC-3 cells. Asian J Androl 9:181\u2013188", "journal-title": "Asian J Androl"}, {"key": "9_CR65", "doi-asserted-by": "publisher", "first-page": "1699", "DOI": "10.1210/en.141.5.1699", "volume": "141", "author": "R Shen", "year": "2000", "unstructured": "Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D et al (2000) Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 141:1699\u20131704", "journal-title": "Endocrinology"}, {"key": "9_CR66", "doi-asserted-by": "publisher", "first-page": "455", "DOI": "10.1111/j.1745-7262.2006.00106.x", "volume": "8", "author": "XF Xu", "year": "2006", "unstructured": "Xu XF, Zhou SW, Zhang X, Ye ZQ, Zhang JH et al (2006) Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy. Asian J Androl 8:455\u2013462", "journal-title": "Asian J Androl"}, {"key": "9_CR67", "doi-asserted-by": "publisher", "first-page": "12182", "DOI": "10.1073/pnas.0804700105", "volume": "105", "author": "Y Niu", "year": "2008", "unstructured": "Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA et al (2008) Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A 105:12182\u201312187", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR68", "doi-asserted-by": "publisher", "first-page": "66", "DOI": "10.1002/pros.1048", "volume": "47", "author": "A Chlenski", "year": "2001", "unstructured": "Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R (2001) Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 47:66\u201375", "journal-title": "Prostate"}, {"key": "9_CR69", "doi-asserted-by": "publisher", "first-page": "15085", "DOI": "10.1073/pnas.0603057103", "volume": "103", "author": "IV Litvinov", "year": "2006", "unstructured": "Litvinov IV, Vander Griend DJ, Antony L, Dalrymple S, De Marzo AM et al (2006) Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A 103:15085\u201315090", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR70", "doi-asserted-by": "crossref", "first-page": "101", "DOI": "10.3727/000000003108748658", "volume": "14", "author": "E Scaccianoce", "year": "2003", "unstructured": "Scaccianoce E, Festuccia C, Dondi D, Guerini V, Bologna M et al (2003) Characterization of prostate cancer DU145 cells expressing the recombinant androgen receptor. Oncol Res 14:101\u2013112", "journal-title": "Oncol Res"}, {"key": "9_CR71", "first-page": "837", "volume": "12", "author": "O Nagakawa", "year": "2004", "unstructured": "Nagakawa O, Akashi T, Hayakawa Y, Junicho A, Koizumi K et al (2004) Differential expression of integrin subunits in DU-145/AR prostate cancer cells. Oncol Rep 12:837\u2013841", "journal-title": "Oncol Rep"}, {"key": "9_CR72", "doi-asserted-by": "publisher", "first-page": "403", "DOI": "10.1007/s11626-999-0115-4", "volume": "35", "author": "RM Sramkoski", "year": "1999", "unstructured": "Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S et al (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35:403\u2013409", "journal-title": "In Vitro Cell Dev Biol Anim"}, {"key": "9_CR73", "doi-asserted-by": "publisher", "first-page": "13498", "DOI": "10.1073/pnas.212474399", "volume": "99", "author": "S Yeh", "year": "2002", "unstructured": "Yeh S, Tsai MY, Xu Q, Mu XM, Lardy H et al (2002) Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A 99:13498\u201313503", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR74", "doi-asserted-by": "publisher", "first-page": "12679", "DOI": "10.1073/pnas.0704940104", "volume": "104", "author": "CT Wu", "year": "2007", "unstructured": "Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S et al (2007) Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. Proc Natl Acad Sci U S A 104:12679\u201312684", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR75", "doi-asserted-by": "publisher", "first-page": "105", "DOI": "10.1093/jb/mvi118", "volume": "138", "author": "T Matsumoto", "year": "2005", "unstructured": "Matsumoto T, Takeyama K, Sato T, Kato S (2005) Study of androgen receptor functions by genetic models. J Biochem 138:105\u2013110", "journal-title": "J Biochem"}, {"key": "9_CR76", "doi-asserted-by": "publisher", "first-page": "3674", "DOI": "10.1210/en.2007-0248", "volume": "148", "author": "KA Walters", "year": "2007", "unstructured": "Walters KA, Allan CM, Jimenez M, Lim PR, Davey RA et al (2007) Female mice haploinsufficient for an inactivated androgen receptor (AR) exhibit age-dependent defects that resemble the AR null phenotype of dysfunctional late follicle development, ovulation, and fertility. Endocrinology 148:3674\u20133684", "journal-title": "Endocrinology"}, {"key": "9_CR77", "doi-asserted-by": "crossref", "first-page": "792", "DOI": "10.1016/j.ccr.2011.05.006", "volume": "19", "author": "DJ Mulholland", "year": "2011", "unstructured": "Mulholland DJ, Tran LM, Li Y, Cai H, Morim A et al (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19:792--804", "journal-title": "Cancer Cell"}, {"key": "9_CR78", "first-page": "6182", "volume": "52", "author": "AP Verhagen", "year": "1992", "unstructured": "Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM et al (1992) Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res 52:6182\u20136187", "journal-title": "Cancer Res"}, {"key": "9_CR79", "first-page": "3865", "volume": "114", "author": "AT Collins", "year": "2001", "unstructured": "Collins AT, Habib FK, Maitland NJ, Neal DE (2001) Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 114:3865\u20133872", "journal-title": "J Cell Sci"}, {"key": "9_CR80", "doi-asserted-by": "publisher", "first-page": "495", "DOI": "10.1038/nature08361", "volume": "461", "author": "X Wang", "year": "2009", "unstructured": "Wang X, Kruithof-de Julio M, Economides KD, Walker D, Yu H et al (2009) A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461:495\u2013500", "journal-title": "Nature"}, {"key": "9_CR81", "first-page": "128", "volume": "3", "author": "Y Tang", "year": "2009", "unstructured": "Tang Y, Hamburger AW, Wang L, Khan MA, Hussain A (2009) Androgen deprivation and stem cell markers in prostate cancers. Int J Clin Exp Pathol 3:128\u2013138", "journal-title": "Int J Clin Exp Pathol"}, {"key": "9_CR82", "doi-asserted-by": "publisher", "first-page": "9199", "DOI": "10.1158/0008-5472.CAN-07-0806", "volume": "67", "author": "W Kleeberger", "year": "2007", "unstructured": "Kleeberger W, Bova GS, Nielsen ME, Herawi M, Chuang AY et al (2007) Roles for the stem cell associated intermediate filament nestin in prostate cancer migration and metastasis. Cancer Res 67:9199\u20139206", "journal-title": "Cancer Res"}, {"key": "9_CR83", "first-page": "1063", "volume": "16", "author": "DJ Yu", "year": "2010", "unstructured": "Yu DJ, Tang YQ, Shi YF, Wang YC, Zhuo J et al (2010) Proportion of intermediate epithelial cells and human prostate cancer. Zhonghua Nan Ke Xue 16:1063\u20131067", "journal-title": "Zhonghua Nan Ke Xue"}, {"key": "9_CR84", "doi-asserted-by": "publisher", "first-page": "e20202", "DOI": "10.1371/journal.pone.0020202", "volume": "6", "author": "Y Niu", "year": "2011", "unstructured": "Niu Y, Wang J, Shang Z, Huang SP, Shyr CR et al (2011) Increased CK5/CK8-positive intermediate cells with stromal smooth muscle cell atrophy in the mice lacking prostate epithelial androgen receptor. PLoS One 6:e20202", "journal-title": "PLoS One"}, {"key": "9_CR85", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1002/ijc.11335", "volume": "107", "author": "GR Cunha", "year": "2003", "unstructured": "Cunha GR, Hayward SW, Wang YZ, Ricke WA (2003) Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer 107:1\u201310", "journal-title": "Int J Cancer"}, {"key": "9_CR86", "doi-asserted-by": "publisher", "first-page": "221", "DOI": "10.1016/j.jsbmb.2004.10.017", "volume": "92", "author": "GR Cunha", "year": "2004", "unstructured": "Cunha GR, Ricke W, Thomson A, Marker PC, Risbridger G et al (2004) Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J Steroid Biochem Mol Biol 92:221\u2013236", "journal-title": "J Steroid Biochem Mol Biol"}, {"key": "9_CR87", "doi-asserted-by": "publisher", "first-page": "13", "DOI": "10.1210/en.2004-1123", "volume": "146", "author": "WW Barclay", "year": "2005", "unstructured": "Barclay WW, Woodruff RD, Hall MC, Cramer SD (2005) A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer. Endocrinology 146:13\u201318", "journal-title": "Endocrinology"}, {"key": "9_CR88", "doi-asserted-by": "publisher", "first-page": "511", "DOI": "10.1158/0008-5472.CAN-06-1478", "volume": "67", "author": "P Cano", "year": "2007", "unstructured": "Cano P, Godoy A, Escamilla R, Dhir R, Onate SA (2007) Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cancer Res 67:511\u2013519", "journal-title": "Cancer Res"}, {"key": "9_CR89", "doi-asserted-by": "publisher", "first-page": "538", "DOI": "10.1007/s11626-010-9309-z", "volume": "46", "author": "X Sun", "year": "2010", "unstructured": "Sun X, He H, Xie Z, Qian W, Zhau HE et al (2010) Matched pairs of human prostate stromal cells display differential tropic effects on LNCaP prostate cancer cells. In Vitro Cell Dev Biol Anim 46:538\u2013546", "journal-title": "In Vitro Cell Dev Biol Anim"}, {"key": "9_CR90", "doi-asserted-by": "publisher", "first-page": "2790", "DOI": "10.1111/j.1582-4934.2008.00279.x", "volume": "12", "author": "Y Li", "year": "2008", "unstructured": "Li Y, Li CX, Ye H, Chen F, Melamed J et al (2008) Decrease in stromal androgen receptor associates with androgen-independent disease and promotes prostate cancer cell proliferation and invasion. J Cell Mol Med 12:2790\u20132798", "journal-title": "J Cell Mol Med"}, {"key": "9_CR91", "doi-asserted-by": "publisher", "first-page": "e16027", "DOI": "10.1371/journal.pone.0016027", "volume": "6", "author": "MJ Tanner", "year": "2011", "unstructured": "Tanner MJ, Welliver RC Jr, Chen M, Shtutman M, Godoy A et al (2011) Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One 6:e16027", "journal-title": "PLoS One"}, {"key": "9_CR92", "doi-asserted-by": "publisher", "first-page": "e18796", "DOI": "10.1371/journal.pone.0018796", "volume": "6", "author": "KF Chambers", "year": "2011", "unstructured": "Chambers KF, Pearson JF, Aziz N, O\u2019Toole P, Garrod D et al (2011) Stroma regulates increased epithelial lateral cell adhesion in 3D culture: a role for actin/cadherin dynamics. PLoS One 6:e18796", "journal-title": "PLoS One"}, {"key": "9_CR93", "doi-asserted-by": "publisher", "first-page": "12188", "DOI": "10.1073/pnas.0804701105", "volume": "105", "author": "Y Niu", "year": "2008", "unstructured": "Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S et al (2008) Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci U S A 105:12188\u201312193", "journal-title": "Proc Natl Acad Sci U S A"}, {"key": "9_CR94", "doi-asserted-by": "crossref", "first-page": "517", "DOI": "10.1002/pros.21264", "volume": "71", "author": "S Yu", "year": "2011", "unstructured": "Yu S, Zhang C, Lin CC, Niu Y, Lai KP et al (2011) Altered prostate epithelial development and IGF-1 signal in mice lacking the androgen receptor in stromal smooth muscle cells. Prostate 71:517\u2013524", "journal-title": "Prostate"}, {"key": "9_CR95", "unstructured": "Yu S, Yeh CR, Niu Y, Chang HC, Tsai YC et al. (2011) Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts. Prostate", "DOI": "10.1002/pros.21264", "doi-asserted-by": "crossref"}, {"key": "9_CR96", "first-page": "967", "volume": "16", "author": "R Zeng", "year": "2010", "unstructured": "Zeng R, Liu ZY, Sun YH, Xu CL, Gao X et al (2010) Expressions of the androgen receptor in normal prostate, benigh prostatic hyperplasia and prostate cancer. Zhonghua Nan Ke Xue 16:967\u2013972", "journal-title": "Zhonghua Nan Ke Xue"}, {"key": "9_CR97", "doi-asserted-by": "publisher", "first-page": "135", "DOI": "10.1080/014850190518143", "volume": "51", "author": "EL Salazar", "year": "2005", "unstructured": "Salazar EL, Mercado E, Calzada L (2005) Prostatic cancer/benign prostatic hypertrophy. Subcellular distribution of estradiol/androgen receptors. Arch Androl 51:135\u2013139", "journal-title": "Arch Androl"}, {"key": "9_CR98", "doi-asserted-by": "publisher", "first-page": "1399", "DOI": "10.1097/01.ju.0000139539.94828.29", "volume": "172", "author": "G Andriole", "year": "2004", "unstructured": "Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R et al (2004) Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172:1399\u20131403", "journal-title": "J Urol"}, {"key": "9_CR99", "doi-asserted-by": "publisher", "first-page": "2179", "DOI": "10.1210/jc.2003-030330", "volume": "89", "author": "RV Clark", "year": "2004", "unstructured": "Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB et al (2004) Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 89:2179\u20132184", "journal-title": "J Clin Endocrinol Metab"}, {"key": "9_CR100", "doi-asserted-by": "publisher", "first-page": "7294", "DOI": "10.1158/0008-5472.CAN-09-3982", "volume": "70", "author": "CP Liao", "year": "2010", "unstructured": "Liao CP, Adisetiyo H, Liang M, Roy-Burman P (2010) Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 70:7294\u20137303", "journal-title": "Cancer Res"}, {"key": "9_CR101", "doi-asserted-by": "publisher", "first-page": "90", "DOI": "10.1002/pros.21043", "volume": "70", "author": "DJ Vander Griend", "year": "2010", "unstructured": "Vander Griend DJ, D\u2019Antonio J, Gurel B, Antony L, Demarzo AM et al (2010) Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 70:90\u201399", "journal-title": "Prostate"}, {"key": "9_CR102", "doi-asserted-by": "publisher", "first-page": "858", "DOI": "10.1038/cr.2008.84", "volume": "18", "author": "VA Odero-Marah", "year": "2008", "unstructured": "Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J et al (2008) Receptor activator of NF-kappaB ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 18:858\u2013870", "journal-title": "Cell Res"}, {"key": "9_CR103", "doi-asserted-by": "publisher", "first-page": "769", "DOI": "10.1096/fj.09-136994", "volume": "24", "author": "ML Zhu", "year": "2010", "unstructured": "Zhu ML, Kyprianou N (2010) Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 24:769\u2013777", "journal-title": "FASEB J"}, {"key": "9_CR104", "doi-asserted-by": "publisher", "first-page": "3876", "DOI": "10.1158/1078-0432.CCR-10-2815", "volume": "17", "author": "C Massard", "year": "2011", "unstructured": "Massard C, Fizazi K (2011) Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17:3876\u20133883", "journal-title": "Clin Cancer Res"}, {"key": "9_CR105", "doi-asserted-by": "publisher", "first-page": "674", "DOI": "10.1007/s10637-010-9388-4", "volume": "29", "author": "FM Chu", "year": "2011", "unstructured": "Chu FM, Picus J, Fracasso PM, Dreicer R, Lang Z et al (2011) A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human alpha(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest New Drugs 29:674\u2013679", "journal-title": "Invest New Drugs"}, {"key": "9_CR106", "doi-asserted-by": "publisher", "first-page": "787", "DOI": "10.1126/science.1168175", "volume": "324", "author": "C Tran", "year": "2009", "unstructured": "Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA et al (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324:787\u2013790", "journal-title": "Science"}, {"key": "9_CR107", "doi-asserted-by": "publisher", "first-page": "535", "DOI": "10.1016/j.ccr.2010.04.027", "volume": "17", "author": "RJ Andersen", "year": "2010", "unstructured": "Andersen RJ, Mawji NR, Wang J, Wang G, Haile S et al (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17:535\u2013546", "journal-title": "Cancer Cell"}, {"key": "9_CR108", "doi-asserted-by": "publisher", "first-page": "348", "DOI": "10.1038/nm1547", "volume": "13", "author": "Z Yang", "year": "2007", "unstructured": "Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC et al (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 13:348\u2013353", "journal-title": "Nat Med"}, {"key": "9_CR109", "doi-asserted-by": "publisher", "first-page": "3739", "DOI": "10.1172/JCI39335", "volume": "119", "author": "JJ Lai", "year": "2009", "unstructured": "Lai JJ, Lai KP, Chuang KH, Chang P, Yu IC et al (2009) Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest 119:3739\u20133751", "journal-title": "J Clin Invest"}, {"key": "9_CR110", "doi-asserted-by": "publisher", "first-page": "32ra35", "DOI": "10.1126/scitranslmed.3001143", "volume": "2", "author": "MH Wu", "year": "2010", "unstructured": "Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH et al (2010) Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2:32ra35", "journal-title": "Sci Transl Med"}, {"key": "9_CR111", "doi-asserted-by": "publisher", "first-page": "50902", "DOI": "10.1074/jbc.M300676200", "volume": "278", "author": "HK Lin", "year": "2003", "unstructured": "Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT et al (2003) Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem 278:50902\u201350907", "journal-title": "J Biol Chem"}, {"key": "9_CR112", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1002/mc.20121", "volume": "44", "author": "H Miyamoto", "year": "2005", "unstructured": "Miyamoto H, Altuwaijri S, Cai Y, Messing EM, Chang C (2005) Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog 44:1\u201310", "journal-title": "Mol Carcinog"}, {"key": "9_CR113", "doi-asserted-by": "publisher", "first-page": "575", "DOI": "10.1016/j.ccr.2011.04.008", "volume": "19", "author": "BS Carver", "year": "2011", "unstructured": "Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19:575\u2013586", "journal-title": "Cancer Cell"}], "container-title": ["Advances in Rapid Sex-Steroid Action"], "link": [{"URL": "http://www.springerlink.com/index/pdf/10.1007/978-1-4614-1764-4_9", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 4, 21]], "date-time": "2019-04-21T21:39:22Z", "timestamp": 1555882762000}, "score": 22.975044, "issued": {"date-parts": [[2011, 12, 14]]}, "ISBN": ["9781461417637", "9781461417644"], "references-count": 113, "URL": "http://dx.doi.org/10.1007/978-1-4614-1764-4_9", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T18:22:58Z", "timestamp": 1574792578431}, "reference-count": 0, "publisher": "Georg Thieme Verlag KG", "issue": "S 1", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Exp Clin Endocrinol Diabetes"], "DOI": "10.1055/s-2006-932967", "type": "journal-article", "created": {"date-parts": [[2017, 6, 8]], "date-time": "2017-06-08T07:03:09Z", "timestamp": 1496905389000}, "source": "Crossref", "is-referenced-by-count": 0, "title": ["An acutely stimulated androgen secretion does not affect 5\u03b1-reductase activity in healthy men"], "prefix": "10.1055", "volume": "114", "author": [{"given": "MF", "family": "Hartmann", "sequence": "first", "affiliation": []}, {"given": "SA", "family": "Wudy", "sequence": "additional", "affiliation": []}, {"given": "T", "family": "Remer", "sequence": "additional", "affiliation": []}], "member": "194", "published-online": {"date-parts": [[2006, 2, 28]]}, "container-title": ["Experimental and Clinical Endocrinology & Diabetes"], "language": "en", "link": [{"URL": "http://www.thieme-connect.de/DOI/DOI?10.1055/s-2006-932967", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 8]], "date-time": "2017-06-08T07:05:23Z", "timestamp": 1496905523000}, "score": 22.5495, "issued": {"date-parts": [[2006, 2, 28]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[2006, 2, 28]]}, "published-print": {"date-parts": [[2006]]}, "issue": "S 1"}, "URL": "http://dx.doi.org/10.1055/s-2006-932967", "ISSN": ["0947-7349", "1439-3646"], "issn-type": [{"value": "0947-7349", "type": "print"}, {"value": "1439-3646", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T05:11:58Z", "timestamp": 1574313118748}, "reference-count": 0, "publisher": "The Endocrine Society", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "published-print": {"date-parts": [[1990, 4]]}, "DOI": "10.1210/jcem-70-4-1019", "type": "journal-article", "created": {"date-parts": [[2009, 7, 21]], "date-time": "2009-07-21T01:45:44Z", "timestamp": 1248140744000}, "page": "1019-1022", "source": "Crossref", "is-referenced-by-count": 18, "title": ["Measurement of Inhibin Concentrations in Men: Study of Changes after Castration and Comparison with Androgen Levels in Testicular Tissue, Spermatic Venous Blood, and Peripheral Venous Blood"], "prefix": "10.1210", "volume": "70", "author": [{"given": "H.", "family": "ISHIDA", "sequence": "first", "affiliation": []}, {"given": "H.", "family": "TASHIRO", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "WATANABE", "sequence": "additional", "affiliation": []}, {"given": "N.", "family": "FUJII", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "IMAMURA", "sequence": "additional", "affiliation": []}, {"given": "S.", "family": "MINOWADA", "sequence": "additional", "affiliation": []}, {"given": "M.", "family": "SHINOHARA", "sequence": "additional", "affiliation": []}, {"given": "K.", "family": "FUKUTANI", "sequence": "additional", "affiliation": []}, {"given": "Y.", "family": "ASO", "sequence": "additional", "affiliation": []}, {"given": "D. M.", "family": "DE KRETSER", "sequence": "additional", "affiliation": []}], "member": "80", "container-title": ["The Journal of Clinical Endocrinology & Metabolism"], "language": "en", "link": [{"URL": "http://academic.oup.com/jcem/article-pdf/70/4/1019/10508969/jcem1019.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 8, 25]], "date-time": "2017-08-25T03:56:03Z", "timestamp": 1503633363000}, "score": 22.513144, "issued": {"date-parts": [[1990, 4]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1990, 4]]}, "issue": "4"}, "alternative-id": ["10.1210/jcem-70-4-1019"], "URL": "http://dx.doi.org/10.1210/jcem-70-4-1019", "ISSN": ["0021-972X", "1945-7197"], "issn-type": [{"value": "0021-972X", "type": "print"}, {"value": "1945-7197", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 11, 30]], "date-time": "2019-11-30T17:18:11Z", "timestamp": 1575134291845}, "reference-count": 0, "publisher": "Society for Neuroscience", "issue": "11", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Journal of Neuroscience"], "published-print": {"date-parts": [[2005, 3, 16]]}, "DOI": "10.1523/jneurosci.5139-04.2005", "type": "journal-article", "created": {"date-parts": [[2005, 3, 16]], "date-time": "2005-03-16T20:52:47Z", "timestamp": 1111006367000}, "page": "2977-2982", "source": "Crossref", "is-referenced-by-count": 376, "title": ["Impaired Memory Retrieval after Psychosocial Stress in Healthy Young Men"], "prefix": "10.1523", "volume": "25", "author": [{"given": "S.", "family": "Kuhlmann", "sequence": "first", "affiliation": []}], "member": "393", "container-title": ["Journal of Neuroscience"], "language": "en", "deposited": {"date-parts": [[2011, 8, 23]], "date-time": "2011-08-23T11:09:48Z", "timestamp": 1314097788000}, "score": 22.191656, "issued": {"date-parts": [[2005, 3, 16]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2005, 3, 16]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1523/jneurosci.5139-04.2005", "ISSN": ["0270-6474", "1529-2401"], "issn-type": [{"value": "0270-6474", "type": "print"}, {"value": "1529-2401", "type": "electronic"}], "subject": ["General Neuroscience"]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T11:01:14Z", "timestamp": 1574766074949}, "reference-count": 32, "publisher": "Wiley", "issue": "1", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1", "start": {"date-parts": [[2017, 4, 26]], "date-time": "2017-04-26T00:00:00Z", "timestamp": 1493164800000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://onlinelibrary.wiley.com/termsAndConditions", "start": {"date-parts": [[2017, 4, 26]], "date-time": "2017-04-26T00:00:00Z", "timestamp": 1493164800000}, "delay-in-days": 0, "content-version": "vor"}], "funder": [{"DOI": "10.13039/100000049", "name": "National Institute on Aging", "doi-asserted-by": "publisher", "award": []}, {"DOI": "10.13039/100000002", "name": "National Institutes of Health", "doi-asserted-by": "publisher", "award": ["RO1AG037603"]}, {"DOI": "10.13039/100009633", "name": "Eunice Kennedy Shriver National Institute of Child Health and Human Development", "doi-asserted-by": "publisher", "award": ["K24HD082231", "HD042454"]}, {"DOI": "10.13039/100007812", "name": "University of Washington", "doi-asserted-by": "publisher", "award": ["P30 DK035816"]}, {"DOI": "10.13039/100000968", "name": "American Heart Association", "doi-asserted-by": "publisher", "award": []}, {"name": "Robert B. McMillen Professorship", "award": ["5T32DK007247-37"]}, {"name": "VA Advanced Fellowship in Geriatrics", "award": []}, {"name": "VA Puget Sound Health Care System in Seattle", "award": []}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clin Endocrinol"], "published-print": {"date-parts": [[2017, 7]]}, "DOI": "10.1111/cen.13342", "type": "journal-article", "created": {"date-parts": [[2017, 3, 31]], "date-time": "2017-03-31T04:52:59Z", "timestamp": 1490935979000}, "page": "59-67", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Dose-response effects of sex hormone concentrations on body composition and adipokines in medically castrated healthy men administered graded doses of testosterone gel"], "prefix": "10.1111", "volume": "87", "author": [{"ORCID": "http://orcid.org/0000-0003-1239-2614", "authenticated-orcid": false, "given": "Arthi", "family": "Thirumalai", "sequence": "first", "affiliation": [{"name": "Department of Medicine; University of Washington; Seattle WA USA"}]}, {"given": "Katya B.", "family": "Rubinow", "sequence": "additional", "affiliation": [{"name": "Department of Medicine; University of Washington; Seattle WA USA"}]}, {"given": "Lori A.", "family": "Cooper", "sequence": "additional", "affiliation": [{"name": "Endocrinology; The Polyclinic; Seattle WA USA"}]}, {"given": "John K.", "family": "Amory", "sequence": "additional", "affiliation": [{"name": "Department of Medicine; University of Washington; Seattle WA USA"}]}, {"given": "Brett T.", "family": "Marck", "sequence": "additional", "affiliation": [{"name": "Geriatric Research, Education and Clinical Center; VA Puget Sound Health Care System; Seattle WA USA"}]}, {"given": "Alvin M.", "family": "Matsumoto", "sequence": "additional", "affiliation": [{"name": "Geriatric Research, Education and Clinical Center; VA Puget Sound Health Care System; Seattle WA USA"}, {"name": "Division of Gerontology & Geriatric Medicine; Department of Medicine; University of Washington School of Medicine; Seattle WA USA"}]}, {"given": "Stephanie T.", "family": "Page", "sequence": "additional", "affiliation": [{"name": "Department of Medicine; University of Washington; Seattle WA USA"}]}], "member": "311", "published-online": {"date-parts": [[2017, 4, 26]]}, "reference": [{"issue": "Suppl 1", "key": "10.1111/cen.13342-BIB0001|cen13342-cit-0001", "first-page": "S3", "article-title": "Fundamental aspects of hypogonadism in the aging male", "volume": "5", "author": "Matsumoto", "year": "2003", "journal-title": "Rev Urol"}, {"key": "10.1111/cen.13342-BIB0002|cen13342-cit-0002", "doi-asserted-by": "crossref", "first-page": "68", "DOI": "10.1210/jc.2007-1792", "article-title": "Low serum testosterone and mortality in older men", "volume": "93", "author": "Laughlin", "year": "2008", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0003|cen13342-cit-0003", "doi-asserted-by": "crossref", "first-page": "435", "DOI": "10.1530/EJE-09-0284", "article-title": "Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Troms\u00f8 Study", "volume": "161", "author": "Vikan", "year": "2009", "journal-title": "Eur J Endocrinol"}, {"key": "10.1111/cen.13342-BIB0004|cen13342-cit-0004", "doi-asserted-by": "crossref", "first-page": "747", "DOI": "10.1530/EJE-09-0943", "article-title": "Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men", "volume": "162", "author": "Vikan", "year": "2010", "journal-title": "Eur J Endocrinol"}, {"key": "10.1111/cen.13342-BIB0005|cen13342-cit-0005", "doi-asserted-by": "crossref", "first-page": "2457", "DOI": "10.1056/NEJMoa1206168", "article-title": "Gonadal steroids and body composition, strength, and sexual function in men", "volume": "369", "author": "Finkelstein", "year": "2013", "journal-title": "N Engl J Med"}, {"key": "10.1111/cen.13342-BIB0006|cen13342-cit-0006", "doi-asserted-by": "crossref", "first-page": "E1172", "DOI": "10.1152/ajpendo.2001.281.6.E1172", "article-title": "Testosterone dose-response relationships in healthy young men", "volume": "281", "author": "Bhasin", "year": "2001", "journal-title": "Am J Physiol Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0007|cen13342-cit-0007", "doi-asserted-by": "crossref", "first-page": "3280", "DOI": "10.1210/JC.2015-1542", "article-title": "Serum testosterone (T) level variability in T gel-treated older hypogonadal men: treatment monitoring implications", "volume": "100", "author": "Swerdloff", "year": "2015", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0008|cen13342-cit-0008", "doi-asserted-by": "crossref", "first-page": "1233", "DOI": "10.1056/NEJM197905313002201", "article-title": "Androgens and the evolution of male-gender identity among male pseudohermaphrodites with 5alpha-reductase deficiency", "volume": "300", "author": "Imperato-Mcginley", "year": "1979", "journal-title": "N Engl J Med"}, {"key": "10.1111/cen.13342-BIB0009|cen13342-cit-0009", "first-page": "3689", "article-title": "Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens", "volume": "80", "author": "Morishima", "year": "1995", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0010|cen13342-cit-0010", "doi-asserted-by": "crossref", "first-page": "931", "DOI": "10.1001/jama.2012.227", "article-title": "Effect of testosterone supplementation with and without a dual 5alpha-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial", "volume": "307", "author": "Bhasin", "year": "2012", "journal-title": "JAMA"}, {"key": "10.1111/cen.13342-BIB0011|cen13342-cit-0011", "doi-asserted-by": "crossref", "first-page": "2937", "DOI": "10.1210/jc.2016-1483", "article-title": "Stable intraprostatic dihydrotestosterone in healthy medically castrate men treated with exogenous testosterone", "volume": "101", "author": "Thirumalai", "year": "2016", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0012|cen13342-cit-0012", "doi-asserted-by": "crossref", "first-page": "5959", "DOI": "10.1210/jc.2003-032123", "article-title": "A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2\u00a0weeks in healthy young men", "volume": "89", "author": "Herbst", "year": "2004", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0013|cen13342-cit-0013", "doi-asserted-by": "crossref", "first-page": "3806", "DOI": "10.1210/jc.2010-0360", "article-title": "Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency", "volume": "95", "author": "Roth", "year": "2010", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0014|cen13342-cit-0014", "doi-asserted-by": "crossref", "first-page": "412", "DOI": "10.1007/BF00280883", "article-title": "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", "volume": "28", "author": "Matthews", "year": "1985", "journal-title": "Diabetologia"}, {"key": "10.1111/cen.13342-BIB0015|cen13342-cit-0015", "doi-asserted-by": "crossref", "first-page": "416", "DOI": "10.2337/dc08-1775", "article-title": "Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the search for diabetes in Youth case-control study", "volume": "32", "author": "Guy", "year": "2009", "journal-title": "Diabetes Care"}, {"key": "10.1111/cen.13342-BIB0016|cen13342-cit-0016", "doi-asserted-by": "crossref", "first-page": "678", "DOI": "10.1210/jc.2004-1184", "article-title": "Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle", "volume": "90", "author": "Bhasin", "year": "2005", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0017|cen13342-cit-0017", "doi-asserted-by": "crossref", "first-page": "1167", "DOI": "10.1210/jc.2002-020918", "article-title": "The male contraceptive regimen of testosterone and levonorgestrel significantly increases lean mass in healthy young men in 4\u00a0weeks, but attenuates a decrease in fat mass induced by testosterone alone", "volume": "88", "author": "Herbst", "year": "2003", "journal-title": "J\u00a0Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0018|cen13342-cit-0018", "doi-asserted-by": "crossref", "first-page": "15", "DOI": "10.1016/0303-7207(92)90004-P", "article-title": "Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene", "volume": "88", "author": "Deslypere", "year": "1992", "journal-title": "Mol Cell Endocrinol"}, {"key": "10.1111/cen.13342-BIB0019|cen13342-cit-0019", "doi-asserted-by": "crossref", "first-page": "746", "DOI": "10.1111/cen.12452", "article-title": "Testosterone and dihydrotestosterone and incident ischaemic stroke in men in the Cardiovascular Health Study", "volume": "81", "author": "Shores", "year": "2014", "journal-title": "Clin Endocrinol"}, {"key": "10.1111/cen.13342-BIB0020|cen13342-cit-0020", "doi-asserted-by": "crossref", "first-page": "2061", "DOI": "10.1210/jc.2013-3576", "article-title": "Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study", "volume": "99", "author": "Shores", "year": "2014", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0021|cen13342-cit-0021", "doi-asserted-by": "crossref", "first-page": "211", "DOI": "10.1186/s12916-014-0211-5", "article-title": "Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis", "volume": "12", "author": "Borst", "year": "2014", "journal-title": "BMC Med"}, {"key": "10.1111/cen.13342-BIB0022|cen13342-cit-0022", "doi-asserted-by": "crossref", "first-page": "1502", "DOI": "10.1210/jc.2004-1933", "article-title": "Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T", "volume": "90", "author": "Page", "year": "2005", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0023|cen13342-cit-0023", "doi-asserted-by": "crossref", "first-page": "4078", "DOI": "10.1210/jcem.86.9.7821", "article-title": "A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency", "volume": "86", "author": "Ly", "year": "2001", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0024|cen13342-cit-0024", "doi-asserted-by": "crossref", "first-page": "621", "DOI": "10.7326/0003-4819-153-10-201011160-00004", "article-title": "Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial", "volume": "153", "author": "Idan", "year": "2010", "journal-title": "Ann Intern Med"}, {"key": "10.1111/cen.13342-BIB0025|cen13342-cit-0025", "doi-asserted-by": "crossref", "first-page": "168", "DOI": "10.1111/exd.12024", "article-title": "Androgen actions on the human hair follicle: perspectives", "volume": "22", "author": "Inui", "year": "2013", "journal-title": "Exp Dermatol"}, {"key": "10.1111/cen.13342-BIB0026|cen13342-cit-0026", "doi-asserted-by": "crossref", "first-page": "136", "DOI": "10.1210/jcem.87.1.8172", "article-title": "The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men", "volume": "87", "author": "Singh", "year": "2002", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0027|cen13342-cit-0027", "doi-asserted-by": "crossref", "first-page": "1533", "DOI": "10.1210/jc.2009-1579", "article-title": "Androgen abuse in athletes: detection and consequences", "volume": "95", "author": "Basaria", "year": "2010", "journal-title": "J\u00a0Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0028|cen13342-cit-0028", "doi-asserted-by": "crossref", "first-page": "R99", "DOI": "10.1530/EJE-15-0262", "article-title": "Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study", "volume": "174", "author": "Corona", "year": "2016", "journal-title": "Eur J Endocrinol"}, {"key": "10.1111/cen.13342-BIB0029|cen13342-cit-0029", "first-page": "85", "article-title": "Testosterone administration suppresses adiponectin levels in men", "volume": "26", "author": "Page", "year": "2005", "journal-title": "J Androl"}, {"key": "10.1111/cen.13342-BIB0030|cen13342-cit-0030", "doi-asserted-by": "crossref", "first-page": "E1088", "DOI": "10.1210/jc.2013-2807", "article-title": "Acute and short-term chronic testosterone fluctuation effects on glucose homeostasis, insulin sensitivity, and adiponectin: a randomized, double-blind, placebo-controlled, crossover study", "volume": "99", "author": "Host", "year": "2014", "journal-title": "J Clin Endocrinol Metab"}, {"key": "10.1111/cen.13342-BIB0031|cen13342-cit-0031", "doi-asserted-by": "crossref", "first-page": "500", "DOI": "10.1111/j.1365-2265.2004.02007.x", "article-title": "Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy", "volume": "60", "author": "Lanfranco", "year": "2004", "journal-title": "Clin Endocrinol"}, {"key": "10.1111/cen.13342-BIB0032|cen13342-cit-0032", "doi-asserted-by": "crossref", "first-page": "295", "DOI": "10.1093/jn/134.2.295", "article-title": "Energy homeostasis, obesity and eating disorders: recent advances in endocrinology", "volume": "134", "author": "Gale", "year": "2004", "journal-title": "J Nutr"}], "container-title": ["Clinical Endocrinology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fcen.13342", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://onlinelibrary.wiley.com/wol1/doi/10.1111/cen.13342/fullpdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 20]], "date-time": "2019-09-20T12:10:27Z", "timestamp": 1568981427000}, "score": 21.80281, "issued": {"date-parts": [[2017, 4, 26]]}, "references-count": 32, "journal-issue": {"published-print": {"date-parts": [[2017, 7]]}, "issue": "1"}, "URL": "http://dx.doi.org/10.1111/cen.13342", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0300-0664"], "issn-type": [{"value": "0300-0664", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T01:53:43Z", "timestamp": 1574733223053}, "publisher-location": "Cham", "reference-count": 38, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319427683", "type": "print"}, {"value": "9783319427690", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2017, 1, 1]], "date-time": "2017-01-01T00:00:00Z", "timestamp": 1483228800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2017]]}, "DOI": "10.1007/978-3-319-42769-0_22", "type": "book-chapter", "created": {"date-parts": [[2017, 1, 9]], "date-time": "2017-01-09T11:12:18Z", "timestamp": 1483960338000}, "page": "327-342", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Chemotherapy and Androgen Receptor-Directed Treatment of Castration Resistant Metastatic Prostate Cancer"], "prefix": "10.1007", "author": [{"given": "S.", "family": "Osanto", "sequence": "first", "affiliation": []}, {"given": "S. A. C.", "family": "Luelmo", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2017, 1, 10]]}, "reference": [{"key": "22_CR1", "doi-asserted-by": "crossref", "first-page": "1028", "DOI": "10.1056/NEJMoa1315815", "volume": "371", "author": "ES Antonarakis", "year": "2014", "unstructured": "Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.", "journal-title": "N Engl J Med"}, {"issue": "13", "key": "22_CR2", "doi-asserted-by": "publisher", "first-page": "1307", "DOI": "10.1016/S1470-2045(13)70479-0", "volume": "14", "author": "JC Araujo", "year": "2013", "unstructured": "Araujo JC, Trudel GC, Saad F, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 2013;14(13):1307\u201316. doi: 10.1016/S1470-2045(13)70479-0 . Epub 2013 Nov 8.", "journal-title": "Lancet Oncol"}, {"key": "22_CR3", "doi-asserted-by": "crossref", "first-page": "517", "DOI": "10.1016/j.ejca.2009.11.007", "volume": "46", "author": "AJ Armstrong", "year": "2010", "unstructured": "Armstrong AJ, Tannock IF, de Wit R, et al. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46:517\u201325.", "journal-title": "Eur J Cancer"}, {"key": "22_CR4", "doi-asserted-by": "crossref", "first-page": "1273", "DOI": "10.1023/A:1012258723075", "volume": "12", "author": "TM Beer", "year": "2001", "unstructured": "Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12:1273\u20139.", "journal-title": "Ann Oncol"}, {"issue": "5", "key": "22_CR5", "doi-asserted-by": "publisher", "first-page": "808", "DOI": "10.1038/bjc.2012.339", "volume": "107", "author": "TM Beer", "year": "2012", "unstructured": "Beer TM, Smith DC, Hussain A, et al. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer. 2012;107(5):808\u201313. doi: 10.1038/bjc.2012.339 . Epub 2012 Jul 31.", "journal-title": "Br J Cancer"}, {"key": "22_CR1000", "unstructured": "Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424\u201333.", "DOI": "10.1056/NEJMoa1405095", "doi-asserted-by": "crossref"}, {"issue": "suppl 15", "key": "22_CR6", "doi-asserted-by": "crossref", "first-page": "8", "DOI": "10.1016/S0093-7754(01)90149-6", "volume": "4", "author": "W Berry", "year": "2001", "unstructured": "Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001;4 suppl 15:8\u201315.", "journal-title": "Semin Oncol"}, {"key": "22_CR7", "doi-asserted-by": "crossref", "first-page": "2439", "DOI": "10.1016/S0022-5347(05)64163-8", "volume": "168", "author": "W Berry", "year": "2002", "unstructured": "Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002;168:2439\u201343.", "journal-title": "J Urol"}, {"issue": "21", "key": "22_CR8", "doi-asserted-by": "crossref", "first-page": "1995", "DOI": "10.1056/NEJMoa1014618", "volume": "364", "author": "JS Bono de", "year": "2011", "unstructured": "de Bono JS, Logothetis CJ, Molina A, et al. COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.", "journal-title": "N Engl J Med"}, {"key": "22_CR9", "doi-asserted-by": "crossref", "first-page": "1147", "DOI": "10.1016/S0140-6736(10)61389-X", "volume": "376", "author": "JS Bono de", "year": "2010", "unstructured": "de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147\u201354.", "journal-title": "Lancet"}, {"issue": "1", "key": "22_CR10", "doi-asserted-by": "crossref", "first-page": "53", "DOI": "10.1016/j.eururo.2014.05.005", "volume": "67", "author": "E Efstathiou", "year": "2015", "unstructured": "Efstathiou E, Titus M, Wen S, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015;67(1):53\u201360.", "journal-title": "Eur Urol"}, {"key": "22_CR11", "doi-asserted-by": "crossref", "first-page": "994", "DOI": "10.1016/S1470-2045(07)70284-X", "volume": "8", "author": "K Fizazi", "year": "2007", "unstructured": "Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymard JC, Logothetis CJ, Pignon JP, Michiels S. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007;8:994\u20131000.", "journal-title": "Lancet Oncol"}, {"issue": "2", "key": "22_CR12", "doi-asserted-by": "publisher", "first-page": "329", "DOI": "10.1093/annonc/mds505", "volume": "24", "author": "A Heidenreich", "year": "2013", "unstructured": "Heidenreich A, Real SK, Szkarlat K, Bogdanova N, et al. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human \u03b1\u03bd integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2013;24(2):329\u201336. doi: 10.1093/annonc/mds505 . Epub 2012 Oct 26.", "journal-title": "Ann Oncol"}, {"key": "22_CR13", "doi-asserted-by": "crossref", "first-page": "2506", "DOI": "10.1200/JCO.1999.17.8.2506", "volume": "17", "author": "PW Kantoff", "year": "1999", "unstructured": "Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506\u201313.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "22_CR14", "doi-asserted-by": "crossref", "first-page": "117", "DOI": "10.1016/S1470-2045(12)70537-5", "volume": "14", "author": "P-L Kellokumpu-Lehtinen", "year": "2013", "unstructured": "Kellokumpu-Lehtinen P-L, Harmenberg U, Joensuu T, et al. 2-weekly versus 3-weekly docetaxel to treat castration resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol. 2013;14(2):117\u201324.", "journal-title": "Lancet Oncol"}, {"key": "22_CR15", "unstructured": "Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol. 2010;28(suppl):344s, abstr LBA4511."}, {"issue": "13", "key": "22_CR16", "doi-asserted-by": "crossref", "first-page": "1534", "DOI": "10.1200/JCO.2011.39.4767", "volume": "30", "author": "WK Kelly", "year": "2012", "unstructured": "Kelly WK, et al. Randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastastic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534\u201340.", "journal-title": "J Clin Oncol"}, {"issue": "2", "key": "22_CR17", "doi-asserted-by": "publisher", "first-page": "99", "DOI": "10.1016/j.clgc.2012.01.009", "volume": "10", "author": "G Liu", "year": "2012", "unstructured": "Liu G, Chen YH, Dipaola R, et al. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer. 2012;10(2):99\u2013105. doi: 10.1016/j.clgc.2012.01.009 . Epub 2012 Mar 3.", "journal-title": "Clin Genitourin Cancer"}, {"issue": "18", "key": "22_CR18", "doi-asserted-by": "publisher", "first-page": "1697", "DOI": "10.1056/NEJMoa1506859", "volume": "373", "author": "J Mateo", "year": "2015", "unstructured": "Mateo J, Carreira S, Sandhu S, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373(18):1697\u2013708. doi: 10.1056/NEJMoa1506859 .", "journal-title": "N Engl J Med"}, {"issue": "2", "key": "22_CR19", "doi-asserted-by": "publisher", "first-page": "76", "DOI": "10.1200/JCO.2012.48.5268.Epub2013Dec9", "volume": "32", "author": "MD Michaelson", "year": "2014", "unstructured": "Michaelson MD, Oudard S, Ou YC, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol. 2014;32(2):76\u201382. doi: 10.1200/JCO.2012.48.5268.Epub2013Dec9 .", "journal-title": "J Clin Oncol"}, {"key": "22_CR20", "doi-asserted-by": "publisher", "first-page": "5709", "DOI": "10.1002/cncr.27674", "volume": "118", "author": "JB Nelson", "year": "2012", "unstructured": "Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer. 2012;118:5709\u201318. doi: 10.1002/cncr.27674 . Epub 2012 Jul 11.", "journal-title": "Cancer"}, {"key": "22_CR21", "doi-asserted-by": "crossref", "first-page": "49", "DOI": "10.2165/00002512-199507010-00006", "volume": "7", "author": "CM Perry", "year": "1995", "unstructured": "Perry CM, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1995;7:49\u201374.", "journal-title": "Drugs Aging"}, {"key": "22_CR22", "doi-asserted-by": "crossref", "first-page": "1513", "DOI": "10.1056/NEJMoa041318", "volume": "351", "author": "DP Petrylak", "year": "2004", "unstructured": "Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl Med. 2004;351:1513\u201320.", "journal-title": "N Engl Med"}, {"issue": "4", "key": "22_CR23", "doi-asserted-by": "publisher", "first-page": "417", "DOI": "10.1016/S1470-2045(15)70025-2", "volume": "16", "author": "DP Petrylak", "year": "2015", "unstructured": "Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K. Docetaxel and prednisone with or without lenalidomide in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015;16(4):417\u201325. doi: 10.1016/S1470-2045(15)70025-2 . Epub 2015 Mar 3.", "journal-title": "Lancet Oncol"}, {"issue": "(5) Suppl 17", "key": "22_CR24", "first-page": "14", "volume": "26", "author": "J Picus", "year": "1999", "unstructured": "Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone refractory prostate cancer: preliminary results. Semin Oncol. 1999;26((5) Suppl 17):14\u20138.", "journal-title": "Semin Oncol"}, {"key": "22_CR1001", "unstructured": "Quin et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013;14(9):893\u2013900. doi: 10.1016/S1470-2045(13)70294-8. Epub 2013 Jul 17.", "DOI": "10.1016/S1470-2045(13)70294-8", "doi-asserted-by": "crossref"}, {"key": "22_CR25", "doi-asserted-by": "crossref", "first-page": "2457", "DOI": "10.1002/1097-0142(19931015)72:8<2457::AID-CNCR2820720825>3.0.CO;2-Z", "volume": "72", "author": "BJ Roth", "year": "1993", "unstructured": "Roth BJ, Yeap BY, Wilding G, et al. Taxol in advanced, hormone-refractory carcinoma of the prostate. Cancer. 1993;72:2457\u201360.", "journal-title": "Cancer"}, {"issue": "2", "key": "22_CR26", "doi-asserted-by": "publisher", "first-page": "138", "DOI": "10.1056/NEJMoa1209096", "volume": "368", "author": "CJ Ryan", "year": "2013", "unstructured": "Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348. doi: 10.1056/NEJMoa1209096 . Epub 2012 Dec 10.", "journal-title": "N Engl J Med"}, {"issue": "2", "key": "22_CR27", "doi-asserted-by": "crossref", "first-page": "152", "DOI": "10.1016/S1470-2045(14)71205-7", "volume": "16", "author": "CJ Ryan", "year": "2015", "unstructured": "Ryan CJ, Smith MR, Fizazi K. et al; for the COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled Phase 3 study. Lancet Oncol. 2015;16(2):152\u201360.", "journal-title": "Lancet Oncol"}, {"key": "22_CR28", "unstructured": "Scher HI, Fizazi K, Fred Saad F, et al. for the AFFIRM Investigators*. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397. 27 Sept 2012. doi: 10.1056/NEJMoa1207506 .", "DOI": "10.1056/NEJMoa1207506", "doi-asserted-by": "publisher"}, {"issue": "16", "key": "22_CR29", "doi-asserted-by": "publisher", "first-page": "2191", "DOI": "10.1200/JCO.2010.32.8815", "volume": "29", "author": "HI Scher", "year": "2011", "unstructured": "Scher HI, Jia X, Chi K, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29(16):2191\u20138. doi: 10.1200/JCO.2010.32.8815 . Epub 2011 Apr 11.", "journal-title": "J Clin Oncol"}, {"key": "22_CR30", "unstructured": "Small E, Demkow T, Gerritsen WR, et al. Proceedings genitourinary cancer symposium (February 26\u201328, 2009, Orlando, FL), A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer, suppl, abstr 7."}, {"issue": "32", "key": "22_CR31", "doi-asserted-by": "publisher", "first-page": "5431", "DOI": "10.1200/JCO.2008.20.1228", "volume": "27", "author": "CN Sternberg", "year": "2009", "unstructured": "Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing afterprior chemotherapy: the SPARC trial. J Clin Oncol. 2009;27(32):5431\u20138. doi: 10.1200/JCO.2008.20.1228 . Epub 2009 Oct 5.", "journal-title": "J Clin Oncol"}, {"key": "22_CR32", "doi-asserted-by": "crossref", "first-page": "1502", "DOI": "10.1056/NEJMoa040720", "volume": "351", "author": "IF Tannock", "year": "2004", "unstructured": "Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.", "journal-title": "N Engl J Med"}, {"issue": "8", "key": "22_CR33", "doi-asserted-by": "publisher", "first-page": "760", "DOI": "10.1016/S1470-2045(13)70184-0", "volume": "14", "author": "IF Tannock", "year": "2013", "unstructured": "Tannock IF, Fizazi K, Ivanov S, et al. VENICE investigators. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol. 2013;14(8):760\u20138. doi: 10.1016/S1470-2045(13)70184-0 . Epub 2013 Jun 4.", "journal-title": "Lancet Oncol"}, {"key": "22_CR34", "doi-asserted-by": "crossref", "first-page": "1756", "DOI": "10.1200/JCO.1996.14.6.1756", "volume": "14", "author": "IF Tannock", "year": "1996", "unstructured": "Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756\u201364.", "journal-title": "J Clin Oncol"}, {"key": "22_CR36", "doi-asserted-by": "crossref", "first-page": "431", "DOI": "10.1002/1097-0142(20000715)89:2<431::AID-CNCR31>3.0.CO;2-B", "volume": "89", "author": "C Trivedi", "year": "2000", "unstructured": "Trivedi C, Redman B, Flaherty LE, et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormonerefractory prostate carcinoma. Cancer. 2000;89:431\u201343.", "journal-title": "Cancer"}, {"key": "22_CR37", "doi-asserted-by": "crossref", "first-page": "1098", "DOI": "10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G", "volume": "71", "author": "A Yagoda", "year": "1993", "unstructured": "Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098\u2013109.", "journal-title": "Cancer"}], "container-title": ["Management of Prostate Cancer"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-42769-0_22", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 6, 25]], "date-time": "2017-06-25T07:38:56Z", "timestamp": 1498376336000}, "score": 21.79676, "issued": {"date-parts": [[2017]]}, "ISBN": ["9783319427683", "9783319427690"], "references-count": 38, "URL": "http://dx.doi.org/10.1007/978-3-319-42769-0_22", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 22]], "date-time": "2019-11-22T12:38:29Z", "timestamp": 1574426309247}, "reference-count": 0, "publisher": "American Medical Association (AMA)", "issue": "23", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["JAMA"], "published-print": {"date-parts": [[1939, 12, 2]]}, "DOI": "10.1001/jama.1939.02800480032008", "type": "journal-article", "created": {"date-parts": [[2011, 11, 29]], "date-time": "2011-11-29T09:15:26Z", "timestamp": 1322558126000}, "source": "Crossref", "is-referenced-by-count": 139, "title": ["THE PRODUCTION OF PERSISTENT ARTERIAL HYPERTENSION BY CELLOPHANE PERINEPHRITIS"], "prefix": "10.1001", "volume": "113", "author": [{"given": "IRVINE H.", "family": "PAGE", "sequence": "first", "affiliation": []}], "member": "10", "container-title": ["Journal of the American Medical Association"], "language": "en", "link": [{"URL": "http://jamanetwork.com/journals/jama/fullarticle/1159080", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 16]], "date-time": "2016-12-16T12:04:23Z", "timestamp": 1481889863000}, "score": 21.729734, "issued": {"date-parts": [[1939, 12, 2]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1939, 12, 2]]}, "issue": "23"}, "URL": "http://dx.doi.org/10.1001/jama.1939.02800480032008", "ISSN": ["0002-9955"], "issn-type": [{"value": "0002-9955", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T12:11:22Z", "timestamp": 1574770282452}, "reference-count": 30, "publisher": "Informa Healthcare", "issue": "8", "funder": [{"DOI": "10.13039/100000090", "name": "Congressionally Directed Medical Research Programs", "doi-asserted-by": "publisher", "award": ["W81XWH-13-2-0093"]}, {"DOI": "10.13039/100000002", "name": "National Institutes of Health", "doi-asserted-by": "publisher", "award": ["PNW Prostate SPORE-CA097186", "PO1-CA090381"]}, {"name": "Veterans Affairs Research Service", "award": ["Merit Award"]}], "content-domain": {"domain": ["www.tandfonline.com"], "crossmark-restriction": true}, "short-container-title": ["Expert Opinion on Therapeutic Targets"], "published-print": {"date-parts": [[2016, 8, 2]]}, "DOI": "10.1517/14728222.2016.1159676", "type": "journal-article", "created": {"date-parts": [[2016, 2, 29]], "date-time": "2016-02-29T16:50:32Z", "timestamp": 1456764632000}, "page": "903-906", "update-policy": "http://dx.doi.org/10.1080/tandf_crossmark_01", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer"], "prefix": "10.1517", "volume": "20", "author": [{"given": "M. T.", "family": "Schweizer", "sequence": "first", "affiliation": []}, {"given": "S. R.", "family": "Plymate", "sequence": "additional", "affiliation": []}], "member": "3197", "published-online": {"date-parts": [[2016, 3, 21]]}, "reference": [{"key": "CIT0001", "DOI": "10.1073/pnas.0401123101", "doi-asserted-by": "publisher"}, {"key": "CIT0002", "DOI": "10.1186/s13045-015-0225-2", "doi-asserted-by": "publisher"}, {"key": "CIT0003", "DOI": "10.1016/j.cell.2015.05.001", "doi-asserted-by": "publisher"}, {"key": "CIT0004", "DOI": "10.1210/er.2011-1033", "doi-asserted-by": "publisher"}, {"key": "CIT0005", "DOI": "10.1158/0008-5472.CAN-10-1998", "doi-asserted-by": "publisher"}, {"key": "CIT0006", "DOI": "10.1038/onc.2013.284", "doi-asserted-by": "publisher"}, {"key": "CIT0007", "DOI": "10.1158/1078-0432.CCR-13-1863", "doi-asserted-by": "publisher"}, {"key": "CIT0008", "DOI": "10.1093/nar/gkv262", "doi-asserted-by": "publisher"}, {"key": "CIT0009", "DOI": "10.1158/0008-5472.CAN-11-3892", "doi-asserted-by": "publisher"}, {"key": "CIT0010", "DOI": "10.1056/NEJMoa1315815", "doi-asserted-by": "publisher"}, {"key": "CIT0011", "unstructured": "Liu G, Li A, Sun S, et al. Identification of ARv567es expression profile in the prostate cancer clinical samples with a newly developed antibody [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18\u201322; Philadelphia (PA): AACR. Cancer Res. 2015;75(15 Suppl). Abstract no. 5159.", "DOI": "10.1158/1538-7445.AM2015-5159", "doi-asserted-by": "crossref"}, {"key": "CIT0012", "DOI": "10.1016/j.eururo.2014.05.005", "doi-asserted-by": "publisher"}, {"key": "CIT0013", "DOI": "10.1073/pnas.1012443107", "doi-asserted-by": "publisher"}, {"key": "CIT0014", "DOI": "10.1158/1078-0432.CCR-11-0728", "doi-asserted-by": "publisher"}, {"key": "CIT0015", "DOI": "10.1158/0008-5472.CAN-08-0594", "doi-asserted-by": "publisher"}, {"key": "CIT0016", "DOI": "10.1158/0008-5472.CAN-08-3795", "doi-asserted-by": "publisher"}, {"key": "CIT0017", "DOI": "10.1158/0008-5472.CAN-08-2764", "doi-asserted-by": "publisher"}, {"key": "CIT0018", "DOI": "10.1172/JCI41824", "doi-asserted-by": "publisher"}, {"key": "CIT0019", "DOI": "10.1158/0008-5472.CAN-15-0381", "doi-asserted-by": "publisher"}, {"key": "CIT0020", "DOI": "10.1158/0008-5472.CAN-12-3630", "doi-asserted-by": "publisher"}, {"key": "CIT0021", "DOI": "10.1172/JCI66398", "doi-asserted-by": "publisher"}, {"key": "CIT0022", "DOI": "10.1021/jm500802j", "doi-asserted-by": "publisher"}, {"key": "CIT0023", "DOI": "10.1593/neo.111436", "doi-asserted-by": "publisher"}, {"key": "CIT0024", "DOI": "10.1158/1078-0432.CCR-14-0292", "doi-asserted-by": "publisher"}, {"key": "CIT0025", "DOI": "10.1158/1078-0432.CCR-13-3296", "doi-asserted-by": "publisher"}, {"key": "CIT0026", "author": "Asangani IA", "year": "2016", "journal-title": "Mol Cancer Res"}, {"key": "CIT0027", "DOI": "10.1002/pros.22649", "doi-asserted-by": "publisher"}, {"key": "CIT0028", "DOI": "10.1158/1535-7163.MCT-13-0027", "doi-asserted-by": "publisher"}, {"key": "CIT0029", "DOI": "10.1210/me.2012-1165", "doi-asserted-by": "publisher"}, {"key": "CIT0030", "DOI": "10.1002/pros.22566", "doi-asserted-by": "publisher"}], "container-title": ["Expert Opinion on Therapeutic Targets"], "language": "en", "link": [{"URL": "http://www.tandfonline.com/doi/pdf/10.1517/14728222.2016.1159676", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 5]], "date-time": "2019-09-05T03:35:30Z", "timestamp": 1567654530000}, "score": 21.566586, "issued": {"date-parts": [[2016, 3, 21]]}, "references-count": 30, "journal-issue": {"published-online": {"date-parts": [[2016, 3, 15]]}, "published-print": {"date-parts": [[2016, 8, 2]]}, "issue": "8"}, "alternative-id": ["10.1517/14728222.2016.1159676"], "URL": "http://dx.doi.org/10.1517/14728222.2016.1159676", "relation": {"cites": []}, "ISSN": ["1472-8222", "1744-7631"], "issn-type": [{"value": "1472-8222", "type": "print"}, {"value": "1744-7631", "type": "electronic"}], "assertion": [{"value": "The publishing and review policy for this title is described in its Aims & Scope.", "order": 1, "name": "peerreview_statement", "label": "Peer Review Statement"}, {"value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=iett20", "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=iett20", "order": 2, "name": "aims_and_scope_url", "label": "Aim & Scope"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}